2018 Annual Meeting
Program At-a-Glance

Wednesday, 14 November, 2018

12:00 pm - 6:00 pm  Registration and Poster Set Up  Salon de Cavalieri 1 & Gallery
6:00 pm - 8:00 pm  Welcome Reception  San Pietro Gallery

Thursday, 15 November, 2018

6:00 am - 7:00 pm  Registration  Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am  Coffee and Posters  Salon de Cavalieri 1 & Gallery
7:00 am - 11:00 am  TARPSWG Semiannual Meeting  Ellisse Room
8:00 am - 5:30 pm  4th International Sarcoma Nurse and Allied Professionals Meeting (iSNAP) - "Collaboration in Sarcoma Care - Realizing Better Outcomes"  Caravaggio Room

9:00 am - 11:00 am  SARC PROGRAM  Salon del Cavalieri 2,3,4
10:30 am - 11:00 am  Morning Coffee Break  Salon de Cavalieri 1 & Gallery
11:15 am - 11:30 am  OPENING REMARKS  Salon del Cavalieri 2,3,4
11:30 am - 1:00 pm  SESSION 1 – Sarcoma of the Year: Intimal Sarcoma  Salon del Cavalieri 2,3,4
1:00 pm - 2:00 pm  Lunch  Belle Arti & Garden Lobby
2:00 pm - 3:30 pm  SESSION 2 – Soft Tissue Sarcoma: Chemotherapy  Salon del Cavalieri 2,3,4
3:30 pm - 4:00 pm  Afternoon Coffee Break  Salon de Cavalieri 1 & Gallery
4:00 pm - 6:00 pm  SESSION 3 – GIST  Salon del Cavalieri 2,3,4
6:00 pm - 7:00 pm  Poster Viewing Reception  Salon de Cavalieri 1 & Gallery
Friday, 16 November, 2018

6:00 am - 6:00 pm  Registration  
Salon de Cavalieri 1 & Gallery

7:00 am - 8:00 am  Coffee and Posters  
Salon de Cavalieri 1 & Gallery

7:00 am - 8:00 am  Executive Committee Meeting  
San Giovanni

8:00 am - 10:00 am  SESSION 4 – Soft Tissue Sarcoma: Targeted Therapy  
Salon del Cavalieri 2,3,4

10:00 am - 10:30 am  Morning Coffee Break  
Salon de Cavalieri 1 & Gallery

10:30 am - 11:00 am  Presentation of Young Investigator Awards  
Salon del Cavalieri 2,3,4

11:00 am - 12:00 pm  HERMAN SUIT LECTURE – Cristina Antonescu  
Salon del Cavalieri 2,3,4

12:00 pm - 1:30 pm  Lunch  
Belle Arti & Garden Lobby

1:30 pm - 3:30 pm  SESSION 5 – Benign and Intermediate Grade Bone/Soft Tissue Lesions  
Salon del Cavalieri 2,3,4

3:30 pm - 4:00 pm  Afternoon Coffee Break  
Salon de Cavalieri 1 & Gallery

4:00 pm - 6:00 pm  SESSION 6 – Ewing Sarcoma  
Salon del Cavalieri 2,3,4

7:00 pm - 10:00 pm  Gala – Reception and Dinner at the beautiful Villa Miani next door to the Cavalieri Hotel. Cocktail Attire  
Villa Miani

Saturday, 17 November, 2018

6:30 am - 5:30 pm  Registration  
Salon de Cavalieri 1 & Gallery

7:00 am - 8:00 am  Coffee and Posters  
Salon de Cavalieri 1 & Gallery

8:00 am - 9:00 am  Poster Discussion  
Salon del Cavalieri 2,3,4

9:00 am - 10:30 am  SESSION 7 – Osteosarcoma/Chondrosarcoma/Chordoma  
Salon del Cavalieri 2,3,4

10:30 am - 11:00 am  Morning Coffee Break  
Salon de Cavalieri 1 & Gallery

11:00 am - 12:00 pm  NINA AXELRAD LECTURE – Jean-Yves Blay  
Salon del Cavalieri 2,3,4

12:00 pm - 1:00 pm  Lunch  
Belle Arti & Garden Lobby

1:00 pm - 1:30 pm  Liddy Shriver Early Career Research Award  
Salon del Cavalieri 2,3,4

1:30 pm - 3:30 pm  SESSION 8 – Soft Tissue Sarcoma: Biology  
Salon del Cavalieri 2,3,4

3:30 pm - 4:00 pm  Afternoon Coffee Break  
Salon de Cavalieri 1 & Gallery

4:00 pm - 5:30 pm  SESSION 9 – Soft Tissue Sarcoma: Local Therapy  
Salon del Cavalieri 2,3,4

5:30 pm - 6:00 pm  CTOS Business Meeting  
Salon del Cavalieri 2,3,4

6:00 pm  ADJOURN
TARPSWG Semiannual Meeting

Thursday, November 15th
07.00 to 11.00 am

Cavalieri Hotel, Rome
Ellisse Room

Agenda

07.00-07.15 Welcome introduction (A. Gronchi)

07.15-08.00 RESAR project – an update on site activation, recruitment status and plans  
(M. Fiore M. Fairweather and D. Strauss)

08.00-08.20 Report from the REC committee on 2017-2018 activities and status of ongoing projects  
(C. Nessim)

08.20-08.45 The STREXIT project  
(C. Swallow)

08.45-09.30 STRASS 2 study  
(W. Van Houdt)

09.30-09.45 Recurrent RPS series: secondary manuscripts after the nomogram  
(CP Raut)

09.45-10.00 RT in primary retroperitoneal Liposarcoma: a propensity matched substudy from the original 1007 series  
(R. Haas)

10.00-10.15 Chemotherapy in primary RPS; a propensity matched substudy from the original 1007 series  
(C. Honoré)

10.15-11.00 TARPSWG governance and formalization: present perspective and future directions  
(all)

11.00 Start of CTOS official program

8.30 TARPSWG dinner
2018 Annual Meeting
November 14 - 17, 2018
Rome Cavalieri Hotel • Rome, Italy

Wednesday, 14 November, 2018

12:00 pm - 6:00 pm  Registration  Salon de Cavalieri 1 & Gallery
6:00 pm - 8:00 pm  Welcome Reception  San Pietro Gallery

Thursday, 15 November, 2018

6:00 am - 7:00 pm  Registration  Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am  Coffee and Posters  Salon de Cavalieri 1 & Gallery
7:00 am - 11:00 am  TARPSWG Semiannual Meeting  Ellisse Room
8:00 am - 5:30 pm  4th International Sarcoma Nurse and Allied Professionals Meeting (iSNAP) - "Collaboration in Sarcoma Care - Realizing Better Outcomes"  Caravaggio Room

9:00 am - 11:00 am  – SARC PROGRAM –  Salon del Cavalieri 2,3,4

Chawla/Rosenfeld Developmental Therapeutics Symposium
Emerging and Novel Biologically Targeted Approaches for Sarcoma Patients

Introduction
Elizabeth Lawlor, MD, PhD
Robert Maki, MD, PhD

Enhancing Activity of B7-H3 CAR T Cells for Pediatric Sarcomas
Robbie Majzner, MD

Discussion / Q & A

Translating PARP Inhibition as a Therapeutic Target into Benefit for Patients with Sarcoma
Sandra Strauss, MD, PhD

Discussion / Q & A

Epigenetic Changes following the Loss of PRC2 in MPNST: Emerging Therapeutic Opportunities
Keila Torres, MD, PhD

Discussion / Q & A

2019 Career Development Update
Elizabeth Lawlor, MD, PhD

10:30 am - 11:00 am  Morning Coffee Break  Salon de Cavalieri 1 & Gallery
**Thursday, 15 November, 2018**

11:15 am - 11:30 am **OPENING REMARKS**

11:30 am - 1:00 pm **– SESSION 1 –**

**Sarcoma of the Year: Intimal Sarcoma**

**Moderators:** Olivier Mir and Elizabeth Baldini

**Biology and Pathology of Intimal Sarcoma** – A. Paolo dei Tos

**Paper 001**

**SYSTEMIC TREATMENTS IN MDM2 + INTIMAL SARCOMA: A MULTICENTRE EXPERIENCE WITH ANTHRACYCLINE, GEMCITABINE AND PAZOPANIB WITHIN THE WORLD SARCOMA NETWORK (WSN)**

Anna Maria Frezza¹; Tarek Assi²; Luigi Mariani³; Armelle Dufresne⁴; Siontis Brittany⁵; Kan Yonemori⁶; Emi Noguchi⁶; Eytan-Ami⁷; Mrinal Gounder⁸; Robin Jones⁹; Pawel Tetycz⁴; Florence Duffaud¹⁰; Maria Abbondanza Pantaleo¹¹; Vinod Ravi¹²; Bruno Vincenzi¹³; Giacomo Giulio Baldi¹⁴; Alexander Fedenko¹⁵; Hans Gelderblom¹⁷; Robert Maki¹⁸; Jean-Yves Blay²; Axel Le Cesne²; Scott Schuetze³; Paolo Casali¹; Katherine Thornton⁷; Silvia Stacchiotti¹

¹Medical Oncology 2, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ²Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France; ³Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale Tumori, Milano, Milan, Italy; ⁴Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France; ⁵Department of Medicine, University of Michigan, Ann Arbor, MI, USA; ⁶Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; ⁷Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ⁸Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁹Sarcoma Unit, Royal Marsden NHS Foundation Trust/ Institute of Cancer Research, London, United Kingdom; ¹⁰Maria Sklodowska-Curie Institute-Oncology Center, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland; ¹¹Sant’Orsola Malpighi Hospital, Department of Specialized, Experimental and Diagnostic Medicine, Bologna, Italy; ¹²Department of Oncology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France; ¹³Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹⁴Medical Oncology, University Campus Bio-Medico, Rome, Italy; ¹⁵Medical Oncology, Nuovo Ospedale “S. Stefano”, Prato, Italy; ¹⁶Medical Oncology, N.N. Blokhin Russian Cancer Research, Moscow, Russian Federation; ¹⁷Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands; ¹⁸Medical Oncology, Northwell Health and Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

**Paper 002**

**PRIMARY MALIGNANT SARCOMAS OF THE HEART AND GREAT VESSELS: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES**

Luke Smith¹; Han Hsi Wong²; Marius Berman³; Dochka Davidson³; Gail Horan²; David Jenkins³; Helen Hatcher²

¹School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; ²Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; ³Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

**Paper 003**

**CLINICAL “REAL WORLD” NEXT GENERATION SEQUENCING REVEALS UNIQUE ABERRATIONS IN INTIMAL SARCOMA**

Jason Roszik; Anthony P. Conley; Roman Groisberg; Vinod Ravi; Roberto Carmagnani Pestana; Shiraj Sen; Vivek Subbiah

The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Paper 004  3042847  
OUTCOMES OF MULTIMODALITY TREATMENT WITH INDUCTION CHEMOTHERAPY, MAXIMAL RESECTION, AND PROTON BASED RADIATION THERAPY FOR CARDIAC AND PULMONARY VESSEL SARCOMAS  
Yen-Lin E. Chen; Rouyu Miao; Edwin Choy; Gregory M. Cote; Thomas F. DeLaney  
1Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; 2Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA  

Discussion – Robert Maki

1:00 pm - 2:00 pm  
Lunch  Belle Arti & Garden Lobby

2:00 pm - 3:30 pm  
– SESSION 2 –  Salon del Cavalieri 2,3,4  
Soft Tissue Sarcoma: Chemotherapy

Moderators: Wei-Wu (Tom) Chen and Claudia Valverde

Paper 005  3042630  
THE IMPACT OF CHEMOTHERAPY ON SURVIVAL OF PATIENTS WITH EXTREMITY AND TRUNK WALL SOFT TISSUE SARCOMA: REVISITING THE RESULTS OF THE EORTC-STBSG 62931 RANDOMISED TRIAL USING SARCULATOR, A VALIDATED NOMOGRAM-BASED RISK ASSESSMENT TOOL  
Sandro Pasquali; Sara Pizzamiglio; Nathan Touati; Saskia Litiere; Sandrine Marreaud; Bernd Kasper; Hans Gelderblom; Silvia Stacchiotti; Ian Judson; Angelo P. Dei Tos; Paolo Verderio; Paolo Casali; Penella J. Wolf; Alessandro Gronchi  
1Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 2European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; 3University of Heidelberg, Heidelberg, Germany; 4Leiden University Medical Centre, Leiden, Netherlands; 5The Royal NHS Fundation Trust, London, United Kingdom; 6Treviso General Hospital, Treviso, Italy; 7University of Sheffield, Sheffield, United Kingdom

Paper 006  3042737  
PROPENSITY SCORE MATCHING ANALYSIS OF DOXORUBICIN PLUS DACARBAZINE, DOXORUBICIN PLUS IFOSFAMIDE OR DOXORUBICIN ALONE AS FIRST-LINE TREATMENT FOR ADVANCED, METASTATIC OR UNRESECTABLE LEIOMYSARCOMA: A RETROSPECTIVE STUDY FROM THE EORTC SOFT TISSUE AND BONE SARCOMA GROUP  
Lorenzo D’Ambrosio; Nathan Touati; Jean-Yves Blay; Tiziana Venesio; Ronan Flippot; Anna M. Czarnecka; Sophie Piperno-Neumann; Javier Martin-Broto; Roberta Sanfilippo; Daniela Katz; Florence Duffaud; Bruno Vincenzi; Daniel P. Stark; Filomena Mazzeo; Armin Tuchscherer; Saskia Litiere; Ward Sents; Silvia Stacchiotti; Hans Gelderblom; Alessandro Gronchi  
1Department of Oncology, University of Torino, Torino, Italy; 2European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; 3University Claude Bernard Lyon I, Centre Leon Bержard, Lyon, France; 4Medical Oncology - Sarcoma Unit, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; 5Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; 6Medical Oncology, Institute Curie, Paris, France; 7Medical Oncology, Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain; 8Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 9Assaf Harofeh Medical Center, Zrifin, Israel; 10Service d’Oncologie Médicale Chu la Timone, Marseille, France; 11University Campus Bio-Medico of Rome, Roma, Italy; 12Sarcoma Unit, University of Heidelberg, Mannheim University Medical Center, ITM - Interdisciplinary Tumor Center Mannheim, Mannheim, Germany; 13St James’s Institute of Oncology, Leeds, United Kingdom; 14Clinique Universitaire Saint-Luc, Institut Roi Albert II, Brussels, Belgium; 15University Hospital Cologne, Köln, Germany; 16Leiden University Medical Center, Leiden, Netherlands; 17Gustave Roussy Cancer Center, Villejuif, France
PHASE 1B STUDY OF OLARATUMAB PLUS DOXORUBICIN AND IFOSFAMIDE IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA: INITIAL RESULTS

Sebastian Bauer; Neeta Somaiah; Silvia Stacchiotti; Peter Reichardt; Hector Soto Parra; Rainer Hamacher; Andrew Lithio; Gary Mo; Samuel Ramagé; Jonathan Trent

1 West German Cancer Center, University of Duisburg-Essen, Essen, Germany; 2 MD Anderson Cancer Center, University of Texas, Houston, TX, USA; 3 Fondazione IRCCS Istituto Nazionale dei Tumor, Milan, Italy; 4 Helios Klinikum Berlin-Buch, Berlin, Germany; 5 Department of Medical Oncology, Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele, Catania, Italy; 6 Eli Lilly and Company, Indianapolis, IN, USA; 7 Miller School of Medicine/Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

ANTHRACYCLINE-BASED VERSUS GEMCITABINE-BASED ADJUVANT CHEMOTHERAPY IN FIGO STAGE 1 UTERINE LEIOMYOSARCOMA

Roberta Sanfilippo; Rosanna Mancari; Sara Manglaviti; Giorgio Bogani; Domenica Lorusso; Elena Fumagalli; Rossella Bertulli; Angelo Paolo Dei Tos; Paola Collini; Francesco Raspagliesi; Nicoletta Colombo; Paolo Casali

1 Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 2 Gynaecology department, IEO, Milan, Italy; 3 General Hospital Treviso, Trevisto, Italy

EUROPEAN PHASE I/II TRASTS TRIAL OF TRABECTEDIN PLUS RADIOTHERAPY IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA (STS): A COLLABORATIVE SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) SARCOMA GROUPS STUDY

Javier Martín-Broto; Antonio Lopez-Pousa; Nadia Hindi; Josefina Cruz; Javier Peinado; Carlo Morosi; Josep Isern Verdu; Maria Carmen Dolado; Rosa María Alvarez Alvarez; Ana Alvarez González; Tiziana Venesio; Marco Gatti; Pablo Luna Fra; Ignacio Alastuey; Jean-Yves Blay; Marie-Pierre Sunyach; Alessandro Gronchi; Jesus Romero

1 Institute of Biomedicine Research (IBIS)- University Hospital Virgen del Rocio/CSIC/University of Seville, Seville, Spain; 2 Hospital Sant Pau, Barcelona, Spain; 3 University Hospital of Canary Islands, Santa Cruz De Tenerife, Spain; 4 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 5 University Hospital Gregorio Marañon, Madrid, Spain; 6 Candilo Cancer Institute- FPO, IRCCS, Candiolo, Italy; 7 University Hospital Son Espales, Palma de Mallorca, Spain; 8 Centre Léon Bérard, Lyon, France; 9 Hospital Puerta de Hierro, Madrid, Spain; 10 University Hospital Virgen del Rocio, Seville, Spain

Discussion – Florence Duffaud

3:30 pm - 4:00 pm Afternoon Coffee Break

4:00 pm - 6:00 pm – SESSION 3 – GIST

Moderators: Richard Riedel and Sebastian Bauer

MULTICENTRIC RETROSPECTIVE ANALYSIS OF PATIENTS WITH KIT EXON 9 MUTATED GIST

Almudena Callejo Goena; Sara Faouzi; Olivier Bouche; Thomas Chevalier; Nicolas Isambert; Florence Duffaud; Olivier Collard; Nicolas Penel; Olivier Mir; Philippe Terrier; Jean-Yves Blay; Axel Le Cesne

1 Medical Oncology, Cruces University Hospital, Barakaldo, Bizkaia, Spain; 2 Medical Oncology, Gustave Roussy Institute, Villejuif, France; 3 Digestive Oncology, Chu Robert Debre, Reims, France; 4 Medical Oncology, Chu La Timone and Aix Marseille Universite (Amu), Marseille, France; 5 Department of Early Clinical Trials, Centre Georges-François Leclerc, Dijon, France; 6 Medical Oncology, Institut De Cancérologie De La Loire – Lucien Neuwirth, La Loire, France; 7 Medical Oncology, Oscar Lambret Center, Lille, France; 8 Department Of Pathology, Gustave Roussy Institute, Villejuif, France; 9 Medical Oncology, Centre Leon Berard, Lyon, France
Paper 011 3041313
A WEB-BASED SURVEY OF PERCEIVED COGNITIVE IMPAIRMENTS AND OTHER PATIENT-REPORTED OUTCOMES IN GIST PATIENTS
Robert Ferguson1; Jessica Manculich1; Hsuan Chang2; Beth Snitz3; Dana Bovbjerg4; Anette Duensing5
1Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Dept. of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; 3Dept. of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 4Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Dept. of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 5Cancer Therapeutics Program, UPMC Hillman Cancer Center, Dept. of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Paper 012 3027631
AVAPRITINIB IS HIGHLY ACTIVE AND WELL-TOLERATED IN PATIENTS (PTS) WITH ADVANCED GIST DRIVEN BY DIVERSE VARIETY OF ONCOGENIC MUTATIONS IN KIT AND PDGFRA
Michael Heinrich1; Margaret von Mehren2; Robin L. Jones3; Sebastian Bauer4; Yoon-Koo Kang5; Patrick Schöffski6; Ferry Eskens7; Cesar Serrano8; Philippe Cassier9; Olivier Mir10; William D. Tap11; Piotr Rutkowski12; Jonathan Trent13; Shreyas Kumar Patel14; Sant P. Chawla15; Teresa Zhou16; Tamieka Lauz17; Oleg Schmidt-Kittler18; Khalid K. Mamlouk19; Beni B. Wolf20; Suzanne George21
1OHSU Knight Cancer Institute, Portland, OR, USA; 2Fox Chase Cancer Centre, Philadelphia, PA, USA; 3University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; 4Erasmus MC Cancer Institute, Rotterdam, Netherlands; 5Vall d’ Hebron Institute of Oncology, Barcelona, Spain; 6Centre Léon Bérard, Lyon, France; 7Institut Gustave Roussy; Edouard Vaillant Villejuif, Villejuif, France; 8Memorial Sloan Kettering Cancer Centre, New York, NY, USA; 9Maria Sklodowska-Curie Institute - Oncology Center, Warszawa, Poland; 10Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; 11MD Anderson Cancer Center, Houston, TX, USA; 12Sarcoma Oncology Centre, Santa Monica, CA, USA; 13Blueprint Medicines Corporation, Cambridge, MA, USA; 14OHSU, Portland, OR, USA; 15University Miami, Miami, FL, USA

Paper 013 3033840
INITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFRAINHIBITOR, IN PATIENTS (PTS) WITH GASTROINTESTINAL Stromal Tumor (GIST) BY NUMBER OF PRIOR REGIMENS
Suzanne George1; Michael Heinrich10; Ping Chi4; Albiruni Razak5; Margaret von Mehren6; Michael Gordon7; Kristen Ganjoo8; Neeta Somaiah8; Jonathan Trent11; Julie Wolf9; Rodrigo Ruiz-Soto1; Oliver Rosen1; Filip Janku8
1Deciphera, Waltham, MA, USA; 2Stanford University, Palo Alto, CA, USA; 3Dana-Farber Cancer Institute, Boston, MA, USA; 4MSKCC, New York, NY, USA; 5Princess Margaret Cancer Centre, Toronto, ON, Canada; 6Fox Chase Cancer Center, Philadelphia, PA, USA; 7Pinnacle Oncology Hematology, Scottsdale, AZ, USA; 8MDACC, Houston, TX, USA; 9Biostats Consultants, Denver, CO, USA; 10OHSU, Portland, OR, USA; 11University Miami, Miami, FL, USA

Discussion – Victor Villalobos

Paper 014 3041747
NON-INVASIVE DETECTION OF CTDNA REVEALS INTRATUMOR HETEROGENEITY AND IS ASSOCIATED WITH TUMOR BURDEN IN GASTROINTESTINAL Stromal Tumor
Boye Kjetil1; Heidi Namlos2; Skyler J. Mishkin3; Tale Baray3; Susanne Lorenz2; Bodil Bjerkehagen2; Eva Stratford2; Else Munthe2; Brian A. Kudlow2; Ola Myklebost2; Leonardo A. Meza-Zepeda2
1Department of Oncology, Oslo University Hospital, Oslo, Norway; 2Department of Tumor Biology, Oslo University Hospital, Oslo, Norway; 3Archer DX, Inc., Boulder, CO, USA; 4Genomics Core Facility, Oslo University Hospital, Oslo, Norway; 5Department of Pathology, Oslo University Hospital, Oslo, Norway
Utility of Circulating Tumor DNA (ctDNA) in the Management of Patients with Gastrointestinal Stromal Tumor (GIST): Analysis of 184 Patients

Junaid Arshad1; Breelyn A. Wilky1; Ali Roberts2; Becky Nagy2; Jonathan Trent1

1Sarcoma Medical Oncology, Sylvester Comprehensive Cancer Center, Miami, FL, USA; 2Guardant Health, Redwood City, CA, USA

Clinical Value of ct-DNA in Localized and Advanced GIST: Cross-Validation of Amplicon-Based NGS with DD-PCR in Matched Tissue and Plasma Samples

Cesar Serrano1; Ana Vivancos5; Antonio Lopez-Pousa12; Judit Matito5; Francesco M. Mancuso5; Claudia Valverde11; Sergi Quiroga4; Stefania Landolfi2; Sandra Castro7; Cristina Dopazo7; Ana Sebio12; Anna C. Virgili Manrique12; Maria M Menso6; Javier Martin-BROTO6; Alfonso Garcia-Valverde10; Jordi Rosell10; Jonathan A. Fletcher3; Suzanne George4; Joan Carles11; Joaquin Arribas10

1Preclinical Research Program and Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO); Vall d’Hebron University Hospital, Barcelona, Barcelona, Spain; 2Pathology, Vall d’Hebron University Hospital, Barcelona, Spain; 3Pathology, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA; 4Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 5Genomic Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 6Radiology, Vall d’Hebron University Hospital, Barcelona, Spain; 7Surgical Oncology Division, Vall d’Hebron University Hospital, Barcelona, Spain; 8Radiology, Sant Pau Hospital, Barcelona, Spain; 9Medical Oncology, Virgen del Rocío Hospital, Sevilla, Spain; 10Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 11Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain; 12Medical Oncology, Sant Pau Hospital, Barcelona, Spain

Discussion – Bartosz Chmielowski

6:00 pm - 7:00 pm Poster Viewing Reception Salon de Cavalieri 1 & Gallery
Friday, 16 November, 2018

6:00 am - 6:00 pm  Registration  Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am  Coffee and Posters  Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am  Executive Committee Meeting  San Giovanni

8:00 am - 10:00 am  – SESSION 4 –  Salon del Cavalieri 2,3,4

**Soft Tissue Sarcoma: Targeted Therapy**

Moderators: Thierry Alcindor and Robin Jones

---

**Paper 017**

3016595

**PROSPECTIVE TRIAL OF CRIZOTINIB (C) IN PATIENTS (PTS) WITH ADVANCED, INOPERABLE INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMFT) WITH AND WITHOUT ALK ALTERATIONS: EORTC PHASE II STUDY 90101 “CREATE”**

Patrick Schöffski1; Jozef Suljarsky2; Hans Gelderblom3; Jean-Yves Blay4; Sandra Strauss5; Silvia Stacchiotti6; Piotr Rutkowski7; Lars Lindner1; Michael Leahy12; Antoine Italiano13; Maria Debic-Rychter14; Raf Sciot4; Sandrine Marreaud5; Axelle Nzokirantevye4; Agnieszka Wozniak6; 1General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; 2Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; 3Department of Pathology, University Hospitals Leuven, Leuven, Belgium; 4European Organisation for Research and Treatment of Cancer, Brussels, Belgium; 5Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium; 6Université Cl. Bernard Lyon 1, Centre Léon Bérard, Lyon, France; 7Department of Oncology, University College London Hospitals NHS Trus, London, United Kingdom; 8Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; 9Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland; 10Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; 11The Christie NHS Foundation Trust, Manchester, United Kingdom; 12Institut Bergonie, Bordeaux, France; 13Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium

---

**Paper 018**

3006132

**ACTIVITY AND SAFETY OF CRIZOTINIB IN PATIENTS WITH ADVANCED CLEAR CELL SARCOMA (CCSA) WITH MET ALTERATIONS. EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PHASE 2 TRIAL 90101 “CREATE”**

Patrick Schöffski1; Agnieszka Wozniak6; Silvia Stacchiotti2; Piotr Rutkowski7; Jean-Yves Blay6; Lars Lindner1; Sandra Strauss5; Alan Anthoney12; Florence Duffaud14; Stephan Richter13; Raf Sciot4; Debic-Rychter Maria10; Sandrine Marreaud5; Laurence Collette1; Sebastian Bauer11; 1General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; 2Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium; 3Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; 4Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 5Université Claude Bernard Lyon Institute, Centre Léon Bérard, Lyon, France; 6Department of Pathology, University Hospitals Leuven, Leuven, Belgium; 7European Organisation for Research and Treatment of Cancer, Brussels, Belgium; 8Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; 9Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany; 10Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, United Kingdom; 11University Cancer Center/Medical Dept, University Hospital Carl Gustav Carus, Dresden, Germany; 12Medical Oncology Unit, La Timone University Hospital, Marseille, France
MILADEMETAN, AN ORAL MDM2 INHIBITOR, IN WELL-DIFFERENTIATED/DE-DIFFERENTIATED LIPOSARCOMA: RESULTS FROM A PHASE 1 STUDY IN PATIENTS WITH SOLID TUMORS AND LYMPHOMAS

Mrinal Gounder1; Todd M. Bauer2; Gary K. Schwartz4; Amy M. Weise5; Patricia LoRusso5; Prasanna Kumar4; Shuquan Chen6; Jeannie Mendell6; Jarema Kochan4; Oleg Zernovak4; David S. Hong7
1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA; 2Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA; 3Columbia University Medical Center, New York, NY, USA; 4Karmanos Cancer Institute, Detroit, MI, USA; 5Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, USA; 6Daichi Sankyo, Inc., Basking Ridge, NJ, USA; 7The University of Texas MD Anderson Cancer Center, Houston, TX, USA

PHASE 2 STUDY OF THE CDK4 INHIBITOR ABEMACICLIB IN DEDIFFERENTIATED LIPOSARCOMA

Mark A. Dickson1; Sandra D’Angelo1; Mrinal Gounder1; Mary L. Keohan1; Ciara M. Kelly1; Ping Chi1; Cristina Antonsecu4; Jonathan Landa2; Li-Xuan Qin3; Andrew Koff6; Aimee M. Crago3; Sam Singer3; William D. Tap1
1Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Radiology, Memorial Sloan Kettering, New York, NY, USA; 3Surgery, Memorial Sloan Kettering, New York, NY, USA; 4Pathology, Memorial Sloan Kettering, New York, NY, USA; 5Biostatistics, Memorial Sloan Kettering, New York, NY, USA; 6Molecular Biology, Sloan Kettering Institute, New York, NY, USA

PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA

Geraldine O’Sullivan Coyne1; Elad Sharon2; Nancy Moore1; Robert Meehan3; Naoko Takebe4; Lamin Juwara4; Laurence Rubinstein2; William Read2; Richard F. Riedel1; Priscilla Merriam2; James Hu4; Melissa Burgess4; James Doroshow2; Alice Chen1
1Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; 2Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA; 3Moderna Therapeutics, Cambridge, MA, USA; 4National Cancer Institute, Bethesda, MD, USA; 5Emory Cancer Center, Atlanta, GA, USA; 6University of Southern California, Los Angeles, CA, USA; 7Duke University School of Medicine, Durham, NC, USA; 8Dana Farber Cancer Institute, Boston, MD, USA; 9UPMC Hillman Cancer Center, Pittsburgh, PA, USA

EZH2 INHIBITOR TAZEMETOSTAT (TAZ) INTERIM DATA IN ADULTS AND PEDIATRIC PATIENTS WITH INI1-NEGATIVE SOFT-TISSUE SARCOMAS (STS) INCLUDING EPITHELIODE SARCOMA (ES) (NCT02601950, NCT02601937)

Mrinal Gounder1; Patrick Schöffski2; Silvia Stacchiotti3; Victor Villalobos4; Rashmi Chugh5; Mark Agulnik6; Steven Attia7; Tom Wei-Wu Chen8; Gupta Abha9; Thierry Jahan10; Robin Jones11; Antoine Italiano12; Jean-Yves Bley12; Gregory M. Cote13; George Demetri14; Elizabeth Loggers15; Ravin Ratan16; Maryam Fouladi17; Margaret Macy18; Guy Makin19; Alicia Clawson20; Scott Daigle20; Chelsea Mencio20; Inbal Sapir20; Franck Bourdeaut21
1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; 3Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 4University of Colorado, Denver, CO, USA; 5Michigan Medicine Comprehensive Cancer Center, Ann Arbor, MI, USA; 6Northwestern Memorial Hospital, Chicago, IL, USA; 7Mayo Clinic in Florida, Jacksonville, FL, USA; 8National Taiwan University Hospital, Taipei City, Japan; 9Princess Margaret Hospital, Toronto, ON, Canada; 10University of California, San Francisco, CA, USA; 11Institut Bergonie, Bordeaux, France; 12Centre Léon Bérard, Lyon, France; 13Massachusetts General Hospital, Boston, MA, USA; 14Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA; 15Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 16MD Anderson Cancer Center, Houston, TX, USA; 17Children's Hospital of Cincinnati, Cincinnati, OH, USA; 18Children's Hospital Colorado, Aurora, CO, USA; 19University of Manchester, Manchester, United Kingdom; 20Epizyme, Cambridge, MA, USA; 21Curie Institute, Paris, France; 22The Royal Marsden Hospital and Institute for Cancer Research, London, United Kingdom
Friday, 16 November, 2018

Paper 023 3029169

ACTIVITY OF LAROTRECTINIB IN SARCOMA PATIENTS WITH TRK FUSION CANCER
Noah Federman1; Daniel Orbach2; Shivaani Kummar3; Alexander Drilon4; Ulrik Lassen5; Birgit Geoerger6; Cornelis M. van Tillburg1; Theodore W. Laetsch3; Steven DuBois4; Ramamoorthy Nagasubramanian10; Neerav Shukla6; Michela Casanova11; Soledad Gallego12; Stefan Bielack13; Atrayee Basu-Mallick14; Mohamad Farid15; Jyoti Patel16; Vicki Keedy17; Scott Cruickshank18; Nora C. Ku18; Michael C. Cox18; Alberto Pappo19; George Demetri20; Douglas Hawkins21
1Departments of Pediatrics and Orthopaedics, Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA, USA; 2SIREDO Oncology Center, Institut Curie, PSL University, Paris, France; 3Stanford Cancer Center, Palo Alto, CA, USA; 4Memorial Sloan Kettering Cancer Center, New York, NY, USA; 5Rigshospitalet, Copenhagen, Denmark; 6Gustave Roussy Cancer Center, Villejuif, France; 7Hopp Children’s Cancer Center at the NCT Heidelberg (KitZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany; 8University of Texas Southwestern Medical Center/Children’s Health, Dallas, TX, USA; 9Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA; 10Nemours Children’s Hospital, Orlando, FL, USA; 11Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 12Hospital Universitario Vall d’Hebron, Barcelona, Spain; 13Olghospital, Klinikum Stuttgart, Stuttgart, Germany; 14Thomas Jefferson University, Philadelphia, PA, USA; 15National Cancer Centre, Singapore, Singapore; 16University of Chicago, Chicago, IL, USA; 17Vanderbilt University School of Medicine, Nashville, TN, USA; 18Loxo Oncology Inc., South San Francisco, CA, USA; 19St Jude Children’s Research Hospital, Memphis, TN, USA; 20Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; 21Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Discussion – Neeta Somaiah

10:00 am - 10:30 am  Morning Coffee Break  Salon de Cavalieri 1 & Gallery

10:30 am - 11:00 am  Presentation of Young Investigator Awards  Salon del Cavalieri 2,3,4

Paper 036 3035962

SLFN11 IS A SIGNIFICANT DETERMINANT OF PARP INHIBITOR SENSITIVITY IN PEDIATRIC SARCOMAS
Jessica Garrell; Marcia M. Mellado-Lagarde; Jia Xie; Brandon Bianski; Kaley Blankenship; Michael Clay; Armita Bahrami; Sara Federico; Christopher L. Tinkle; Elizabeth Stewart; Anang Shelat
St. Jude Children’s Research Hospital, Memphis, TN, USA

Paper 021 3042818

PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA
Geraldine O’Sullivan Coyne1; Elad Sharon2; Nancy Moore3; Robert Meehan1; Naoko Takebe1; Lamin Juwara4; Laurence Rubinstein2; William Read2; Richard F. Riedel3; Priscilla Merriam3; James Hu4; Melissa Burgess3; James Doroshow1; Alice Chen1
1Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; 2Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA; 3Moderna Therapeutics, Cambridge, MA, USA; 4National Cancer Institute, Bethesda, MD, USA; 5Emory Cancer Center, Atlanta, GA, USA; 6University of Southern California, Los Angeles, CA, USA; 7Duke University School of Medicine, Durham, NC, USA; 8Dana Farber Cancer Institute, Boston, MD, USA; 9UPMC Hillman Cancer Center, Pittsburgh, PA, USA
### How Molecular Discoveries Changed our Morphology-Based Profession

**Cristina Antonescu**  
*(Memorial Sloan Kettering Cancer Center, New York, NY)*

### Benign and Intermediate Grade Bone/Soft Tissue Lesions

**Moderators:** William Tseng and Katherine Thornton

| Paper | 3042858 | RISK FACTORS IN TENOSYNOVIAL GIANT CELL TUMOURS OF LARGE JOINTS, EVALUATED IN 30 INTERNATIONAL SARCOMA CENTERS  | Monique Mastboom; Emanuela Palmerini; Floortje Verspoor; Anja Rueten-Budde; Silvia Stacchiotti; Eric Staals; Gerard Schaap; Paul Jutte; Will Aston; Andreas Leithner; Dietmar Dammerer; Akihiko Takeuchi; Quirina Thio; Xiaohui Niu; Jay Wunder; Michiel A. van de Sande Orthopaedics oncology, Leiden University Medical Center, Amsterdam, Noord Holland, Netherlands |
| Paper | 3038487 | POSITIVE ASSOCIATION BETWEEN TUMOR RESPONSE AND PATIENT-REPORTED OUTCOMES IN PHASE 3 ENLIVEN STUDY OF PEXIDARTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT) | Heather L. Gelhorn¹; Charles Peterfy²; Xin Ye³; Rebecca M. Speck⁴; Emanuela Palmerini⁵; Silvia Stacchiotti⁶; Jayesh Desai⁷; Andrew Wagner⁸; Thierry Alcindor⁹; Kristen Ganjoo¹⁰; Javier Martin-Broto¹¹; Christopher Ryan¹²; Qiang Wang¹³; Dale Shuster¹⁴; William D. Tap¹⁵; Hans Gelderblom¹⁶ |
| Paper | 3042414 | PRIMARY VASCULAR TUMORS OF BONE: AN ANALYSIS OF 427 PATIENTS | Marta Sbaraglia¹; Alberto Righi²; Marco Gambarotti³; Dino Gibertoni³; Stefania Benini³; Piero Picci³; Angelo Paolo Dei Tos¹ |

---

Paper 027

PHASE II TRIAL OF PAZOPANIB IN ADVANCED EXTRASKELETAL MYXOID CHONDROSARCOMA. A COLLABORATIVE SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) SARCOMA GROUPS STUDY

Silvia Stacchiotti1; Stefano Ferrari2; Antonio Redondo3; Emanuela Palmerini2; Nadia Hindi4; Maria A. Vaz5; Anna Maria Frezza1; Antonio Gutierrez2; Antonio Lopez-Pousa6; Tiziana Venesio7; Antoine Italiano8; Sarah N. Dumont9; Jean-Yves Blay10; Nicolas Penel11; Daniel Bernabeu12; Enrique De Alava13; Dominique Ranchere-Vince10; Gian Paolo Dagrada1; Paola Collini1; Josefina Cruz14; Javier Martín-Broto15

1Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2Cancer Medicine, Istituto Ortopedico Rizzoli, Bologna, Italy; 3Cancer Medicine, La Paz Institute for Health Research, Madrid, Spain; 4University Hospital Virgen del Rocio, Sevilla, Spain; 5Hospital Universitario Ramón y Cajal, Cajal, Spain; 6Hospital Universitario Son Espases, Palma, Spain; 7Cancer Medicine, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; 8Institut Bergonie, Bordeaux, France; 9Cancer Medicine, Goustitte Roussy, Villejuif, France; 10Centre Léon Bérard, Lyon, France; 11Centre Oscar Lambret, Lille, France; 12Radiology, University Hospital La Paz, Madrid, France; 13Institute of Biomedicine of Sevilla, Sevilla, Spain; 14University Hospital of Canarias, Tenerife, Spain; 15Sant Pau Hospital, Barcelona, Spain

Discussion – Paolo Casali

---

Paper 028

LONGITUDINAL DISTRESS ASSESSMENT AND RESPONSE TOOL (DART) SCREENING IN ADULTS WITH AGGRESSIVE FIBROMATOSIS: HIGH PREVALENCE OF PERSISTENT EMOTIONAL DISTRESS

Abha Gupta1; Nicole Byers1; Sally Burtenshaw2; Katrina Inglely2; Carol Swallow2; Savtaj Brar2; Anthony M. Griffin2; Peter Ferguson2; Jay Wunder2; Albiruni Razak1; Rebecca Gladdy2; Roberta Klein3; Madeline Li3

1Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada; 2Surgery, Mount Sinai Hospital, Toronto, ON, Canada; 3Psychiatry, Princess Margaret Cancer Center, Toronto, ON, Canada

---

Paper 029

CAN WAIT AND SEE BE THE STANDARD OF CARE FOR INITIAL APPROACH TO PRIMARY SPORADIC DESMOID TUMORS? PRELIMINARY DATA FROM AN ITALIAN SARCOMA GROUP PROSPECTIVE STUDY

Chiara Colombo1; Marco Fiore1; Tiziana Venesio2; Erica Palesandro2; Paola Boccone2; Lorenzo D’Ambrosio2; Alba Bianco1; Paola Collini1; Elena Palassini1; Silvia Stacchiotti1; Angelo Paolo Dei Tos1; Paolo Casali1; Federica Perrone1; Alessandro Gronchi1

1Fondazione IRCCS Istituto Tumori Milano, Milan, Italy; 2IRCCS Istituto Candiolo, Torino, Italy; 3Ospedale di Treviso, Treviso, Italy

Discussion – Bernd Kasper

---

Paper 030

INCORPORATION OF CTNNB1 MUTATION STATUS INTO A PRE-OPERATIVE DESMOID LOCAL RECURRENCE NOMOGRAM IMPROVES PREDICTIVE VALUE

Iris Wei1; Anthony Villano1; Andrea Knezovic2; Bhumika Jadeja1; Li-Xuan Qin2; Meera Hameed1; Sam Singer1; Aimee M. Crago1

1Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Discussion – Bernd Kasper

---

3:30 pm - 4:00 pm Afternoon Coffee Break

Salon de Cavalieri 1 & Gallery
<table>
<thead>
<tr>
<th>Paper</th>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>031</td>
<td>3027408</td>
<td><strong>EASY-TO-USE PRACTICAL CLINICAL TOOL FOR SURVIVAL ESTIMATION IN EWING SARCOMA AT DIAGNOSIS AND AFTER SURGERY</strong></td>
<td>Sarah E. Bosma; Carlo Lancia; Anja J. Rütten-Budde; Andreas Ranft; Hans Gelderblom; Marta Fiocco; Michiel A. van de Sande; Sander Dijkstra; Uta Dirksen</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Moderators: Abha Gupta and Piero Picci</strong></td>
<td></td>
</tr>
<tr>
<td>032</td>
<td>3042243</td>
<td><strong>RETROSPECTIVE ANALYSIS OF USE OF WHOLE LUNG IRRADIATION FOR PATIENTS WITH NEWLY DIAGNOSED EWING SARCOMA AND PULMONARY METASTASES</strong></td>
<td>Hadeel Halalsheh; Sue Kaste; Matthew J. Krasin; April Sykes; Natasha Sahr; Sheri Spunt; Sara Federico; Alberto Pappo; Michael W. Bishop</td>
</tr>
<tr>
<td>033</td>
<td>3042780</td>
<td><strong>WHOLE-LUNG IRRADIATION AFTER HIGH-DOSE BUSULFAN/MELPHALAN CONDITIONING THERAPY IN EWING SARCOMA WITH LUNG METASTASES: A MULTICENTRIC STUDY</strong></td>
<td>Massimo E. Abate; Letizia Ronchi; Barbara Diletto; Lorenza Gandola; Nadia Puma; Angela Tamburin; Maurizio Mascarin; Elisa Coassin; Arcangelo Prete; Sebastian Asaftei; Carla Manzitti; Luca Coccoli; Mariella Capasso; Tiziana Venesio; Emilia Pecori; Marta Pierobon; Anna Paioli; Elisa Carretta; Giovanni Piero Frezza; Alessio Giuseppe Morganti; Stefano Ferrari; Piero Picci; Alessandra Longhi; Silvia Cammelli; Roberto Luksch</td>
</tr>
<tr>
<td>034</td>
<td>3042627</td>
<td><strong>THE WNT-DEPENDENT SECRETOME ALTERS TUMOR: TUMOR MICROENVIRONMENT CROSSTALK TO PROMOTE INVASION AND ANGIogenesis IN EWING SARCOMA</strong></td>
<td>Allegra Hawkins; Elisabeth Pedersen; Sonja Konzen; Colin Sperring; Sydney Treichel; Elizabeth Lawlor</td>
</tr>
</tbody>
</table>
Paper 035  3042245
A PHASE I STUDY OF THE POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITOR, NIRAPARIB (NIR), IN COMBINATION WITH IRINOTECAN (IRN) IN PATIENTS WITH ADVANCED EWING SARCOMA: RESULTS OF SARC025 ARM 2
Sandra J. Strauss1; Karla V Ballman2; Kam Zaki1; Lee Helman3; Brigitte Widemann4; Douglas Hawkins5; Leo Mascarenhas6; J.W Glod7; Jay Ji8; Ziping Zhang8; Birgit Geoerger7; Jeremy Whelan1; Denise Reinke8; Shreyaskumar Patel9; Rashmi Chugh10
1University College London Hospitals NHS Trust, London, United Kingdom; 2Weill Cornell Medicine, New York, NY, USA; 3Children’s Center for Cancer and Blood Diseases, Los Angeles, CA, USA; 4National Cancer Institute Centre for Cancer Research, Bethesda, MD, USA; 5Seattle Children’s Hospital, Seattle, OR, USA; 6National Clinical Target Validation Laboratory, Bethesda, MD, USA; 7Institut Gustave Roussy, Paris, France; 8SARC, Ann Arbor, MI, USA; 9MD Anderson, Houston, TX, USA; 10University of Michigan, Ann Arbor, MI, USA

Paper 036  3035962
SLFN11 IS A SIGNIFICANT DETERMINANT OF PARP INHIBITOR SENSITIVITY IN PEDIATRIC SARCOMAS
Jessica Gartrell; Marcia M. Mellado-Largarde; Jia Xie; Brandon Bianski; Kaley Blankenship; Michael Clay; Armita Bahrami; Sara Federico; Christopher L. Tinkle; Elizabeth Stewart; Anang Shelat
St. Jude Children’s Research Hospital, Memphis, TN, USA

Paper 037  3027426
INNOVATIVE TARGETED THERAPY FOR EWING SARCOMA
Shunya Ohmura1; Martin F. Orth1; Aruna Marchetto1; Stefanie Stein1; Julia S. Gerke1; Giuseppina Sannino1; Julian Musa1; Fabienne Wehweck1; Maximilian M. Knott1; Jing Li1; Tilman Hölting1; Laura Romero-Pérez1; Florencia Cidre-Aranaz1; Horacio Bach2; Wolfgang Hartmann2; Uta Dirksen4; Thomas Kirchner5; Thomas G. Grünewald6
1Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; 2Department of Medicine, Division of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada; 3Gerhard-Domagk Institute of Pathology, University Hospital of Muenster, Muenster, Germany; 4Division of Hematology and Oncology, Department of Pediatrics III, West German Cancer Centre, University Hospital Essen, Essen, Germany; 5Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany; 6Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany

Discussion – Stephen Lessnick

7:00 pm - 10:00 pm Gala – Reception and Dinner at the beautiful Villa Miani next door to the Cavalieri Hotel. Cocktail Attire

Villa Miani
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am - 5:30 pm</td>
<td>Registration</td>
<td>Salon de Cavalieri 1 &amp; Gallery</td>
</tr>
<tr>
<td>7:00 am - 8:00 am</td>
<td>Coffee and Posters</td>
<td>Salon de Cavalieri 1 &amp; Gallery</td>
</tr>
<tr>
<td>8:00 am - 9:00 am</td>
<td><strong>– POSTER DISCUSSION –</strong></td>
<td>Salon del Cavalieri 2,3,4</td>
</tr>
</tbody>
</table>

### Circulating Tumor DNA – Brian Crompton

**Poster 127** 3042631  
PILOT STUDY EVALUATING THE CONCORDANCE OF CIRCULATING TUMOR DNA ALTERATIONS WITH TUMOR-BASED SEQUENCING IN SOFT TISSUE SARCOMA  
Bryce Demoret¹; Sherri Z. Millis²; Gabriel Tinoco¹; David Liebner¹; James L. Chen¹  
¹The Ohio State University, Columbus, OH, USA; ²Foundation Medicine, Cambridge, MA, USA

**Poster 128** 3042674  
CIRCSARC; NON-INVASIVE MONITORING OF SARCOMAS PATIENTS BY CIRCULATING TUMOUR DNA IN PLASMA  
Heidi M. Namloës¹; Seyed Hossein Moosavi¹; Bodil Bjerkehagen⁴; Olga Zaikova³; Susanne Lorenz⁴; Lars Aasheim⁴; Eivind Hovig¹; Nina L. Jebsen⁴; Ola Myklebost⁴; Boye Kjetil¹; Leonardo A. Meza-Zepeda¹  
¹Department of Tumor Biology, Oslo University Hospital, Oslo, Norway; ²Department of Pathology, Oslo University Hospital, Oslo, Norway; ³Department of Surgery, Oslo University Hospital, Oslo, Norway; ⁴Department of Oncology, Haukeland University Hospital, Bergen, Norway; ⁵Department of Clinical Science, University of Bergen, Bergen, Norway; ⁶Department of Oncology, Oslo University Hospital, Oslo, Norway

**Poster 129** 3042933  
ULTRA-SENSITIVE DETECTION OF TRANSLOCATIONS IN THE CELL-FREE DNA OF PEDIATRIC SARCOMA PATIENTS  
Avanthi T. Shah¹; Tej Azad²; Jake Chabon³; Stan Leung¹; Aviv Spillinger¹; Heng-Yi Liu¹; Marcus Breese¹; Maximilian Diehn⁴; Ash A. Alizadeh⁴; Alejandro Sweet-Cordero¹  
¹Pediatrics, UCSF, San Francisco, CA, USA; ²Stanford University School of Medicine, Stanford, CA, USA; ³Stanford Cancer Institute, Stanford, CA, USA

**Poster 130** 3043078  
NONINVASIVE MOLECULAR PROFILING AND RESPONSE MONITORING BY CELL-FREE DNA ANALYSIS IN OSTEOSARCOMA  
Emily Slotkin¹; Julie Yang²; Dana Tsui²  
¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Poster 132** 3042854  
TREATMENT MONITORING IN PATIENTS WITH PEDIATRIC SARCOMAS USING CIRCULATING TUMOR DNA ANALYSIS: A FEASIBILITY STUDY  
Jun Zhao¹; Braden McDonald³; Tania Contente-Cuomo³; Ahuva Odenheimer²; Michelina de la Maza¹; Pooja Hingorani¹; Muhammed Murtaza²  
¹Pediatric Hematology/Oncology, Phoenix Children’s Hospital, Phoenix, AZ, USA; ²Center for Non-invasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ, USA
Geonomics – Roberta Maestro

Poster 182 3042599

DISCOVERY AND CHARACTERIZATION OF RECURRENT, TARGETABLE ALK FUSIONS IN LEIOMYOSARCOMA
Lara E. Davis¹; Kevin Nusser¹; Joanna Przybyl²; Janet Pittsenbarger¹; Nicole Hofmann¹; Sushama Varma³; Sujay Vennami³; Maria Debie-Rychter³; Matt van de Rijn³; Monika Davare¹
¹Oregon Health & Science University, Portland, OR, USA; ²Stanford University, Stanford, CA, USA; ³KU Leuven, Leuven, Belgium

Poster 183 3014793

GENOME INFORMED THERAPY FOR OSTEOSARCOMA
Leanne Sayles¹; Marcus Breese¹; Amanda Koehne¹; Stan Leung¹; Avanthi T. Shah¹; Sheri Spunt²; Steven Dubois³; Douglas Hawkins³; Alejandro Sweet-Cordero¹
¹Pediatrics, University of California San Francisco, San Francisco, CA, USA; ²Pediatrics, Stanford University, San Francisco, CA, USA; ³Pediatrics, University of Washington, Seattle, WA, USA

Poster 185 3042669

COMPREHENSIVE GENOMIC PROFILING OF SYNOVIAL SARCOMAS IDENTIFIES GENOMICALLY DEFINED SUBGROUPS WITH CHARACTERISTIC ALTERATION PATTERNS
Sherri Z. Millis¹; Peter Vorenkamp³; Petra Vorenkamp³; Jeffrey Ross¹; Siraj Ali¹; Sally Trabucco¹; James L. Chen²
¹Foundation Medicine, Inc., Phoenix, AZ, USA; ²The Ohio State University, Columbus, OH, USA; ³Live For Others Foundation, Laguna Beach, CA, USA

Poster 186 3042566

THE FUSION LANDSCAPE AND ACTIONABLE ALTERATIONS OF SARCOMA REVEALED BY “REAL WORLD” GENOMIC SEQUENCING
Jason Roszik¹; Anthony P. Conley¹; Roman Groisberg¹; Roberto Carmagnani Pestana¹; Shiraj Sen¹; Vivek Subbiah¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Poster 188 3042711

UTILITY OF FOUNDATIONONE HEME PROFILING IN SARCOMA: INSTITUTIONAL EXPERIENCE AND CLINICAL OUTCOMES
Adrienne Victor¹; Deepak Sahasrabudhe¹; Megan Baumgart¹
¹Medical Oncology, University of Rochester, Rochester, NY, USA

Immunotherapy – Sandra D’Angelo

Poster 216 3014823

NEOADJUVANT THERAPY INDUCES A POTENT INFLAMMATORY AND CORRESPONDING REGULATORY RESPONSE WITHIN THE SARCOMA IMMUNE MICROENVIRONMENT
Teresa Kim¹; Matthew Spraker¹; Y. David Seo¹; Kimberly Smythe²; Robert Pierce³; Taylor Hain³; Edward Y. Kim³; Gabrielle Kane³; Isaac Jenkins³; Qianchuan (Chad) He³; Seth Pollack²
¹Surgery, University of Washington, Seattle, WA, USA; ²Clinical Research Division, Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ³Radiation Oncology, University of Washington, Seattle, WA, USA; ⁴Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁵Clinical Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
RESPONSE TO SUBSEQUENT THERAPY IN NY-ESO-1 POSITIVE SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY

Sant P. Chawla; Seth Pollack; Matthew Block; Mihaela Druta; Khanh Do; John C. Morris; Joseph W. Kim; Chet Bohac; Hailing Lu; Sacha Gnjatic; Robin L. Jones; P. Hwu; Neeta Somaiah

1Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; 2Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; 3Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; 4Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 5Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; 6Medical Oncology, Yale University, New Haven, CT, USA; 7Medical Oncology, Mayo Clinic, Rochester, MN, USA; 8Clinical Development, Immune Design, South San Francisco, CA, USA; 9Science, Immune Design, Seattle, WA, USA; 10Immunology, Mt. Sinai, New York City, NY, USA; 11Medical Oncology, Royal Marsden, London, United Kingdom; 12Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 13Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

IMMUNE RESPONSE, SAFETY, AND OVERALL SURVIVAL OF NY-ESO-1+ SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY

Sant P. Chawla; Seth Pollack; Matthew Block; Mihaela Druta; Khanh Do; John C. Morris; Joseph W. Kim; Chet Bohac; Hailing Lu; Sacha Gnjatic; R. L. Jones; P. Hwu; Neeta Somaiah

1Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; 2Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; 3Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; 4Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 5Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; 6Medical Oncology, Yale University, New Haven, CT, USA; 7Medical Oncology, Mayo Clinic, Rochester, MN, USA; 8Science, Immune Design, Seattle, WA, USA; 9Immunology, Mt. Sinai, New York City, NY, USA; 10Medical Oncology, Royal Marsden, London, United Kingdom; 11Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 12Medical Oncology, Mayo Clinic, Rochester, MN, USA

ACTIVITY OF TREMELIMUMAB AND DURVALUMAB IN ADVANCED SARCOMAS: PRELIMINARY RESULTS OF A SIGNAL-SEEKING PHASE 2 TRIAL

Maya Kansara; Subotheni Thavaneswaran; John Grady; Mark Cowley; Audrey Silvestri; Mandy L. Ballinger; Elektra Hajdu; Emily Collignon; Lucille Sebastian; Katrin Sjoquist; Wendy Hague; Amy Prawira; Anthony Joshua; Charles Bailey; Ulf Schmitz; Trevor Pugh; Torsten O. Nielsen; Amanda R. Dancsok; Chee Lee; John Simes; David M. Thomas

1Cancer Genomic Medicine, Garvan Institute, Sydney, NSW, Australia; 2NHMRC Clinical Trials Centre, Sydney, NSW, Australia; 3Gene and Stem Cell Therapy Program, Centenary Institute, Sydney, NSW, Australia; 4Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; 5Vancouver Coastal Health Research Institute and Faculty of Medicine, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada

INTERFERON GAMMA MAKES “COLD” SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA “HOT”: RESULTS OF A PHASE 0 TRIAL

Shihong Zhang; Venu Pillarisetty; Lee D. Cranmer; Stanley Riddell; R. L. Jones; Seth Pollack

1Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 2Surgery, University of Washington, Seattle, WA, USA; 3Royal Marsden Hospital, London, United Kingdom
Vascular Tumors – Silvia Stacchiotti

Poster 002  3042315
PITFALLS IN ANGIOSARCOMA DIAGNOSIS: LESSONS LEARNED FROM CENTRAL REVIEW OF 657 DUTCH CASES
Marije Weidema, Melissa Hillebrandt-Roeffen, Ingrid Desar, Yvonne Versleijen-Jonkers, Winette van der Graaf, Uta Flucke
1Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands; 2Pathology, Radboud University Medical Center, Nijmegen, Netherlands

Poster 005  3037976
THE ANGIOSARCOMA PROJECT: GENERATING THE GENOMIC LANDSCAPE OF A RARE SARCOMA THROUGH A NATIONWIDE PATIENT-DRIVEN INITIATIVE
1Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; 2Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; 3Massachusetts General Hospital, Boston, MA, USA; 4Data Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; 5Brigham and Women’s Hospital, Boston, MA, USA; 6Dana-Farber Cancer Institute, Cambridge, MA, USA; 7Broad Institute of MIT and Harvard, Cambridge, MA, USA

Poster 006  3042503
A RETROSPECTIVE REVIEW OF PATIENTS WITH ANGIOSARCOMA TREATED IN BRITISH COLUMBIA
Alannah Smrke, Jeremy Hamm, Anand Karvat, Christine Simmons, Amirrtha Srikanthan
1BC Cancer, Vancouver, BC, Canada

Poster 008  3042562
NEOADJUVANT CHEMOTHERAPY ASSOCIATED WITH ENHANCED LOCAL CONTROL IN RADIATION-INDUCED ANGIOSARCOMA OF BREAST AND CHEST
Audrey Michot, Marie Karanian, Maryck Lae, Romuald Wernert, Marie-Pierre Sunyach, Dimitri Tzanis, Jean-Marie Guilloit, Maria Rios, Antoine Giraud, François Le Loarer, Jean-Yves Blay, Eberhard Stoeckle
1Surgery, Institut Bergonié, Bordeaux, France; 2Pathology, Leon Berard, Lyon, France; 3Surgery, Institut de Cancerologie de l’Ouest, Angers, France; 4Radiotherapy, Centre Leon Berard, Lyon, France; 5Surgery, Institut Curie, Paris, France; 6Surgery, Centre Francois Baclesse, Caen, France; 7Medical Oncology, Institut de Cancerologie de Lorraine, Nancy, France; 8Epidemiology and Clinical Research Unit, Institut Bergonié, Bordeaux, France; 9Pathology, Institut Bergonié, Bordeaux, France; 10Medical Oncology, Centre Leon Berard, Lyon, France; 11Pathology, Institut Curie, Paris, France
Osteosarcoma/Chondrosarcoma/Chordoma
Moderators: Vicki Keedy and Kirsten Sundby Hall

Paper 038 3042790

**STRESS MEDIATED TRANSLATIONAL CONTROL OF CHILDHOOD BONE SARCOMA METASTASIS**

Amal M. EL-Naggar; Syam Somasekharan; Hongwei Cheng; Gian Luca Negri; Didier Surdez; Olivier Delattre; Poul H. Sorensen

1Molecular Oncology, BC Cancer & University of British Columbia, Vancouver, BC, Canada; 2Vancouver Prostate Centre, Vancouver, BC, Canada; 3Canada’s Michael Smith Genome Sciences Centre, Vancouver, BC, Canada; 4Centre de recherche de l’Institut Curie, Paris, France

Paper 039 3035462

**PROSPECTIVE PHASE II STUDY OF SCANNED BEAM PROTON THERAPY FOR SPINE SARCOMAS**

David J. Konieczkowski; Yen-Lin E. Chen; Karen De Amorim Bernstein; Beow Yeap; Matthew DiMaria; Wenquin Jiang; Nannette Thomas; Suzanne L. McGovern; John T. Mullen; Joseph H. Schwab; Francis Hornicek; Thomas F. DeLaney

1Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; 2Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA; 3Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA, USA; 4Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; 5Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA; 6Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA; 7Department of Orthopedic Surgery, University of California Los Angeles, Los Angeles, MA, USA

Paper 040 2993960

**APATINIB FOR ADVANCED OSTEOSARCOMA AFTER FAILURE OF STANDARD MULTIMODAL THERAPY: AN OPEN LABEL PHASE 2 CLINICAL TRIAL (NCT02711007)**

Lu Xie; Jie Xu; Xin Sun; Xiaodong Tang; Taiqiang Yan; Rongli Yang; Wei Guo

Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, China

Paper 041 3042511

**SARC024: REGORAFENIB IN PATIENTS WITH REFRACTORY OSTEOSARCOMA**

Lara E. Davis; Christopher Ryan; John Crowley; Kristen Ganjoo; Elizabeth Loggers; Sant P. Chawla; Mark Agulnik; Michael B. Livingston; Damon Reed; Vicki Keedy; Daniel A. Rushing; Scott Okuno; Denise Reinke; Richard F. Riedel; Steven Attia; Leo Mascarenhas; Robert Maki

1Oregon Health and Science University, Portland, OR, USA; 2Cancer Research and Biostatistics, Seattle, WA, USA; 3Stanford Cancer Institute, Stanford, CA, USA; 4Seattle Cancer Care Alliance, Seattle, WA, USA; 5Sarcoma Oncology Research Center, Santa Monica, CA, USA; 6Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 7Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; 8H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 9Vanderbilt University Medical Center, Nashville, TN, USA; 10Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA; 11Mayo Clinic, Rochester, MN, USA; 12SARC, Ann Arbor, MI, USA; 13Duke University Medical Center, Durham, NC, USA; 14Mayo Clinic, Jacksonville, FL, USA; 15Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA, USA; 16Monter Cancer Center, Northwell Health and Cold Spring Harbor Laboratory, Lake Success, NY, USA
CABOZANTINIB IN PATIENTS WITH ADVANCED OSTEOSARCOMAS AND EWING SARCOMAS: A FRENCH SARCOMA GROUP (FSG)/ US NATIONAL CANCER INSTITUTE PHASE II COLLABORATIVE STUDY

Antoine Italiano; Nicolas Penel; Emmanuelle Bompas; Sophie Piperno-Neumann; Marina Pulido; Natacha Entz-Werle; Axel Le Cesne; Christine Chevreau; Florence Duffaud; Isabelle Ray-Coquard; Maud Toulmonde; Carine Bellera; Jean-Yves Blay

1 Institut Bergonié, Bordeaux, France; 2 Centre Oscar Lambret, Lille, France; 3 Institut Cancerologie de l'Ouest, Nantes, France; 4 Institut Curie, Paris, France; 5 CHU de Strasbourg, Strasbourg, France; 6 Institut Gustave Roussy, Villejuif, France; 7 Oncopole Toulouse, Toulouse, France; 8 APHM Marseille, Marseille, France; 9 Centre Leon Berard, Lyon, France

Discussion – Katherine Janeway

10:30 am - 11:00 am  Morning Coffee Break  Salon de Cavalieri 1 & Gallery

11:00 am - 12:00 pm  – NINA AXELRAD LECTURE –  Salon del Cavalieri 2,3,4

Academic Clinical Trials in Sarcomas at the Time of Genomic Revolution

Jean-Yves Blay

(Centre Léon BERARD Lyon, France)

12:00 pm - 1:00 pm  Lunch  Belle Arti & Garden Lobby

1:00 pm - 1:30 pm  Liddy Shriver Early Career Research Award  Salon del Cavalieri 2,3,4

Cigall Kadoch

1:30 pm - 3:30 pm  – SESSION 8 –  Salon del Cavalieri 2,3,4

Soft Tissue Sarcoma: Biology

Moderators: Torsten Nielsen and Poul Sorensen

WHOLE GENOME SEQUENCING OF 1,111 SARCOMA PROBANDS REVEALS POT-1 AS A SARCOMA PREDISPOSITION GENE

Mandy L. Ballinger; Mark Pinese; Emma Rath; Paul James; Ajay Puri; Nicolas Isambert; Martin Tattersall; Beatrice Seddon; Ian Judson; Winette van der Graaf; Nicolas Penel; Axel Lecesne; Coonoor Chandrasekar; Jean-Emmanuel Kurtz; Joshua Schiffman; R. Lor Randall; Florence Duffaud; Jin-Hee Ahn; Rory Rickard; Jean-Yves Blay; Isabelle Ray-Coquard; David M. Thomas

1 Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; 2 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; 3 Tata Memorial Hospital, Mumbai, India; 4 Centre Georges Francois Leclerc, Dijon, France; 5 University of Sydney, Sydney, New South Wales, Australia; 6 University College Hospital, London, United Kingdom; 7 The Royal Marsden NHS Foundation Trust, London, United Kingdom; 8 Centre Oscar Lambret, Lille, France; 9 Institute Gustave Roussy, Villejuif, France; 10 Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom; 11 Hopitaux Universitaires de Strasbourg, Strasbourg, France; 12 Huntsman Cancer Institute, Salt Lake City, UT, USA; 13 La Timone University Hospital, Marseille, France; 14 Asan Medical Centre, Seoul, Korea (the Republic of); 15 Derriford Hospital, Plymouth, United Kingdom; 16 Centre Leon Berard, Lyon, France
Paper 044 3042786
SEQCOMPLEX UNRAVELLING OMICS LANDSCAPE AND TARGETING ONCOGENIC PATHWAYS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS - AN INTEGRATED APPROACH
Maud Toulmonde¹; Damien Geneste¹; Stephanie Verbeke¹; Julien Adam²; Fabiola Cecchi³; Banafshe Larijani³; Francois Bertucci³; Florent Petitprez³; Audrey Laroche¹; Carlo Lucchesi¹; Antoine Italiano¹; Todd Hembrough³
¹Institut Bergonié, Bordeaux, France; ²Gustave Roussy, Villejuif, France; ³Nantomics, Rockville, MD, USA; ³Fastbase Solutions Ltd, Plentzia, Spain; ⁵UMRS 1138 - Centre de Recherche des Cordeliers, Paris, France; ⁶Institut Paoli Calmettes, Marseille, France

Paper 045 3010210
RATIONALES FOR TARGETING/CO-TARGETING LEIOMYSARCOMA PATHWAYS: BIOLOGIC PROFILES IN 712 UTERINE OR SOFT-TISSUE LMS
Inga-Marie Schaefer¹; Elizabeth G. Demicco²; Magdalena Matusiak³; Sebastian Bauer⁴; Frédéric Chibon⁵; Davis Ingram⁶; Jason L. Hornick¹; Wei-Lien Wang⁶; Alexander J. Lazar⁶; Matt van de Rijn⁵; Jonathan A. Fletcher³
¹Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ²Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; ³Department of Pathology, Stanford University Medical Center, Stanford, CA, USA; ⁴Department of Medical Oncology, West German Cancer Center, Essen, Germany; ⁵Centre de Recherches en Cancérologie de Toulouse, Toulouse, France; ⁶Departments of Pathology & Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Paper 046 3042897
CHROMATIN STATE TRANSITIONS ASSOCIATED WITH PRC2 FUNCTIONAL LOSS DRIVE A DE-DIFFERENTIATED PHENOTYPE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Veena Kochat¹; Ayush Raman¹; Sharon Landers¹; Christopher Terranova¹; Chia-Chin Wu²; Xizeng Mao²; Davis Ingram³; Zachary Mulder¹; Michelle Yeagley¹; Hannah Beird³; Angela Bhal¹; John Slopis³; Ian McCutcheon³; Jianhua Zhang³; Phillip Futreal³; Wei-Lien Wang³; Alexander J. Lazar³; Kunal Rai³; Kiela E. Torres¹
¹Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Genomic Medicine Department, MD Anderson Cancer Center, Houston, TX, USA; ³Pathology, MD Anderson Cancer Center, Houston, TX, USA; ⁴NeuroOncology Department, MD Anderson Cancer Center, Houston, TX, USA; ⁵NeuroSurgery Department, MD Anderson Cancer Center, Houston, TX, USA

Paper 047 3042069
TWIST BRIDGES P53 AND MDM2 AND REDUCES THE EFFICACY OF MDM2 INHIBITORS
Sara Piccinin¹; Elena Doriguzzi Breatta¹; Sara Lombardi¹; Mattia Lombardi¹; Flavia Pivetta¹; Michela Armellini¹; Camillo Rosano²; Roberta Maestro¹
¹CRO Aviano, Aviano, Italy; ²San Martino National Cancer Institute, Genova, Italy

Discussion – Judith Bovee

3:30 pm - 4:00 pm  Afternoon Coffee Break
Soft Tissue Sarcoma: Local Therapy

Moderators: Kenneth Cardona and Alessandro Gronchi

Paper 048

LONG-TERM COMPARISON OF LOCAL RECURRENCE AFTER CONVENTIONAL AND INTENSITY-MODULATED RADIATION THERAPY FOR PRIMARY SOFT TISSUE SARCOMAS OF THE EXTREMITY

Joanna C. Yang1; Michael Folkert2; Aimee M. Crago3; Sam S. Yoon3; Sam Singer3; Kaled Alektiar3
1Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA; 3Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Paper 049

CAN WE CURE PATIENTS WITH ABDOMINAL DESMOPLASTIC SMALL ROUND CELL TUMOR? RESULTS OF A RETROSPECTIVE MULTICENTRIC STUDY ON 100 PATIENTS

Charles Honoré1; Jean-Baptiste Delhomme2; Elise Nassi3; Gwenael Ferron4; Emmanuelle Bompas5; Olivier Glehen6; Antoine Italiano7; Francois Bertucci8; Daniel Orbach9; Jean-Yves Blay10; Christine Chevreau11; Olivier Mir3
1Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; 2General and Digestive Surgery, Strasbourg University Hospital, Strasbourg, France; 3Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; 4Surgery, Claudius Régaud Institute, Toulouse, France; 5Medical Oncology, West Cancer Institute, Nantes, France; 6Surgical Oncology, South Lyon University Hospital, Lyon, France; 7Medical Oncology, Bergonié Institute, Bordeaux, France; 8Medical Oncology, Paoli-Calmettes Institute, Marseille, France; 9SIREDO, Institut Curie, Paris, France; 10Medical Oncology, Centre Léon Bérard, Lyon, France; 11Medical Oncology, Claudius Régaud Institute, Toulouse, France

Paper 050

ENHANCED RECOVERY AFTER SURGERY (ERAS) IN PATIENTS UNDERGOING SURGERY FOR SOFT TISSUE SARCOMA (STS): EARLY RESULTS OF A PROSPECTIVE QUALITY IMPROVEMENT PROTOCOL

Heather Lyu1; Lily V. Saadat1; Elizabeth H. Baldini1; Jiping Wang1; Matthias Stopfkuchen-Evans1; Ronald Bleday1; Monica Bertagnolli1; Chandrajit Raut1
1Brigham and Women’s Hospital, Boston, MA, USA; 2Dana Farber Cancer Institute, Boston, MA, USA

Paper 051

DEVELOPMENT OF A DYNAMIC PROGNOSTIC NOMOGRAM TO PREDICT OVERALL SURVIVAL DURING FOLLOW-UP IN PRIMARY EXTREMITY SOFT TISSUE SARCOMA PATIENTS TREATED WITH SURGERY

Dario Callegaro1; Rosalba Miceli2; Sylvie Bonvalot3; Peter Ferguson4; Dirk Strauss5; Antonin Levy6; Anthony M. Griffin7; Andrew J. Hayes8; Silvia Stacchiotti9; Cécile Le Péchoux10; Myles J. Smith11; Marco Fiore1; Angelo Paolo Dei Tos1; Henry Smith1; Charles Catton9; Paolo Casali10; Jay Wunder4; Alessandro Gronchi1
1Surgery, Istituto Nazionale Tumori, Milan, Italy; 2Clinical Epidemiology and Trial Organisation, Istituto Nazionale Tumori, Milan, Italy; 3Surgery, Institut Curie, PSL Research University, Paris, France; 4Surgery, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, ON, Canada; 5Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; 6Radiation Oncology, Gustave Roussy Cancer Campus, Paris Sud University, Villejuif, France; 7Cancer Medicine, Istituto Nazionale Tumori, Milan, Italy; 8Pathology, General Hospital of Treviso, Treviso, Italy; 9Radiation Oncology, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, ON, Canada; 10Oncology and Hemato-Oncology, Istituto Nazionale Tumori, University of Milan, Milan, Italy
THE IMPACT OF UNPLANNED EXCISIONS OF SOFT TISSUE SARCOMAS: A MULTI-INSTITUTIONAL PROPENSITY SCORE ANALYSIS FROM THE US-SARCOMA COLLABORATIVE

Mohammad Zaidi; Cecilia G. Ethun; Yuan Liu; Thuy B. Tran; George Poultsides; Valerie P. Grignol; J. H. Howard; Meena Bedi; Harveshp Mogal; Jennifer Tseng; Kevin K. Roggin; Konstantinos Chouliaras; Konstantinos Votanopoulos; Darren Cullinan; Ryan C. Fields; Shervin Oskouei; Nickolas Reimer; David Monson; Kenneth Cardona

1Surgery, Emory University, Atlanta, GA, USA; 2Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA; 3Surgery, Stanford University, Atlanta, GA, USA; 4Surgery, The Ohio State University, Columbus, OH, USA; 5Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 6Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; 7Surgery, University of Chicago Medicine, Chicago, IL, USA; 8Surgery, Wake Forest University, Winston-Salem, NC, USA; 9Surgery, Washington University School of Medicine, St. Louis, MO, USA

Discussion – Rebecca Gladdy

5:30 pm - 6:00 pm  CTOS Business Meeting  Salon del Cavalieri 2,3,4
Poster 001  3027672
MULTICENTER, OPEN-LABEL PHASE II STUDY OF DAILY ORAL REGORAFENIB FOR CHEMOTHERAPY-
REFRACTORY, METASTATIC AND LOCALLY ADVANCED ANGIOSARCOMA
Mark Agulnik¹; Brian Van Tine²; Steven Attia³; Alfred Rademaker³; Mohammed Milhem⁴; Steven Robinson⁵; Scott Okuno⁵
¹Hematology/ Oncology, Northwestern University, Chicago, IL, USA; ²Washington University, St. Louis, MO, USA; ³Mayo, Jacksonville, FL, USA; ⁴University of Iowa, Iowa City, IA, USA; ⁵Mayo, Rochester, MN, USA

Poster 002  3042315
PITFALLS IN ANGIOSARCOMA DIAGNOSIS: LESSONS LEARNED FROM CENTRAL REVIEW OF 657
DUTCH CASES
Marije Weidema¹; Melissa Hillebrandt-Roeffen¹; Ingrid Desar¹; Yvonne Versleijen-Jonkers¹; Winette van der Graaf¹; Uta Flucke²
¹Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands; ²Pathology, Radboud University Medical Center, Nijmegen, Netherlands

Poster 003  3042833
LOCALIZED RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST: A MONO-INSTITUTIONAL
CASE SERIES
Elena Palassini¹; Silvia Stacchiotti¹; Claudia Sangalli¹; Alessandro Gronchi¹; Carlo Morosi¹; Paola Collini¹; Salvatore Provenzano¹; Rossella Bertulli¹; Giacomo Giulio Baldi¹; Marta Barisella¹; Massimiliano Gennaro¹; Paolo Casali¹
¹IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy

Poster 004  3000082
TRAMETINIB INDUCES RESPONSE IN REFRACTORY HRAS G13D-MUTATED ANGIOSARCOMA OF SCALP
Benjamin Powers¹; Stacie Fogelberg¹; Tiffany Verhulst¹; Andrew Huskey²; Kaylee Drenker²
¹Medical Oncology, U of Kansas Cancer Center, Overland Park, KS, USA; ²Pharmacology, U of Kansas Cancer Center, Kansas City, KS, USA

Poster 005  3037976
THE ANGIOSARCOMA PROJECT: GENERATING THE GENOMIC LANDSCAPE OF A RARE SARCOMA THROUGH
A NATIONWIDE PATIENT-DRIVEN INITIATIVE
Michael Dunphy¹; Esha Jain¹; Elana Anastasio¹; Mary McGillicuddy¹; Rachel Stoddard¹; Beena Thomas¹; Sara Balch¹; Kristin Anderka²; Katie Larkin²; Niall Lennon²; Yen-Lin E. Chen³; Andrew Zimmer⁴; Esme O. Baker⁵; Simone Maiwald⁶; Jen Lapan⁶; Jason L. Homick⁶; Chandrakirti Raut⁶; George Demetri⁶; Eric S. Lander⁶; Todd Golub¹; Nikhil Wagle⁶; Corrie Painter¹
¹Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ²Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ³Massachusetts General Hospital, Boston, MA, USA; ⁴Data Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ⁵Brigham and Women’s Hospital, Boston, MA, USA; ⁶Dana-Farber Cancer Institute, Cambridge, MA, USA; ⁷Broad Institute of MIT and Harvard, Cambridge, MA, USA

Poster 006  3042503
A RETROSPECTIVE REVIEW OF PATIENTS WITH ANGIOSARCOMA TREATED IN BRITISH COLUMBIA
Alannah Smrke¹; Jeremy Hamm¹; Anand Karvat¹; Christine Simmons¹; Amirtha Srikanthan¹
¹BC Cancer , Vancouver, BC, Canada
DETECTION OF ENDOGLIN-EXPRESSING CTCS IN PATIENTS ENROLLED IN AN ADAPTIVE ENRICHMENT PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPS)

Ravi Vinod1; Andrew Brohi1; Robin Jones1; Sant P. Chawla2; Kristen Ganjoo1; Steven Attia1; Atrayee Basu-Mallick1; Darren Davis1; Mario Cervantes3; Wen Liu3; Lilian Liu4; Charles Theuer5; Steven Robinson1; Nicolas Penel1; Silvia Stacchiotti1; Marie Karanian2; Marie-Pierre Sunyach3; François Le Loarer4; Eberhard Stoeckle1
1TRACON Pharma, San Diego, CA, USA; 2University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; 3Moffitt Cancer Center, Tampa, FL, USA; 4Royal Marsden/Institute of Cancer Research, London, United Kingdom; 5Sarcoma Oncology Center, Santa Monica, CA, USA; 6ApoCell, Houston, TX, USA; 7Memorial Sloan Kettering Cancer Center, New York, NY, USA; 8Northwell Health, Lake Success, NY, USA; 9Thomas Jefferson University, Philadelphia, PA, USA; 10Mayo Clinic, Jacksonville, FL, USA; 11Mayo Clinic, Rochester, MN, USA; 12Centre Oscar Lambret, Lille, France; 13Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 14Stanford University, Stanford, CA, USA

NEOADJUVANT CHEMOTHERAPY ASSOCIATED WITH ENHANCED LOCAL CONTROL IN RADIATION-INDUCED ANGIOSARCOMA OF BREAST AND CHEST

Audrey Michot1; Marie Karanian2; Maryck Lae1; Romuald Wernert3; Marie-Pierre Sunyach4; Dimitri Tzanis4; Jean-Marie Guilloit5; Maria Rios6; Antoine Giraud6; Jean-Yves Blay7; Eberhard Stoeckle1
1Surgery, Institut Bergonié, Bordeaux, France; 2Pathology, Leon Berard, Lyon, France; 3Surgery, Institut de Cancerologie de l’Ouest, Angers, France; 4Radiotherapy, Centre Leon Berard, Lyon, France; 5Surgery, Institut Curie, Paris, France; 6Surgery, Centre Francois Baclesse, Caen, France; 7Medical Oncology, Institut de Cancerologie de Lorraine, Nancy, France; 8Epidemiology and Clinical Research Unit, Institut Bergonié, Bordeaux, France; 9Pathology, Institut Bergonié, Bordeaux, France; 10Medical Oncology, Centre Leon Berard, Lyon, France; 11Pathology, Institut Curie, Paris, France

ASSOCIATION OF BETA-BLOCKER USE WITH CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED ANGIOSARCOMA

Andrew Johns1; James L. Chen1; David Liebner1; Lai Wei1; Gabriel Tinoco1
1Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 2Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 3Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA

ACTIVITY AND SAFETY OF CRIZOTINIB IN PATIENTS WITH ADVANCED, METASTATIC ALVEOLAR SOFT PART SARCOMA (ASPS) WITH REARRANGEMENT OF TFE3EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) PHASE 2 TRIAL 90101 “CREATE”

Patrick Schöffski1; Agnieszka Wozniak2; Bernd Kasper3; Steinar Aamdal4; Michael Leahy4; Piotr Rutkowski5; Sebastian Bauer6; Hans Gelderblom7; Antoine Italiano8; Lars Lindner9; Ivo Hennig1; Sandra Strauss1; Branko Zakotnik1; Alan Anthony1; Silvia Stacchiotti1
1General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; 2Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium; 3Department of Oncology, Oslo University Hospital, Oslo, Norway; 4Mannheim University Medical Center, Mannheim, Germany; 5Institut Bergonié, Bordeaux, France; 6The Christie NHS Foundation Trust, Manchester, United Kingdom; 7Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, Poland; 8Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; 9Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; 10Department of Oncology, University College London Hospitals NHS Trust, London, United Kingdom; 11Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; 12Westdeutsches Tumorzentrum, Universitätssklinikum Essen, Essen, Germany; 13Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, United Kingdom; 14Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; 15City Campus, Dept of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
TREATMENT PATTERNS OF ALVEOLAR SOFT PART SARCOMA PATIENTS AND RESPONSE TO MULTIPLE EXPERIMENTAL THERAPIES

Roman Groisberg; Jason Roszik; Shiraj Sen; Anthony P. Conley; Alexander J. Lazar; David S. Hong; Aung Naing; Cynthia E. Herzog; Neeta Somaiah; Maria A. Zarzour; Shreyaskumar Patel; Vivek Subbiah
1Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; 2Genomic Medicine, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA; 3Pathology, MD Anderson Cancer Center, Houston, TX, USA

CLINICAL CHARACTERISTICS OF ALVEOLAR SOFT PART SARCOMA PATIENTS WITH BRAIN METASTASIS

Tonita Bates; Akash Mitra; John A. Livingston; Alexander J. Lazar; Andrew J. Bishop; B. Ashleigh Guadagnolo; Ravin Ratan; Vinod Ravil; Neeta Somaiah; Maria A. Zarzour; Daniela A. Camacopa; Dejka M. Araujo; Robert Benjamin; Shreyaskumar Patel; Anthony P. Conley
1Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Pathology, MD Anderson Cancer Center, Houston, TX, USA; 4Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA

EXPANDING THE HISTONE MUTATION LANDSCAPE IN SARCOMA

Benjamin A. Nacev; Sandra D’Angelo; Mark A. Dickson; Ping Chi; Cristina Antonsecu; Sam Singer; C. David Allis; William D. Tap
1The Rockefeller University, New York, NY, USA; 2Memorial Sloan Kettering Cancer Center, New York, NY, USA

DEVELOPMENT OF A PLASMA MICRORNA BIOMARKER FOR PEDIATRIC OSTEOSARCOMA

Wendy Allen-Rhoades; Meng Liu; Lyazat Kurenbekova; Chad Creighton; Jason T. Yustein
1Pediatrics, Baylor College of Medicine, Houston, TX, USA; 2Medicine, Baylor College of Medicine, Houston, TX, USA

SHIFTING THE PARADIGM IN PRECLINICAL CANCER MODELING: A MOUSE-DOG-HUMAN PERSONALIZED MEDICINE PIPELINE TO IDENTIFY NOVEL THERAPEUTICS FOR OSTEOSARCOMA

Sneha Rao; Erdem Altunel; Wayne Glover; Suzanne Bartholf DeWitt; Laura Selmic; Cindy Eward; Julia Visgauss; Brian Brigman; William Eward; David Hsu; Jason Somarelli
1School of Medicine, Duke University, Durham, NC, USA; 2Medicine, Duke University, Durham, NC, USA; 3Orthopaedic Surgery, Duke University, Durham, NC, USA; 4Veterinary Medicine, University of Illinois at Urbana-Champaign, Champaign, IL, USA; 5Triangle Veterinary Referral Hospital, Holly Springs, NC, USA

XENOSARC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA (STS) – AND UPDATE ON A PRECLINICAL PLATFORM FOR EARLY DRUG TESTING

Agnieszka Wozniak; Jasmien Cornillie; Yemarshet K. Gebreyohannes; Yannick Wang; Jasmien Wellens; Ulla Vanleeuw; Daphne Hompes; Marguerite Stas; Friedl Sinnaeve; Hazem Wafa; Maria Debiec-Rychter; Raf Sciot; Patrick Schöffski
1Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium; 2Department of Surgical Oncology, UZ Leuven, Leuven, Belgium; 3Department of Orthopedic Surgery, UZ Leuven, Leuven, Belgium; 4Department of Human Genetics, KU Leuven, Leuven, Belgium; 5Department of Pathology, UZ Leuven, Leuven, Belgium; 6Department of General Medical Oncology, UZ Leuven, Leuven, Belgium

BMP-2 SIGNALLING INFLUENCES TUMOUR BIOLOGY IN PRE-CLINICAL MODELS OF OSTEOSARCOMA

Joseph K. Kendal; Arvind K. Singla; Asmaa Affan; Kurt Hildebrand; Doha Ilani; Michael J. Monument
1Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, AB, Canada; 2Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; 3McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, Canada; 4Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
PHENOTYPIC CHARACTERIZATION OF IGFR2R KNOCKOUT IN HUMAN OSTEOSARCOMA CELLS

Edmond O'Donnell1; Brian Batko1; Yoav Zvi1; Jonathan Gill2; Micheal Roth2; Richard Gorlick2; Rui Yang1; Bang Hoang1; David Geller1
1Orthopaedic Oncology, Albert Einstein College of Medicine, Bronx, NY, USA; 2Department of Pediatrics, MD Anderson, Houston, TX, USA

THE ODC1/POLYAMINES/C-MYC AXIS PROMOTES OSTEOSARCOMA TUMORGENESIS BY REGULATING GLUTAMINOLYSIS

Hongsheng Wang1; Ling Ren2; Shan Huang2; Zhengdong Cai1; Yingqi Hua1; Amy K. LeBlanc2
1Shanghai General Hospital, Shanghai, China; 2National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

THE TYPE OF NR4A3 FUSION PARTNER DICTATES AN AXON GUIDANCE SWITCH IN EXTRASKELETAL MYXOID CHONDROSARCOMAS

Monica Brenca1; Silvia Stacchiotti2; Kelly Fassetta1; Maurizio Polano1; Dominga Racanelli1; Milijana Janjusevic1; Marta Sbaraglia1; Sabrina Rossi1; Silvia Brich2; Gian Paolo Dagrada2; Chiara Colombo2; Chiara Castelli2; Alessandro Gronchi2; Annalisa Astolfi2; Valentina Indio3; Maria Abbondanza Pantaleo3; Piero Picci3; Paolo Casali2; Angelo P. Dei Tos3; Silvana Pilotti1; Roberta Maestro1
1CRO National Cancer Institute, Aviano, Italy; 2National Cancer Institute of Milan, Milano, Italy; 3Treviso Generasl Hospital, Treviso, Treviso, Italy; 4Istituto Ortopedico Rizzoli, Bologna, Italy; 5University of Bologna, Bologna, Italy

THE MECHANISMS OF ZOLEDRONIC ACID-INDUCED AUTOPHagy ON OSTEOSARCOMA CELLS

Chang-Bae Kong1; EunHo Kim1
1Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea (the Republic of)

ATRX MUTATIONS INCREASE TUMORIGENICITY IN OSTEOSARCOMA

Suzanne Bartholf DeWitt1; Jason Somarelli2; So Young Kim2; Vidya Seshadri2; Robert Floyd2; David Kerr2; Randall T. Kreulen2; Willa Chen2; Gireesh B. Reddy2; Sneha Rao2; Rachael Thomas3; Brian Brigman2; Matthew Breen3; Benjamin Alman4; William Eward5
1Pathology, Duke University, Durham, NC, USA; 2Duke University, Durham, NC, USA; 3NC State University, College of Veterinary Medicine, Raleigh, NC, USA

DOXORUBICIN, GEMCITABINE, IFOSFAMIDE, AND THE EZH2 INHIBITOR EPZ-011989 IN EPITHELIOID SARCOMA: A COMPARISON OF DIFFERENT REGIMENS IN A PATIENT-DERIVED XENOGRAFT

Nadia Zaffaroni1; Anna Maria Frezza1; Valentina Zuco1; Alessandro Gronchi1; Chiara Colombo1; Sandro Pasquali1; Paolo Casali1; Marta Barisella1; Angelo Paolo Dei Tos1; Paola Collini1; Maria Abbondanza Pantaleo1; Annalisa Astolfi1; Valentina Indio1; Monica Tortoreto1; Silvia Stacchiotti1
1Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 2General Hospital of Treviso, Treviso, Italy; 3Interdepartmental Centre of Cancer Research “Giorgio Prodi”, University of Bologna, Bologna, Italy

REACTIVATION OF WILD TYPE P53 BY MDM2 INHIBITION IN SYNOVIAL SARCOMAS

Jennifer Wilson1; Toshihiko Nishisho1; Aimee Laporte1; Neal M. Poulin1; Torsten O. Nielsen1; Kevin B. Jones2; Bertha Brodin1
1Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; 2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; 3Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
MACHINE LEARNING ANALYSIS OF GENE EXPRESSION DATA REVEALS NOVEL DIAGNOSTIC AND PROGNOSTIC BIOMARKERS AND IDENTIFIES THERAPEUTIC TARGETS FOR SOFT TISSUE SARCOMAS

David G. van IJzendoorn1; Karoly Szuhai3; Inge Briaire-de Brujin1; Marie Kostine1; Marieke Kuijjer2; Judith V. Bovee1
1Department of Pathology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands; 2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; 3Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands

THE DEVELOPMENT AND CHARACTERIZATION OF A HUMANIZED XENOGRAFT MURINE MODEL FOR OSTEOSARCOMA

Brian Batko1; Yoav Zvi1; Edmond O'Donnell1; Kenji Sato1; Xi-Quan Du1; Micheal Roth2; Jonathan Gill2; Richard Gorlick3; Alexander J. Lazar1; Rui Yang1; Bang Hoang1; David Geller4
1Department of Orthopedic Surgery, Montefiore Medical Center, Bronx, NY, USA; 2Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

COMBINATION OF CISPLATIN AND HIV PROTEASE INHIBITOR NELFINAVIR SHOWS SYNERGISTIC EFFECTS AGAINST THE GROWTH OF HUMAN OSTEOSARCOMA CELLS

Michelina de la Maza1; Aparna R. Sertil2; Anthony Diaz2; Anuj Shah2; Dustin Daniel2; Saravana Kumar2; Alexa Trenschel2
1CCBD, Phoenix Childrens Hospital, Phoenix, AZ, USA; 2University of Arizona, Phoenix, AZ, USA

PROGNOSTIC IMPACT OF THE FGFR EXPRESSION IN LIPOSARCOMA ROLE OF FGFR AND MDM2 DUAL TARGETING

Bérengère Dadone-Montaudie1; Audrey Laroche-Clary2; Aline Mongis1; Vanessa Chaire2; Ilaria Di Mauro3; Renaud Schiappa2; Emmanuel Chamorey2; Jean-François Michiels2; Florent Peudeutour5; Antoine Italiano6
1Laboratory of solid tumor genetics, Université Côte d’Azur CNRS IRCAN, Nice, France; 2INSERM U1218 Institut Bergonié, Université de Bordeaux, Bordeaux, France; 3Biostatistics, Centre Antoine Lacassagne, Nice, France; 4Pathology, Nice University Hospital, Nice, France; 5Laboratory of solid tumor genetics, Nice University Hospital IRCAN, Nice, France; 6Department of medical oncology INSERM 1218; Institut Bergonié, Bordeaux, France

DISCOVERY SCREEN OF SMALL MOLECULE INHIBITORS OF THE PAX3-FOXO1 FUSION PROTEIN NOMINATES THERAPEUTIC COMBINATION STRATEGIES

John Shern1; Berkley Gryder1; Robert Hawley3; Carly Sayers1; Girma Woldenmichael1; Javed Khan1
1National Cancer Institute, Bethesda, MD, USA

HIGH-THROUGHPUT DRUG SCREENING OF PATIENT-DERIVED SARCOMA TUMOR ORGANOIDS FOR PERSONALIZED THERAPY

Jane Yanagawa3; Noah Federman3; Matthew Mapua1; Jenny Hong1; Benjamin J. DiPardo4; James S. Tomlinson5; Arun S. Singh1; Anusha Kalbasi6; Francis Hornicek5; Sarah Dry3; Scott Nelson3; Fritz C. Eilber5; Nicholas N. Berthelot5; Robert Damoiseaux10; Alice Soragni1
1Division of Hematology-Oncology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; 2Division of Thoracic Surgery, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; 3Division of Pediatrics and Department of Orthopaedics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; 4Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; 5Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA, USA; 6Department of Radiation Oncology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; 7Department of Orthopaedics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; 8Division of Orthopaedic Oncology, Department of Orthopaedics, UCLA, Los Angeles, CA, USA; 9Department of Molecular and Medicinal Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
TARGETING ACTIVATING TRANSCRIPTION FACTOR 6 ALPHA (ATF6 A): A NOVEL APPROACH FOR THE TREATMENT OF PEDIATRIC OSTEOSARCOMA

Aparna R. Sertil1, Pooja Hingoranani2, Justin Montoya2, Daniel Wai3, David Azorsa3

1Basic Medical Sciences, University of Arizona, Phoenix, AZ, USA; 2Hematology and Oncology, Phoenix Childrens Hospital, Phoenix, AZ, USA; 3Child Health, University of Arizona, Phoenix, AZ, USA

ELUCIDATING THE ROLE OF THE EPHRIN TYPE-A RECEPTOR (EPHA2) AS THERAPEUTIC TARGET IN OSTEOSARCOMA USING PATIENT-DERIVED TUMOR XENOGRAFTS

Nino Rainusso1, Meng Liu1, Jason T. Yustein1

1Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA

PATIENT-DERIVED SARCOMA MODELS - FIRST RESULTS FROM THE SARQMA STUDY

Manuela Gaebler1, Alessandra Silvestri2, Peter Reichardt1, Guido Gambara1, Johannes Haybaeck4, Philipp Stroebel6, Maya Niethard2, Markus Templin7, Christian R. Regenbrecht2

1Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch GmbH, Berlin, Germany; 2CPO - Cellular Phenomics & Oncology, Berlin, Germany; 3German Consortium for Translational Research (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Berlin, Germany; 4Department of Pathology, University Hospital Magdeburg, Magdeburg, Germany; 5Department for Pathology, University Hospital Göttingen, Göttingen, Germany; 6Department for Tumor Orthopedics, Helios Klinikum Berlin-Buch GmbH, Berlin, Germany; 7Department for Proteom Analyses, NMI, Reutlingen, Germany

CLEAR CELL SARCOMA OF THE KIDNEY SHOWS ELEVATED LEVELS OF THE ONCOMETABOLITE AND EPIGENETIC MODIFIER L-2-HYDROXYGLUTARATE

Kelsi R. Willis1, Rebecca R. Collins1, Richard L. Boriack2, Dinesh Rakheja1

1Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; 2Pathology and Laboratory Medicine, Children’s Health, Dallas, TX, USA

ANTI-TUMOR EFFECTS OF TAS-115 ON MURINE OSTEOSARCOMA CELL LINE(LM8) WITH HIGH METASTATIC POTENTIAL TO THE LUNG

Naohiro Yasuda1, Sho Nakai1, Takaaki Nakaï1, Yoshinori Imura1, Hironori Tamiya3, Takaaki Tanaka2, Hidetatsu Outani1, Satoshi Takenaka1, Kenichiro Hamada1, Akira Myoui1, Hideki Yoshikawa1, Norifumi Naka3

1Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Suita, Japan; 2Orthopaedic Surgery, Kawachi General Hospital, Osaka, Japan; 3Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan

MESENCHYMAL STROMAL CELLS ENHANCE METASTASIS FORMATION IN OSTEOSARCOMA

Sofia Avnet1, Silvia Lemma1, Giulia Grisendi2, Massimo Dominici2, Dominique Heymann3, Nicola Baldini1

1Rizzoli Orthopaedic Institute, Bologna, Italy; 2Division of Oncology, Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy; 3Institut de Cancérologie de l’Ouest, University of Nantes, Nantes, France

TNK1 IS A NOVEL MOLECULAR TARGET FOR OSTEOSARCOMA TREATMENT AND CONTROLS OSTEOSARCOMA CELL FATE

Toru Hirozane1, Mari Masuda2, Naoko Goto2, Teppie Sugano3, Naofumi Asano3, Eisuke Kobayashi4, Akira Kawai4, Keisuke Horiuchi5, Morio Matsumoto1, Masaya Nakamura1, Masaaki Sawa6, Hideo Morioka7, Robert Nakayama1, Tesshi Yamada2

1Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan; 2Lab of Collaborative Research, National Cancer Center Research Institute, Tokyo, Japan; 3Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital, Tokyo, Japan; 4Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; 5Department of Orthopedic Surgery, National Defense Medical College, Tokyo, Japan; 6Carna Biosciences, Inc., Kobe, Japan; 7Department of Orthopedic Surgery, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
IRE1α-XBP1 INHIBITORS EXERTS ANTITUMOR ACTIVITY IN OSTEOSARCOMAS
Taisei Kurihara; Yoshiyuki Suehara; Takuo Hayashi; Keisuke Akaike; Taketo Okubo; Youngji Kim; Kazuo Kaneko; Tsuyoshi Saito
1Junetendo University, Tokyo, Japan

ESTABLISHMENT OF PATIENT-DERIVED XENOGRAFT MODELS OF MUSCULOSKELETAL SARCOMA SERIALLY EVALUATED WITH COMPREHENSIVE GENE EXPRESSION PROFILING
Michiyuki Hakozaki; Yuu Dobashi; Hitoshi Yamada; Takahiro Tajino; Yoichi Kaneuchi; Junichi Imai; Kiyoaki Katahira; Shin-ichi Konno; Shinya Watanabe
1Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan; 2Medical-Industrial Translational Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, Japan; 3Devision of Orthopaedic Surgery, Southern Tohoku Fukushima Hospital, Fukushima, Japan

IMAGING THE INTERACTION OF OSTEOSARCOMA CELLS WITH HOST STROMAL CELLS AND TUMOR SCAFFOLD COLLAGEN IN THE TUMOR MICROENVIRONMENT
Yasunori Tome; Tasuku Kiyuna; Hiroki Maehara; Hiromichi Oshiro; Robert M. Hoffman; Fuminori Kanaya
1Department of Orthopedic Surgery, University of the Ryukyus, Nishihara, Okinawa, Japan; 2Department of Surgery, University of California, San Diego, San Diego, CA, USA

ACIDIC MICROENVIRONMENTS IN SOFT-TISSUE SARCOMA PROMOTES FOXM1 EXPRESSION AND TUMORIGENESIS
Ryo Miyagi; Toshihiko Nishisho; Shunichi Toki; Koichi Saiyo
1Orthopedic, Institute of Biomedical Sciences Tokushima University Graduate School, Tokushima, Japan

CYTOTOXIC AND ANTI-METASTATIC EFFECTS OF MYCOPHENOLATE MOFETIL IN OSTEOSARCOMA: DRUG REPURPOSING FROM PROTEOMIC DATA
Jeerawan Klangjorhor; Parunya Chaibawat; Pimpisa Teeyakasem; Jongkolnee Settakorn; Kriengsak Lirdprapamongkol; Sarawoot Yama; Jisnuson Svasti; Dumnoensun Pruksakorn
1Orthopedics, Chiang Mai University, Chiang Mai, Thailand; 2Pathology, Chiang Mai University, Chiang Mai, Thailand; 3Chulabhorn Research Institute, Bangkok, Thailand; 4Laboratory Animal Center, Chiang Mai, Thailand

COMPLEX AUTOCRINE AND PARACRINE INTERACTIONS IN A SERIES OF SINGLE-BACKGROUND MURINE FIBROSARCOMA CELL LINES
Jiri Hatina; Michaela Kripnerova; Hamendra Singh Parmar; Zbynek Houdek; Pavel Dvorak; Katerina Houfkova; Martin Pesta; Jitka Kuncova; Jiri Sana; Lenka Radova; Ondrej Slaby
1Institute of Biology, Charles University Faculty of Medicine in Pilsen, Plzen, Czechia; 2Institut of Physiology, Charles University Faculty of Medicine in Pilsen, Plzen, Czechia; 3Molecular Oncology II - Solid Cancer, Central European Institute of Technology, Brno, Czechia

CXCR4 INHIBITORS AS CHEMOSENSITIZER IN BONE MARROW-DERIVED MESENCHYMAL STEM CELL-MEDIATED OSTEOSARCOMA AND SYNOVIAL SARCOMA CELL APOPTOSIS AND MIGRATION
Serena Pollino; Laura Pazzaglia; Elisa Bientinesi; Barbara Dozza; Enrico Lucarelli; Maria Serena Benassi; Emanuela Palmerini
1Experimental Oncology Lab, Ortopedico Rizzoli, Bologna, Italy; 2Osteoarticular Regeneration Lab, Ortopedico Rizzoli, Bologna, Italy; 3Chemotherapy Unit, Ortopedico Rizzoli, Bologna, Italy
THE PHOSPHATASE PTPRG CONTROLS FGFR1 ACTIVITY AND INFLUENCES SENSITIVITY TO FGFR KINASE INHIBITORS
Michal Kostas1; Ellen M. Haugsten1; Yan Zhen2; Vigdis Sørensen; Patrycia Szybowska2; Elisa Fiorito1; Susanne Lorenz1; Antoni Wiedlocha1; Jørgen Wescze1
1Department of Tumor Biology, The Norwegian Radium Hospital, Oslo, Norway; 2Department of Molecular Cell Biology, The Norwegian Radium Hospital, Oslo, Norway

EUTHYROID HYPOTHYROXINEMIA [EH] MODULATED BY EXOGENOUS L-TRIODOTHYRONINE MAY EXTEND SURVIVAL IN ADVANCED SARCOMA-AN UPDATED FOLLOW-UP
Rony Weitzen1; Alec Hercbergs2
1Oncology, Sheba MC-Israel, Ramat Gan, Israel; 2Oncology, Cleveland Clinic, Cleveland, OH, USA

NOVEL BIOINFORMATICS APPROACH FOR SARCOMA PROTEOGENOMICS; MUTATED NUCLEOTIDES AND AMINO-ACIDS GENERATOR (MUNAGE)
Emi Hattori1; Kumiko Shiozawa1; Tadashi Kondo1
1Division of Rare Cancer Research, National Cancer Center Research Institute, Tokyo, Tokyo, Japan

EFFECT OF ANLOTINIB, A NOVEL SMALL MOLECULAR TYROSINE KINASE INHIBITOR, ON GROWTH, METASTASIS AND ANGIGENESIS IN OSTEOSARCOMA
Yingqi Hua1; Gangyang Wang1; Mengxiong Sun1; Tao Zhang1; Wei Sun1; Hongsheng Wang1; Fei Yin1; Zhuoying Wang1; Jing Xu1; Zhenfeng Duan1; Zhongdong Cai1
1Shanghai General Hospital, Shanghai, China; 2David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

EFFECT OF CHEMOTHERAPY ON CANCER STEM CELLS AND TUMOR-ASSOCIATED MACROPHAGES IN A PROSPECTIVE STUDY OF PREOPERATIVE CHEMOTHERAPY IN SOFT TISSUE SARCOMA
Keith M. Skubitz1; Jon Wilson4; Edward Cheng3; Bruce Lindgren2; Amy Skubitz8
1Medicine, University of Minnesota, Edina, MN, USA; 2School of Public Health, University of Minnesota, Minneapolis, MN, USA; 3Orthopaedic Surgery, University of Minnesota, Minneapolis, MN, USA; 4Arkana Laboratoires, Little Rock, AR, USA; 5Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA

DRUG SENSITIVITY TESTING ON PATIENT-DERIVED SARCOMA CELLS PREDICTS PATIENT RESPONSE TO TREATMENT AND IDENTIFIES C-SARC INHIBITORS AS ACTIVE DRUGS FOR TRANSLOCATION SARCOMAS
Bertha Brodin1; Antroula Papakonstantinou3; Elisabet Lidbrink2; Otte Brosjö1; Asle Hesla3; Henrik Bauer2; Swapnil Potdar1; Olli Kallioniemi2; Christina Linder-Stragliotto2
1Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; 2Breast and Sarcoma, Karolinska University Hospital, Stockholm, Sweden; 3Tumor Orthopedics, Karolinska University Hospital, Stockholm, Sweden; 4Institute for Molecular Medicine Finland, Helsinky, Finland; 5Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden

THE EFFECT OF BUPIVACAINE AND LIDOCAINE ON OSTEOSARCOMA CELLS
Troy G. Shields1; Rosalia de Necochea-Campion1; Xiangpeng Yuan1; Nadine L. Williams1; Joseph Elsissy1; Ata Janjuan2; Saied Mirshahidi1; Lee M. Zuckerman1
1Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; 2Biospecimen Laboratory, Loma Linda University Medical Center, Loma Linda, CA, USA; 3Otolaryngology, Loma Linda University Medical Center, Loma Linda, CA, USA

THE PROTEIN EXPRESSION OF NF1; P16INK4A, PTEN AND THEIR INVOLVED SIGNAL PATHWAY FATORS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Peng Zhang1; Guoqing Liu1; Jinyan Liu1; Feifei Feng2; Weitao Yao1
1Bone and soft tissue sarcoma, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China; 2College of Public Health of Zhengzhou University, Zhengzhou, China
TWO NOVEL HUMAN MYXOFIBROSARCOMA CELL LINES REPRESENT A CELLULAR MODEL FOR TUMOR HETEROGENEITY

Birgit Lohberger¹; Nicole Stuendl¹; Andreas Leithner¹; Beate Rinner²; Stefan Sauer³; Karl Kashofer³; Bernadette Liegl-Atzwanger⁴
¹Department of Orthopedics and Trauma, Medical University Graz, Graz, Austria; ²Department of Biomedical Research, Medical University Graz, Graz, Austria; ³Institute of Pathology, Medical University Graz, Graz, Austria

APOPTOTIC INDUCTION AND G1 CELL CYCLE ARREST OF MULTIDRUG RESISTANT SARCOMA CELL LINES BY THE HISTONE DEACETYLASE INHIBITORS VERINOSTAT AND PANOBINOSTAT

Birgit Lohberger¹; Nicole Stuendl¹; Heike Kaltenegger¹; Andreas Leithner¹; Eva Bernhart²
¹Department of Orthopedics and Trauma, Medical University Graz, Graz, Austria; ²Institute of Molecular Biology and Biochemistry, Medical University Graz, Graz, Austria

THERAPEUTIC VULNERABILITIES IN UNDIFFERENTIATED SARCOMAS

Susanne Grunewald¹; Thomas Mühlenberg¹; Johanna Falkenhorst¹; Miriam Christoff¹; Julia Ketzer¹; Stefanie Bertram²; Thomas Herold²; Jürgen Treckmann²; Lars-Eric Podleska³; Elizabeth Demicco³; Priya Chudasama³; Stefan Fröhling³; Sebastian Bauer³
¹Departments of Medical Oncology, University Hospital Essen, West German Cancer Center, Sarcoma Center, Essen, NRW, Germany; ²Department of Pathology, University Hospital Essen, West German Cancer Center, Sarcoma Center, Essen, Germany; ³Department of General-, Visceral- and Transplantation Surgery, University Hospital Essen, Sarcoma Center, Sarcoma Surgery Division, Essen, Germany; ⁴Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; ⁵Division of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Essen, Germany

SCREENING OF SYNERGISTIC REAGENT WITH PAZOPANIB AGAINST OSTEOSARCOMA USING COMPOUND LIBRARY.

Yuki Yada¹; Kunihiro Asanuma¹; Koji Kita¹; Tomohito Hagi¹; Tomoki Nakamura¹; Akihiro Sudo¹
¹Mie University, Yokkaichi, Mie, Japan; ²Mie Prefectural general Medical Center, Yokkaichi, Japan

TARGETTING EPIDERMAL GROWTH FACTOR RECEPTORS AND UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS FOR SARCOMA THERAPY

Ashley J. Graef¹; Jong-Hyuk Kim¹; Daniel A. Vallera¹; Jaime F. Modiano¹
¹University of Minnesota, Minneapolis, MN, USA

IMPROVING ONCOLYTIC VIROTHERAPY USING VANADIUM-BASED COMPOUNDS IN SARCOMAS

Anabel Bergeron¹; Mohammed Selman¹; Andrew Chen¹; Fanny Tzelepis¹; Rozanne Arulanandam¹; Hesham Abdelbary²; Joel Werier³; Debbie Crans³; Jean-Simon Dioio³
¹Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; ²Department of Surgery Orthopaedics, The Ottawa Hospital, Ottawa, ON, Canada; ³Department of Chemistry, Colorado State University, Fort Collins, CO, USA

SOMATIC TUMOR PASSENGER EVENTS ACT AS A FLIGHT RECORDER “BLACK BOX” TO PINPOINT THE CHROMATIN STATE OF THE TUMOR CELL OF ORIGIN

Aaron L. Sarver¹; David L. Largaespada²
¹Masonic Cancer Center, Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA; ²Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
**Poster 060  3042835**

**CANONICAL AND RECIPROCAL FUSION GENE EXPRESSION IN TRANSLOCATION ASSOCIATED SOFT TISSUE SARCOMA TUMORS IS ASSOCIATED WITH DISTINCT MOLECULAR SIGNATURES**

**Joyce Ohm**¹; Spencer E. Rosario¹; Jaspreet E. Chatta²; Anne Grand’Maison²

¹Genetics and Genomics, Roswell Park Cancer Institute, Buffalo, NY, USA; ²Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

**Poster 061  3042904**

**IDENTIFICATION OF SPLICING FACTOR-3B1 AS A PUTATIVE REGULATOR OF OSTEOSARCOMA METASTASIS**

**Pooja Hingorani**¹; Alexa Trenschel²; Anthony Diaz¹; Michelina de la Maza¹; Saravana Kumar¹; Paul Dickman¹; Janet Foote²; Shalini Sharma²; Aparna R. Sertil²

¹Phoenix Children's Hospital, Phoenix, AZ, USA; ²Basic Medical Sciences, University of Arizona, Phoenix, AZ, USA

**Poster 062  3042916**

**IONIZING RADIATION CAUSES SARCOMAS THROUGH MECHANISMS INDEPENDENT OF INCREASING MUTATIONAL LOAD**

**David Kirsch**¹; Chang-Lung Lee¹; Dadong Zhang¹; Alexander Sibley¹; Andrea Daniel¹; Yvonne Mowery¹; Amy Wisdom¹; Jeremy Gresham¹; Anupama Reddy¹; Cassie Love¹; Sandeep Dave¹; Kouros Owzar¹

¹Duke University, Durham, NC, USA

**Poster 063  3042934**

**PRECLINICAL MODELING OF RESISTANT DISEASE USING AUTOPSY SAMPLES FROM PEDIATRIC PATIENTS WITH SOLID TUMORS**

**Sara Federico**¹; Brittney Gordon²; Kaley Blankenship¹; Armita Bahrami³; Michael Clay³; Michael Dyer³; **Elizabeth Stewart**¹

¹Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA; ²Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, TN, USA; ³Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA

**Poster 064  3043040**

**TARGETING STRESS GRANULES: A NOVEL APPROACH TO BLOCK SARCOMA METASTASIS**

**Amal M. EL-Naggar**¹; Yemin Wang¹; Melvin Pan¹; Syam Prakash Somasekharan¹; Hongwei Cheng²; Didier Surdez³; Poul H. Sorensen¹

¹Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada; ²Vancouver Prostate Centre, Vancouver, BC, Canada; ³Centre de Recherche de l’Institut Curie, Paris, France

**Poster 065  2992803**

**INNATE IMMUNITY TOLL LIKE RECEPTORS TLR1/2; TLR6 AND MUCIN MUC5B ARE BINDING INTERACTION PARTNERS WITH ANTIPROLIFERATIVE PEPTIDE PRP-1 IN HUMAN CHONDROSARCOMA**

**Karina Galoian**¹; Amir Qureshi²; Alexandra Moran¹; Parthik Patel¹

¹Orthopedics, University of Miami, Miller School of Medicine, Miami, FL, USA

**Poster 066  2993194**

**INHIBITION OF EMBRYONIC STEM CELL MARKERS EXPRESSION BY PRP-1 LEADS TO ELIMINATION OF CANCER STEM CELL POPULATION IN HUMAN CHONDROSARCOMA**

**Karina Galoian**¹; Alexandra Moran¹; Shannon Saigh²; Aaron Hoyt³

¹Orthopedics, University of Miami, Miller School of Medicine, Miami, FL, USA; ²Flow Cytometry Core, Sylvester Comprehensive Cancer Center, Miami, FL, USA

**Poster 067  3042161**

**TUMOR SUPPRESSOR GENE MUTATION IN THE HEDGEHOG PATHWAY DEFINES A NEW SUBSET OF PLEXIFORM FIBROMYXOMA**

**Sudeep Banerjee**¹; Chih-Min Tang¹; Mayra Yebra¹; Rowan Ustoy¹; Adam Burgoyne⁴; Thomas Savides³; Ann M.P. Tipps²; **Jason Sicklick**¹

¹Surgical Oncology, UCSD, La Jolla, CA, USA; ²Pathology, UCSD, La Jolla, CA, USA; ³Gastroenterology, UCSD, La Jolla, CA, USA; ⁴Medical Oncology, UCSD, La Jolla, CA, USA
THERAPEUTIC EFFECT OF SCLEROSTIN ON OSTEOSARCOMA
Masanori Okamoto1; Kazushige Yoshida; Jun Sasaki; Kaoru Aoki; Munehisa Kito; Yasuo Yoshimura;
Shuichiro Suzuki; Atsushi Tanaka; Akira Takazawa; Hisao Haniel; Takashi Takizawa; Atsushi Sobajima;
Takayuki Kamanaka; Naoto Saito; Hiroyuki Kato
1Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan; 2Institute for Biomedical Sciences, Shinshu University, Matsumoto, Japan

MACROPHAGES FACILITATE OCCURRENCE AND DEVELOPMENT OF HUMAN OSTEOSARCOMA CELLS MEDIATED BY NF-KB
Peng Zhang1; Jinyan Liu1; Feifei Feng2; Weitao Yao
1Bone and soft tissue sarcoma, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China; 2College of Public Health of Zhengzhou University, Zhengzhou, China

CYCLIN-DEPENDENT PROTEIN KINASE 9 (CDK9) IS A NOVEL PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN OSTEOSARCOMA
Zhenfeng Duan1; Hangzhan Ma; Francis Hornicek
1Orthopaedics, UCLA, Los Angeles, CA, USA

METHYLATION-SILENCING OF MULTIPLE TUMOR-SUPPRESSOR AND OSTEO/CHONDROGENESIS RELATED GENES IN OSTEOSARCOMA
Naofumi Asano1; Hideyuki Takeshima1; Satoshi Yamashita1; Hironori Takamatsu1; Naoko Hattori1; Eisuke Kobayashi1; Robert Nakayama1; Morio Matsumoto2; Masaya Nakamura2; Akira Kawai1; Tadashi Kondo2; Toshikazu Ushijima3
1Musculoskeletal Oncology, National Cancer Center, Tokyo, Japan; 2Orthopaedic surgery, Keio University, Tokyo, Japan; 3Epigenomics, National Cancer Center, Tokyo, Japan; 4Rare Cancer Research, National Cancer Center, Tokyo, Japan

IL-6 MEDIATED SELECTIVE TOXICITY FOR TUMOR-INITIATING CELLS FUNCTIONS TO PREVENT OSTEOSARCOMA METASTASIS
Amanda Saraf1; Randall Evans1; Amy Gross1; Sanjana Rajan1; Lindsay Ryan1; Melissa Sammons1; Sarah Winget1; Ryan Roberts1
1Nationwide Children’s Hospital, Columbus, OH, USA

IDENTIFICATION OF INFLAMMATORY FACTORS AND THE NOTCH PATHWAY AS THERAPEUTIC TARGETS FOR SARCOMA-ASSOCIATED CACHEXIA
Feiqi Lu1; Jonathan Mandell1; Alejandro Morales1; Vu Dinh2; Rebecca Watters3; Kurt Weiss1
1Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA; 2Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

ANTIPROLIFERATIVE EFFECT OF BUPIVACAINE ON PATIENT-DERIVED SARCOMA CELLS
Lee M. Zuckerman1; Hamid R. Mirshahidi2; Nadine L. Williams1; Joseph Elsissys1; Troy G. Shields1; Salman Otoukesh3; Saied Mirshahidi2
1Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; 2Biospecimen Laboratory, Loma Linda University Medical Center, Loma Linda, CA, USA; 3Hematology/Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA

THE EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON OSTEOSARCOMA CELLS
Joseph Elsissyy1; Lee M. Zuckerman1; Nadine L. Williams1; Troy G. Shields1; Saied Mirshahidi2
1Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; 2Biospecimen Laboratory, Loma Linda University Medical Center, Loma Linda, CA, USA
THE ATR INHIBITOR M4344 INDUCES TUMOR REGRESSION IN A PATIENT-DERIVED XENOGRAFT MODEL OF ALTERNATIVE LENGTHENING OF TELOMERS (ALT)-POSITIVE OSTEOSARCOMA.

Gregory M. Cote¹; Astrid Zimmermann¹; Jian Ouyang¹; Anupriya Kulkami²; Miguel Rivera²; Edwin Choy²; Frank Zenke²; Lee Zou¹
¹Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Merck KGaA, Darmstadt, Germany

ROLE OF HSF1 IN OSTEOSARCOMA INITIATION AND DEVELOPMENT

Brice W. Moukengue¹; Souad Kolli³; Celine Charrier¹; Severine Battaglia¹; Marc Baud’huin¹; Thibaut Quillard³; Valentina Boeva³; Benjamin Orly¹; Francois Lamoureux¹
¹UMR1238-PHY-OS; University of Nantes, Nantes, France; ²CHU of Nantes and University of Nantes, Nantes, France; ³Institut Cochin, Paris, France

ERIBULIN SHOWS HIGH EFFICACY ON HIGHLY CHEMOTHERAPY-RESISTANT OSTEOSARCOMA IN PATIENT-DERIVED ORTHOTOPIC XENOGRAFT MOUSE MODEL

Tasuku Kiyuna¹; Yasunori Tome¹; Hiroki Maehara¹; Hiromichi Oshiro¹; Robert M. Hoffman²; Fuminori Kanaya¹
¹Orthopedic, University of the Ryukyu, Nishihara, Okinawa, Japan; ²Surgery, University of California, San Diego, CA, USA

DD LIPO CELL LINES AND PDX TO EXPLORE THE ACTIVITY OF ANTICANCER DRUGS AND COMBINATIONS

Chiara Colombo¹; Valentina Zuco¹; Sandro Pasquali¹; Monica Tortoreto¹; Federica Rotundo¹; Marta Barisella¹; Roberta Sanfilippo¹; Silvia Scacchioli¹; Alessandro Gronchi¹; Nadia Zaffaroni¹
¹Fondazione IRCCS Istituto Tumori Milano, Milan, Italy

CIRCULATING TUMOR CELL DETECTION FOR HEMANGIOSARCOMA DIAGNOSIS IN DOGS

Taylor A. DePauw¹; Ashley J. Graef¹; Jaime F. Modiano¹
¹University of Minnesota, Minneapolis, MN, USA

INCIDENCE OF CARDIOMYOPATHY WITH TRABECTEDIN USE IN SOFT TISSUE SARCOMAS

Steven R. Bialick¹; Lee Hartner¹; Arthur Staddon¹
¹Pennsylvania Hospital of the University of Pennsylvania, Philadelphia, PA, USA

A PHASE 1B/2 STUDY OF VORINOSTAT IN COMBINATION WITH GEMCITABINE AND DOCETAXEL IN ADVANCED SOFT TISSUE SARCOMAS (STS)

Melissa Burgess¹; Yan Lin¹; Jan Beumer¹; Hussein Tawbi²
¹Medicine, Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; ²MD Anderson Cancer Center, Houston, TX, USA

EVALUATION OF LENVATINIB, EVEROLIMUS OR THE COMBINATION IN PEDIATRIC SARCOMA MODELS

Raushan Kurmasheva¹; Abhik Bandopadhyay²; Doris Phelps³; Kathryn Bondra¹; Terry Shackelford³; Joel Michalek³; Wendong Zhang¹; Michael Roth¹; Jonathan Gill¹; Richard Gorlick³; Peter Houghton²
¹Pediatrics, MD Anderson Cancer Center, Houston, TX, USA; ²Greehey Children’s Cancer Research Institute, UT Health San Antonio, San Antonio, TX, USA; ³Epidemiology and Biostatistics, UT Health Science Center San Antonio, San Antonio, TX, USA

RADIOTHERAPY (RT) COMBINED WITH TRABECTEDINE FOR LOCALLY ADVANCED OR METASTATIC, SOFT TISSUE SARCOMA (STS): AN UPDATE OF A SINGLE INSTITUTION EXPERIENCE

Federico Navarria¹; Michela Guardacine²; Elisa Palazzari¹; Stefania Basso¹; Marco Gigante¹; Roberto Innocente¹; Gianmaria Miolo¹; Giulio Bertola¹; Angela Buonadonna²; Antonino De Paoli¹
¹Radiation Oncology, National Cancer Institute CRO IRCCS, Aviano (PN), Italy; ²Medical Oncology, National Cancer Institute CRO IRCCS, Aviano (PN), Italy; ³Surgical Oncology, National Cancer Institute CRO IRCCS, Aviano (PN), Italy
LEUCOENCEPHALOPATHY IS A COMMON COMPLICATION IN PATIENTS TREATED WITH HIGH DOSE METHOTREXATE

Sandra Raimbault; Pierre Brugieres; Audrey Longaud; Nathalie Gaspar; Jean Louis Amegnizin; Nathalie Bellier; Brice Fresneau; Christelle Dufour; Jérôme Hodel; Dominique Valteau-Couanet; Laurence Brugieres

1Pediatrie, Gustave Roussy, Villejuif, France; 2Neuroradiology department, Henri Mondor University Hospital, APHP, Créteil, France; 3Paediatrie, Part 2 private hospital, Versailles, France

TARGETING MICROENVIRONMENT AND CELLULAR IMMUNITY IN SARCOMAS WITH WEEKLY TRABECTEDIN COMBINED WITH METRONOMIC CYCLOPHOSPHAMIDE (TARMIC)

Antoine Italiano; Julien Adam; Catherine Sautès-Fridman; Hervé Fridman; Alban Bessede; Xavier Buy; Nadia Badr; Sophie Cousin; Marina Pulido; Maud Toulmonde

1Institut Bergonié, Bordeaux, France; 2Institut Gustave Roussy, Villejuif, France; 3Centre Recherche Cordeliers, Paris, France; 4Immusmol, Bordeaux, France; 5Pharmamar, Madrid, Spain

THE IMPACT OF CHEMOTHERAPY ON PRIMARY BONE TUMORS OF THE VERTEBRAL COLUMN: A NATIONAL CANCER DATABASE REVIEW

Alexander L. Lazarides; David Kerr; Brian L. Dial; Anthony Catanzano; Whitney Lane; Dan Blazer II; William Eward; Brian Brigman; Melissa Erickson; Sergio Mendoza

1Department of Orthopaedics, Duke University Medical Center, Durham, NC, USA; 2Department of Surgery, Duke University Medical Center, Durham, NC, USA

NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA: THE GUSTAVE ROUSSY EXPERIENCE

Sarah N. Dumont; Elena Cojocaru; Matthieu Faron; Leila Haddag; Jean Francois H. Honart; Nicolas Kiavue; Françoise Rimareix; Antonin Levy; Cécile Le Péchoux; Angela Boticella; Philippe Terrier; Julien Adam; Olivier Mir; Andrea Cavalcanti; Charles Honoré; Axel Le Cesne

1Roussy, Gustave, Villejuif, France

REAL-WORLD TREATMENT PATTERNS AMONG ADVANCED SOFT TISSUE SARCOMA PATIENTS RECEIVING SYSTEMIC THERAPY IN A COMMUNITY ONCOLOGY SETTING IN THE UNITED STATES

Eric Nadler; Lisa M. Hess; Pablo Lee; Yajun Emily Zhu; Scott S. Barker; Thomas Wilson; E Susan Amirian

1HEOR, McKesson Specialty Health, The Woodlands, TX, USA; 2Texas Oncology & The US Oncology Network, Dallas, TX, USA; 3Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA

A RETROSPECTIVE STUDY TO ASSESS THE INCIDENCE OF EARLY AND LATE CARDIOTOXICITY EVALUATED BY MUGA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SARCOMA TREATED WITH DOXORUBICIN

Joanna Vitfell-Rasmussen; Naja L. Hansen; Merete Vaage-Nielsen; Bo Zerahn; Anders Krarup-Hansen

1Department of Clinical Physiology and Nuclear Medicine, Herlev and Gentofte University Hospital, Herlev, Denmark; 2Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark; 3Department of Cardiology, Herlev and Gentofte University Hospital, Herlev, Denmark
**NEOADJUVANT CHEMORADIOThERAPY IN ADVANCED SOFT TISSUE SARCOMA (ASTS)**

**Jeronimo Martinez-Garcia**; Pablo Puertas; Antonio Valcarce; Juan Angel Fernandez; Teresa Soria; Gloria Torres; Asuncion Soto; Pilar Sanchez-Henarejos; Ana Puertes; Jose Emilio Hernandez; Maria Dolores Abellan; Andres Lopez-Sanchez; Begoña Torregrosa; Isabel de la Fuente; Enrique Cardenas; Jose Luis Navarro; Clemente Jose Fernandez-Pascual; Maria Jose Roca; Jose Luis Alonso-Romero

1 Medical Oncology, Clinical University Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain; 2 Orthopedics and Traumatology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; 3 Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; 4 Pathology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; 5 Radiology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; 6 Radiotherapy, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; 7 Nuclear Medicine, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; 8 Plastic Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; 9 Thoracic Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain

---

**OLARATUMAB PLUS DOXORUBICIN FOLLOWED BY OLARATUMAB MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH ADVANCED/METASTATIC SOFT TISSUE SARCOMA: REAL-WORLD UTILIZATION AND OUTCOMES IN THE UNITED STATES**

**Victor Villalobos**; Lisa M. Hess; Yajun Emily Zhu; Tomoko Sugihara; Pablo Lee; Volker Wacheck; Scott S. Barker; Andrew Wagner

1 Eli Lilly and Company, Indianapolis, IN, USA; 2 University of Colorado-Denver, Denver, CO, USA; 3 Syneos Health, Raleigh, NC, USA; 4 Harvard University, Boston, MA, USA

---

**PHASE IB STUDY OF DECITABINE IN COMBINATION WITH GEMCITABINE IN TREATMENT OF REFRactory ADVANCED SOFT TISSUE OR BONE SARCOMAS**

**Varun Monga**; Umang Swami; Rebecca Dodd; Munir Tanas; Sarah Mott; Mohammed Milhem

1 Internal Medicine, University of Iowa, Iowa City, IA, USA; 2 Pathology, University of Iowa, Iowa City, IA, USA; 3 Holden Comprehensive Cancer Center, Iowa City, IA, USA

---

**CHARACTERISTICS AND TREATMENT PATTERNS WITH ADVANCED SOFT TISSUE SARCOMA IN KOREA**

**Hyo Song Kim**; Chung Mo Nam; Suk-Yong Jang; Sun Kyu Choi; Minkyung Han; Seonmin Kim; Maria Victoria Moneta; Sae Young Lee; Jae Min CHO; Diego Novick; Sun Young Rha

1 Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea (the Republic of); 2 Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea (the Republic of); 3 Department of Preventive Medicine, Euiji University College of Medicine, Seoul, Korea (the Republic of); 4 Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea (the Republic of); 5 Department of Public Health, Yonsei University Graduate School, Seoul, Korea (the Republic of); 6 Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CiBERSAM, Universitat de Barcelona, Barcelona, Spain; 7 Eli Lilly and Company, Seoul, Korea (the Republic of); 8 Global Patients Outcomes and Real World Evidence, Eli Lilly and Company Limited, Windlesham, Surrey, United Kingdom

---

**TRABECTEDIN-INDUCED MONOCYTES REDUCTION: A POTENTIAL SURROGATE PROGNOSTIC FACTOR?**

**Marianna Silletta**; Giuseppe Badalamenti; roberta sanfilippo; Anna Maria Fresza; Mariella Spalato Ceruso; Andrea Napolitano; Sergio Valeri; Angelo Paolo Dei Tos; Paolo Casali; Silvia Stacchiotti; Alessandro Gronchi; Daniele Santini; Giuseppe Tonini; Bruno Vincenzi

1 Oncology, Campus Bio-Medico, Rome, RM, Italy; 2 Oncology, poli clinico giacomo, Palermo, Italy; 3 Oncology, Istituto Nazionale Tumori, Milan, Italy; 4 Surgical Dep, Campus Bio Medico, Rome, Italy; 5 Università Padova, Padova, Italy

---

**CLINICAL OUTCOME OF ERIEBULIN IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: A COHORT STUDY INCLUDING NON-L-SARCOMAS**

**Makoto Endo**; Nobuhiko Yokoyama; Nokitaka Setsu; Toshifumi Fujiwara; Kenichiro Yahiro; Atsushi Kimura; Eijiro Shimada; Kenji Tsuchihashi; Hitoshi Kusaba; Yoshinao Oda; Yasuharu Nakashima; Yoshihiro Matsumoto

1 Kyushu University, Fukuoka, Japan
Poster 097  3042614

**PZAPANIB NEOADJUVANT TRIAL IN SOFT TISSUE SARCOMAS: A REPORT OF MAJOR WOUND COMPLICATIONS DURING DOSE-FINDING PHASE ON ARST 1321**

*Thomas Scharschmidt*,1; *Yen-Lin E. Chen*,2; *Dian Wang*,2; *Yueh-Yun Chi*,3; *Jing Tian*,3; *Mark Kayton*,4; *R. Lor Randall*,5; *Douglas Hawkins*,6; *Aaron Weiss*,7

1Ohio State University, Columbus, OH, USA; 2Harvard Medical School, Boston, MA, USA; 3Rush Medical Center, Chicago, IL, USA; 4University of Florida, Gainesville, FL, USA; 5Palm Beach Children’s Hospital, West Palm Beach, FL, USA; 6UC Davis, Sacramento, CA, USA; 7Seattle Children’s Hospital, Seattle, WA, USA

---

Poster 098  3042618

**USE OF CARDIOPROTECTIVE DEXRAZOXANE AND MYELOTOXICITY IN ANTHRACYCLINE-TREATED SOFT-TISSUE SARCOMA PATIENTS**

*Mariella Spalato Ceruso*,1; *Andrea Napolitano*,1; *Mariana Silletta*,1; *Alessandro Mazzocca*,1; *Sergio Valeri*,2; *Luca Improta*,2; *Daniele Santini*,1; *Giuseppe Tonini*,1; *Bruno Vincenzi*,1

1Oncology, Campus Bio-Medico, Rome, RM, Italy; 2General Surgery, Campus Bio-Medico, Rome, Italy

---

Poster 099  3042688

**COMBINATION OF ERIBULIN PLUS GEMCITABINE IN L-SARCOMAS**

*Maria Lopez-Alvarez*,1; *David S. Moura*,1; *Paloma Sanchez-Bustos*,1; *Ana Salinas-Villegas*,1; *Nadia Hindi*,1; *Miguel Taron*,2; *Javier Martinez-Broto*,2

1Group of Advanced Therapies and Biomarkers in Oncology, Institute of Biomedicine of Seville, Spain; 2Group of Advanced Therapies and Biomarkers in Oncology, Institute of Biomedicine of Seville, University Hospital Virgen del Rocio, Seville, Spain

---

Poster 100  3042696

**PREDICTIVE ROLE OF HMG PROTEINS FOR RESPONSE TO TRABECTEDIDIN IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS): A SPANISH GROUP FOR RESEARCH ON SARCOMAS (GEIS-38 STUDY)**

*Nadia Hindi*,1; *David S. Moura*,1; *Javier Martinez-Trufero*,2; *Rosa Maria Alvarez Alvarez*,3; *Magda Conceicao*,4; *Luis Miguel de Sande Gonzalez*,3; *María Graññana*,3; *Juan María Cano*,3; *Josefina Cruz*,3; *Claudia Valverde*,3; *Maria A. Vaz*,3; *Javier Lavernia*,1; *Antonio Lopez-Pousa*,1; *Robert Díaz Beveridge*,13; *Isabel Sevilla*,14; *Antonio Gutierrez*,1; *David Marcilla*,15; *Miguel Taron*,2; *Rafael Ramos*,2; *Javier Martinez-Broto*,1

1Institute of Biomedicine Research (IBIS)- University Hospital Virgen del Rocio/CSIC/University of Seville, Seville, Spain; 2University Hospital Miguel Servet, Zaragoza, Spain; 3Hospital Gregorio Marañón, Madrid, Spain; 4Hospital Son Espases, Palma de Mallorca, Spain; 5Hospital of León, Leon, Spain; 6University Hospital San Carlos, Pozuelo de Alarcon, Spain; 7General Hospital of Ciudad Real, Ciudad Real, Spain; 8University Hospital of Canary Islands, Santa Cruz De Tenerife, Spain; 9University Hospital Vall d’Hebron, Barcelona, Spain; 10University Hospital Ramon y Cajal, Madrid, Spain; 11Foundation Instituto Valenciano de Oncologia, Valencia, Spain; 12Hospital Sant Pau, Barcelona, Spain; 13University Hospital La Fe, Valencia, Spain; 14University Hospital Virgen de la Victoria, Málaga, Spain; 15University Hospital Virgen del Rocio, Seville, Spain

---

Poster 101  3042141

**REAL-WORLD EXPERIENCES WITH PZAPANIB TREATMENT FOR PATIENTS WITH ADVANCED SOFT TISSUE AND BONE SARCOMA IN NORTHERN CALIFORNIA**

*Mee-Na Song*,1; *Maily Trieu*,1; *Jeanette Yu*,1; *Manpreet Sidhu*,1; *Danny Sam*,2; *Ming gui Pan*,3

1Oncology, Kaiser Permanente, Santa Clara, CA, USA; 2Internal Medicine Residency Program and Department of Oncology and Hematology, Kaiser Permanente Medical Center, Northern California, USA

---

Poster 102  3008065

**NEUTROPHIL-TO-LYMPHOCYTE RATIO AFTER PZAPANIB TREATMENT PREDICTS RESPONSE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA**

*Hiroshi Kobayashi*,1; *Tomotake Okuma*,2; *Hiroyuki Oka*,1; *Toshihide Hirai*,1; *Takahiro Ohki*,1; *Masachika Ikegami*,1; *Ryoko Sawada*,1; *Yusuke Shinoda*,2; *Toru Akiyama*,3; *Kenji Sato*,4; *Satoshi Abe*,5; *Hirotaka Kawano*,5; *Takahiro Goto*,5; *Sakae Tanaka*,1

1The University of Tokyo Hospital, Tokyo, Japan; 2Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; 3Faculty of Medicine, University of Teikyo, Tokyo, Japan; 4Saitama Medical Center, Jichi Medical University, Saitama, Japan
THE SIGNIFICANT EFFECTS OF PAZOPANIB ON ADVANCED SOFT TISSUE SARCOMA:
A RETROSPECTIVE ANALYSIS IN CHINA
Bushu Xu; Wei Xiao; Yi Que; Xizhi Wen; Xing Zhang
1Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

SHOULD NEOADJUVANT CHEMOTHERAPY BECOME STANDARD TREATMENT FOR HIGH-RISK SOFT TISSUE SARCOMAS? A SINGLE CENTRE RETROSPECTIVE ANALYSIS.
Anna C. Virgili Manrique; Ana Sebio; María J. Quintana; Oscar Gallego; Isidro Gracia; Ana Peiró; Laura Trullols
1Medical Oncology, Hospital Sant Pau, Barcelona, Spain; 2Epidemiology, Sant Pau Hospital, Barcelona, Spain; 3Orthopaedic Surgery and Traumatology, Hospital Sant Pau, Barcelona, Spain; 4Plastic and Reconstructive Surgery, Hospital Sant Pau, Barcelona, Spain; 5Radiation Oncology, Hospital Sant Pau, Barcelona, Spain; 6Radiology, Hospital Sant Pau, Barcelona, Spain; 7Thoracic Surgery, Hospital Sant Pau, Barcelona, Spain; 8General and Digestive Surgery, Hospital Sant Pau, Barcelona, Spain; 9Pathology, Royal Marsden NHSFS Hospital, London, United Kingdom; 10Pathology, Hospital Sant Pau, Barcelona, Spain

GEMCITABINE AND DOCETAXEL AS TREATMENT OPTION FOR ADVANCED ANGIOSARCOMA
Alexander Fedenko; Andrey A. Konev; Anastasia A. Tararykova
1Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Mosow, Russian Federation

TROFOSFAMID AND ETOPOSID – AN EFFECTIVE PALLIATIVE CHEMOTHERAPY FOR RECURRENT MENINGEAL SARCOMA
Mikael Eriksson; Marie Ahlström
1Oncology, Skane University Hospital, Lund, Sweden

TEMOZOLOMID MONOTHERAPY AS AN OPTION IN LOCALLY ADVANCED AND METASTATIC SOLITARY FIBROUS TUMOR: A GUSTAVE ROUSSY SERIES
Sarra Akla; Yasmina Moukasse; Siham Ouguelliti; Sixtine De Percin; Miruna Alina Grecea; Marc Antoine Benderra; Marine Sroussii; Maud Velev; Naima Lezghedi; Olivier Mir; Matthieu Faron; Leila Haddag; Philippe Terrier; Andrea Cavalcanti; Rastislav Bahleda; Axel Le Cesne; Sarah N. Dumont
1Oncology, Gustave Roussy, Arceuil, France; 2National Oncology of Rabat, Rabat, Morocco

HEPATOTOXICITY AS A PREDICTIVE FACTOR FOR SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Rita Paiva; Isabel Fernandes; Teresa Pacheco; Cecilia de Melo Alvim Moreira; Helena Luna Pais; Raquel Brás; André Mansinho; Daniela Macedo; Luís Costa
1Medical Oncology, Hospital de Santa Maria, Lisboa, Portugal

THE RESULTS OF TREATMENT WITH TRABECTEDIN FOR ADVANCED SOFT TISSUE SARCOMAS:
A JAPANESE SINGLE-CENTER EXPERIENCE
Tsukasa Yonemoto; Hiroto Kamoda; Toshinori Tsukanishi; Hideyuki Kinoshita; Takeshi Ishii
1Chiba Cancer Center, Chiba, Japan
SAFETY AND EFFICACY OF OLARATUMAB ADDED TO DOXORUBICIN-BASED COMBINATION CHEMOTHERAPY IN THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMA (STS).

Andrea Espejo1; Vaia Florou2; Ty Subhawong3; Breelyn A. Wilky4; Jonathan Trent4
1Internal Medicine, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, FL, USA; 2Hematology/Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA; 3Musculoskeletal Radiology, Sarcoma Research Program, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA; 4Hematology/Oncology, Sarcoma Research Program, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA

Poster 111 3003237
PREDICTING SURVIVAL IN LOCALIZED CHONDROSARCOMA
Alexander L. Lazarides1; David Kerr1; Sneha Rao1; Whitney Lane2; Jason Somarelli3; Dan Blazer III4; Brian Brigman1; William Eward1
1Department of Orthopaedics, Duke University Medical Center, Durham, NC, USA; 2Department of Surgery, Duke University Medical Center, Durham, NC, USA

Poster 112 3042422
PARP INHIBITORS; A NOVEL THERAPEUTIC STRATEGY FOR CHONDROSARCOMA?
Sanne Venneker1; Alwine B. Kruisselbrink1; Erik H. Danen2; Judith V. Bovee1
1Pathology, Leiden University Medical Center, Leiden, Netherlands; 2Drug Discovery & Safety, Leiden Academic Centre for Drug Research, Leiden, Netherlands

Poster 113 3026463
CLINICAL UTILITY OF 2-HG AS A BIOMARKER IN IDH MUTATED CHONDROSARCOMA
Makoto Nakagawa1; Fumihiro Nakatani2; Makoto Endo2; Akira Kawai2; Akihiko Yoshida2; Shinji Tsutsumi3; Kazushi Araki4; Yasuharu Nakashima5; Issay Kitsayashi1
1Hematological Malignancy, National Cancer Center Research Institute, Tokyo, Japan; 2Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; 3Orthopaedic Surgery, Kyushu University, Fukuoka, Japan; 4Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan; 5Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan

Poster 114 3027412
IMMUNE LANDSCAPE OF HIGH GRADE CHONDROSARCOMAS: IDENTIFICATION OF KEY PLAYERS CREATING AN IMMUNOSUPPRESSIVE TUMOR ENVIRONMENT
Iseulys Richert1; Corinne Bouvier2; Anne Brouchet3; Gonzague De Pinieux3; Jean-Yves Blay4; Aurelie Dutour1
1Apoptosis and pediatric cancers, Centre Leon BERARD, Lyon, France; 2Anatomopathology and Cytology, La Timone Hospital APHM, Marseille, France; 3Anatomopathology and Cytology, Hospital and University of Tours, Tours, France; 4Anatomopathology Cytology, IUCT Oncopole, Toulouse, France; 5Oncology, centre Leon BERARD, Lyon, France

Poster 115 3027640
CLEAR CELL CHONDROSARCOMA: CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES IN 19 PATIENTS
James H. Flint1; Anthony P. Conley2; Justin Bird3; Patrick Lin1; Bryan Moon1; Robert L. Satcher1; Valerae Lewis1
1Orthopedic Oncology, MD Anderson Cancer Center, Houston, TX, USA; 2Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 116 3042912
Gabriel J. Pavey1; Lee D. Cranmer1; Bonny J. Chau1; Matthew J. Thompson2; Elizabeth Loggers3; Seth Pollack3; Michael J. Wagner1; Edward Y. Kim4; Gabrielle Kane4; Teresa S. Kim5
1Medical Oncology Division, University of Washington, Seattle, WA, USA; 2Orthopedics, University of Washington, Seattle, WA, USA; 3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 4Radiation Oncology, University of Washington, Seattle, WA, USA; 5Department of Surgery, University of Washington, Seattle, WA, USA
CLEAR CELL CHONDROSARCOMA: REPORT OF 7 CASES AND METAANALYSIS OF LITERATURE
Alexander Klein1; Hans Roland Dürri; Christof Birkenmaier1; Felix Tauscher1; Volkmar Jansson1; Andrea Baur-Melnyk2
1Musculoskeletal Oncology, Department of Orthopaedic Surgery, Physical Medicine and Rehabilitation, University Hospital, LMU Munich, Munich, Germany; 2Department of Radiology, University Hospital, LMU Munich, Munich, Germany

PROGNOSTIC FACTORS FOR SURVIVAL IN DEDIFFERENTIATED CHONDROSARCOMA
Ruoyu Miao1; Edwin Choy2; Kevin Raskin3; Joseph H. Schwab3; Petur Nielsen4; Vikram Deshpande4; Ivan Chebib4; Thomas F. DeLaney5; Francis Hornicek4; Gregory M. Cote2; Yen-Lin E. Chen1
1Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; 2Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA; 3Department of Orthopedic Oncology, Massachusetts General Hospital, Boston, MA, USA; 4Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

DRUG REPURPOSING AS A SOURCE OF INNOVATIVE THERAPIES IN CHONDROSARCOMA
Pan Pantziarka1; Gauthier Bouche1
1Anticancer Fund, Kingston Upon Thames, Surrey, United Kingdom

CISPLATIN IN ADVANCED CHORDOMA: A RETROSPECTIVE CASE-SERIES ANALYSIS
Bruna B. David1; Salvatore Provenzano1; Bruno Vincenzi2; Tiziana Venesio3; Lorenzo D’Ambrosio3; Giuseppe Badalamenti4; Chiara Ancona5; Andrea Marrarì5; Giacomo G. Baldi6; Antonina Parafioriti7; Noemi Simeone1; Paolo Casalì1; Silvia Stacchiotti1
1Medical Oncology Unit 2 - Adult mesenchymal tumour and rare cancer, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2Department of Medical Oncology, Università Campus Bio-Medico di Roma, Rome, Italy; 3Sarcoma Unit, Candiolo Cancer Institute – FPO, IRCCS, Candiolo, Italy; 4Medical Oncology Unit - Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy; 5Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Italy; 6Medical Oncology Unit, Hospital of Prato, Prato, Italy; 7Anatomia Patologica, ASST PINI-CTO, Milan, Italy

WHAT IS THE RISK OF MORTALITY FOLLOWING LOCAL RECURRENCE OF A SURGICALLY TREATED CHORDOMA OF THE SACRUM?
Mario Hevesi1; Matthew T. Houdek1; Joseph H. Schwab1; Michael Yaszemski1; Jay Wunder1; Peter Ferguson1; Francis Hornicek2; Franklin H. Sim3; John Healey4; Patrick Boland5; Peter S. Rose1
1Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA; 2Mount Sinai Hospital, Toronto, ON, Canada; 3Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA; 4University of California Los Angeles, Los Angeles, CA, USA; 5Memorial Sloan Kettering Cancer Center, New York, NY, USA

FACTORS ASSOCIATED WITH 5-YEAR SURVIVAL IN CHORDOMAS: A NATIONAL CANCER DATABASE STUDY
Brian L. Dial1; David Kerr1; Alexander L. Lazarides1; Whitney Lane2; Dan Blazer III2; Brian Brigman1; William Eward1; Melissa Erickson1; Sergio Mendoza2
1Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA; 2General Surgery, Duke University Medical Center, Durham, NC, USA

CHORDOMA OF THE MOBILE SPINE AND SACRUM: A RETROSPECTIVE ANALYSIS OF A SERIES OF 108 PATIENTS UNDERGOING SURGERY IN THE LONDON SARCOMA SERVICE
Vittoria Colia1; Beatrice Seddon1; Roberto Tirabosco2; Luca Porcu1; Adrienne Flanagan2; Robin Pollock2; Palma Dileo1
1Oncology, University College London Hospital, London, United Kingdom; 2Pathology, Royal National Orthopaedic Hospital NHS Trust, London, United Kingdom; 3Oncology Department, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 4Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 5Surgery, Royal National Orthopaedic Hospital NHS Trust, London, United Kingdom
CIRCULATING TUMOR DNA IS DETECTABLE IN TRANSLOCATION POSITIVE RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG)
Samuel Abbou1; David Hall2; Donald A. Barkauskas3; Kelly Klega4; Anwesha Nag3; Aaron R. Thorne3; Douglas S. Hawkins5; Steven DuBois6; Brian Crompton
1QuadW-COG Childhood Sarcoma Biostatistics and Annotation Office, Children’s Oncology Group, Monrovia, CA, USA; 2Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; 3Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA, USA; 4Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA; 5Hematology/Oncology, Seattle Children’s Hospital, Seattle, WA, USA

RELATIVE FUSION GENE LEVEL IN CIRCULATING CELL-FREE DNA SERVES AS A PROGNOSTIC BIOMARKER IN EWING SARCOMA
Shintaro Iwata1; Hajime Kageyama2; Makiko Itami2; Tsukasa Yonemoto2; Akira Kawai1
1National Cancer Center Hospital, Tokyo, Japan; 2Chiba Cancer Center, Chiba, Japan

PILOT STUDY EVALUATING THE CONCORDANCE OF CIRCULATING TUMOR DNA ALTERATIONS WITH TUMOR-BASED SEQUENCING IN SOFT TISSUE SARCOMA
Bryce Demoret1; Sherri Z. Millis2; Gabriel Tinoco1; David Liebner1; James L. Chen1
1The Ohio State University, Columbus, OH, USA; 2Foundation Medicine, Cambridge, MA, USA

CIRCSARC; NON-INVASIVE MONITORING OF SARCOMAS PATIENTS BY CIRCULATING TUMOUR DNA IN PLASMA
Heidi M. Namløs1; Seyed Hossein Moosavi2; Bodil Bjerkehagen3; Olga Zaikova3; Susanne Lorenz4; Lars Aasheim4; Eivind Hovig1; Nina L. Jebsen5; Ola Myklebost6; Boye Kjetil7; Leonardo A. Meza-Zepeda1
1Department of Tumor Biology, Oslo University Hospital, Oslo, Norway; 2Department of Pathology, Oslo University Hospital, Oslo, Norway; 3Department of Surgery, Oslo University Hospital, Oslo, Norway; 4Department of Core Facilities, Oslo University Hospital, Oslo, Norway; 5Department of Oncology, Haukeland University Hospital, Bergen, Norway; 6Department of Clinical Science, University of Bergen, Bergen, Norway; 7Department of Oncology, Oslo University Hospital, Oslo, Norway

ULTRA-SENSITIVE DETECTION OF TRANSLOCATIONS IN THE CELL-FREE DNA OF PEDIATRIC SARCOMA PATIENTS
Avanthi T. Shah1; Tej Azad2; Jake Chabon2; Stan Leung1; Aviv Spillinger2; Heng-Yi Liu1; Marcus Breese1; Maximilian Diehn3; Ash A. Alizadeh3; Alejandro Sweet-Cordero1
1Pediatrics, UCSF, San Francisco, CA, USA; 2Stanford University School of Medicine, Stanford, CA, USA; 3Stanford Cancer Institute, Stanford, CA, USA

NONINVASIVE MOLECULAR PROFILING AND RESPONSE MONITORING BY CELL-FREE DNA ANALYSIS IN OSTEOSARCOMA
Emily Slotkin1; Julie Yang2; Dana Tsur2
1Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Memorial Sloan Kettering Cancer Center, New York, NY, USA

RNA-SEQUENCING OF TUMOR-EDUCATED PLATELETS, A NOVEL BIOMARKER FOR BLOOD BASED SARCOMA DIAGNOSTICS
Kimberley M. Heinhuis1; Sjors In’t Veld2; Govert Dwarshuis2; Daan van den Broek2; Nik Sol3; Myron Best3; Anne Miek Koenen4; Wijn J. van Houdt4; Frits van Coeorden4; Rick Haas5; Tom Wurdinger6; Neeltje Steeghs1
1Medical Oncology and Clinical Pharmacology, the Netherlands Cancer Institute, Amsterdam, Netherlands; 2Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands; 3Laboratory Medicine, the Netherlands Cancer Institute, Amsterdam, Netherlands; 4Brain Tumor Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands; 5Radiotherapy, the Netherlands Cancer Institute, Amsterdam, Netherlands; 6Surgical Oncology, the Netherlands Cancer Institute, Amsterdam, Netherlands
TREATMENT MONITORING IN PATIENTS WITH PEDIATRIC SARCOMAS USING CIRCULATING TUMOR DNA ANALYSIS: A FEASIBILITY STUDY
Jun Zhao1; Braden McDonald2; Tania Contente-Cuoto2; Ahuva Odenheimer2; Michelina de la Maza1; Pooja Hingorani1; Mohammed Murtaza2
1Pediatric Hematology/Oncology, Phoenix Children’s Hospital, Phoenix, AZ, USA; 2Center for Non-invasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ, USA

DESMOID-TYPE FIBROMATOSIS: A SINGLE INSTITUTION EXPERIENCE.
Ferdinando Carlo Maria Cananzi1; Federico Sicoli1; Laura Samá1; Laura Ruspi1; Damiano Gentile1; Jacopo Galvanin1; Vittorio Quagliuolo2
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy; 2Surgical Oncology Unit, Humanitas Clinical and Research Center, Rozzano (Milan), Italy

YOUNG PATIENTS WITH DESMOID FIBROMATOSIS HAVE HIGH RATES OF LOCAL RECURRENT:
IS IT TIME TO RETHINK TREATMENT STRATEGIES IN THIS SUBSET?
Andrew J. Bishop1; Maria A. Zarzour2; Ravin Ratan3; Kiela E. Torres3; Barry Feig4; Wei-Lien Wang4; Alexander J. Lazar4; Bryan Moon5; Christina Roland6; B. Asheleigh Guadagnolo1
1Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; 2Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 3Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 4Pathology, MD Anderson Cancer Center, Houston, TX, USA; 5Orthopedic Surgery, MD Anderson Cancer Center, Houston, TX, USA

FAP-RELATED DESMOID TUMORS TREATED WITH LOW-DOSE CHEMOTHERAPY:
RESULTS FROM A MULTICENTRE RETROSPECTIVE ANALYSIS
Bruno Vincenzi1; Salvatore Provenzano2; Antonella Brunello3; Giuseppe Badalamenti4; Margherita Nannini5; Toni Ibrahim6; Peter Hohenberger6; Silvia Gasperoni7; Andrea Napolitano8; Mariella Spalato Ceruso1; Marianna Siletta1; Vittelaro Marco1; Angelo Paolo Dei Tos9; Daniele Santini1; Giuseppe Tonini1; Elena Palassi1
1Oncology, Campus Bio-Medico, Rome, RM, Italy; 2Istituto Nazionale Tumori Milano, Milano, Italy; 3Istituto Oncologico Veneto, Padova, Italy; 4Azienda Ospedaliera Universitaria Policlinico “Paolo Giaccone”, Palermo, Italy; 5University of Bologna, Bologna, Italy; 6Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; 7University Hospital Mannheim, Mannheim, Germany; 8Ospedale Universitario Careggi, Firenze, Italy; 9University of Padova, Padova, Italy

SIGNIFICANT RISK FACTORS OF LOCAL RECURRENCE AFTER SURGERY IN EXTRA-PERITONEAL DESMOID-TYPE FIBROMATOSIS: A MULTICENTER STUDY IN JAPAN
Yoshihiro Nishida1; Shunsuke Hamada2; Akira Kawaf3; Toshiyuki Kunisada4; Akira Ogose5; Yoshihiro Matsumoto6; Keisuke Ae7; Junya Toguchida8; Toshifumi Ozaki8; Akihiro Hirakawa8; Tomohisa Sakai9; Koki Shimizu9; Eisuke Kobayashi9; Tabu Gokita10; Takeshi Okamoto9; Tomoya Matsunobu12
1Nagoya University Hospital, Nagoya, Aichi, Japan; 2Aichi Cancer Center Hospital, Nagoya, Japan; 3National Cancer Center Hospital, Tokyo, Japan; 4Okayama University Graduate School of Medicine, Okayama, Japan; 5Uniona Institute of Community Medicine, Niigata University Medical and Dental Hospital, Uonuma, Japan; 6Kyusyu University, Fukuoka, Japan; 7Cancer Institute Hospital, Tokyo, Japan; 8Kyoto University Graduate School of Medicine, Kyoto, Japan; 9The University of Tokyo, Tokyo, Japan; 10Nagoya University Graduate School of Medicine, Nagoya, Japan; 11Saitama Cancer Center, Ina, Japan; 12Kyusyu Rosai Hospital, Kitakyusyu, Kitakyusyu, Japan

EFFECTS OF MATRIX STIFFNESS ON CULTURED CELLS OF DESMOID-TYPE FIBROMATOSIS
Tomohisa Sakai1; Yoshihiro Nishida2; Shunsuke Hamada3; Kunihiro Ikuta4; Takehiro Ota1; Hiroshi Koike1; Koki Shimizu1; Naoki Ishiguro1
1Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan; 2Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan; 3Department of Orthopaedic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
Poster 138 3042486

MUTATION STRATIFICATION OF DESMOID-TYPE FIBROMATOSIS USING A RADIOGENOMICS APPROACH – PRELIMINARY RESULTS

Milea Timbergen1; Martijn Starmans2; Melissa Vos3; Guillaume Padmos3; Dirk Grünhagen2; Geert H.J. V. Leenders2; Kees Vrohoef1; Wiro Niessen4; Stefan Sleijfer1; Stefan Klein3; Jacob Visser2
1Surgical Oncology, Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; 2Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands; 3Radiology and Nuclear Medicine, Medical Informatics, Erasmus MC, University Medical Center, Rotterdam, Netherlands; 4Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; 5Radiology and Nuclear Medicine, Medical Informatics, Erasmus MC, Rotterdam, Netherlands; 6Pathology, Erasmus MC, Rotterdam, Netherlands; 7Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Poster 139 3007734

ACTIVITY OF SORAFENIB IN A DIVERSE POPULATION OF PATIENTS WITH DESMOID TUMORS INCLUDING POOR PERFORMANCE STATUS.

Tejas Suresh1; Stacey Stein1; Mrinal Gounder2; Kenneth Roberts3; Gary Friedlaender4; Dieter Lindskog4; Kirtesh Patel3; Sajid Khan5; Hari Deshpande1
1Medical Oncology, Yale University, New Haven, CT, USA; 2Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Radiation Oncology, Yale University, New Haven, CT, USA; 4Orthopedics, Yale University, New Haven, CT, USA; 5Surgery, Yale University, New Haven, CT, USA

Poster 140 3036230

A CLINICAL COMPARISON OF FAMILIAL (APC MUTATED) VS SPORADIC (CTNNB1 MUTATED) DESMOID TUMORS

Gideon Sandler1; Yi-Ju Chiang1; Janice Cormier1; Kelly Hunt1; Alexander J. Lazar1; Patrick Lynch1; Christina Roland1; Kiela E. Torres1; Y Nancy You1; Barry Feig1
1Oncology, M D Anderson Cancer Center, Sydney, NSW, Australia

Poster 141 3042762

WNT TARGET GENES ARE NOT DIFFERENTIALLY EXPRESSED IN DESMOID TUMORS BEARING DIFFERENT ACTivating BETA-CATENIN MUTATIONS

Milea Timbergen1; Matthijs L. Janssen1; Kees Vrohoef1; Dirk Grünhagen1; Frédéric Chibon2; Marcel Smid4; Stefan Sleijfer1; Erik A.C. Wiemer4
1Surgical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, Zuid Holland, Netherlands; 2Surgical Oncology, Medical Oncology, Erasmus MC Cancer Institute , Rotterdam, Netherlands; 3Centre de Recherches en Cancérologie, Toulouse, France; 4Medical Oncology, Erasmus MC , Rotterdam, Netherlands; 5Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Poster 142 3042792

DESMOID TUMOURS TREATED WITH ORAL VINORELBINE. A RETROSPECTIVE ANALYSIS OF 14 PATIENTS

Anna Estival1; James R. Stewart1; Dharmisha Chauhan1; Alison Dunlop1; Christina Messiou1; Khin Thway1; Omar Al-Muderis1; Aisha Miah1; Shane Zaïdi1; Robin Jones1; Winette van der Graaf1; Charlotte Benson1
1Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom; 2Medical Oncology, Catalan Institut of Oncology, Barcelona, Spain

Poster 143 3042308

TEMOZOLOMIDE COMBINED WITH PARP INHIBITOR OLAPARIB SHOWS SYNERGISTIC EFFECTS IN DESMOPLASTIC SMALL ROUND CELL TUMOR CELLS

Anke van Erp1; Laurens Houdt1; Emmy Fleuren1; Winette van der Graaf1; Yvonne Versleijen-Jonkers3
1Division of Clinical Studies, Clinical and Translational Sarcoma Research, The Institute of Cancer Research, Sutton, United Kingdom; 2Division of Clinical Studies, Clinical and Translational Sarcoma Research and The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Sutton, United Kingdom; 3Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands

Poster 144 3042576

PHASE 2 WEEKLY ORAL ONC201 IN DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) AND CLEAR CELL SARCOMA

Pete Anderson1; Stacey Zahler2; G. T. Budd3; Dale Shepard3; James L. Chen4; Andrea Hayes-Jordan1
1Pediatric Surgery, University of North Carlina Chapel Hill, Chapel Hill, NC, USA; 2Pediatric Heme/Onc/BMT, Cleveland Clinic, Cleveland, OH, USA; 3Medical Oncology, Taussig Cancer Institute, Cleveland, OH, USA; 4Medical Oncology, James Cancer Center, Ohio State University Medical Center, Columbus, OH, USA
IMPROVED 3 AND 5 YEAR SURVIVAL WITH MULTIMODALITY TREATMENT OF DESMOPLASTIC SMALL ROUND CELL TUMOR

Vivek Subbiah1; Salah-Eddine Lamhamedi-Cherradi1; Branko Cuglievan1; Winston Huh1; Pete Anderson1; Raphael Pollock1; Dina Lev1; Wei Qiao1; Mary F. McAleer1; Robert 1Benjamin1; Shreyaskumar Patel1; Cynthia E. Herzog1; Najat Daw1; Barry Feig1; Alexander J. Lazar1; Andrea Hayes-Jordan1; Joseph A. Ludwig1

1MD Anderson Cancer Center, Houston, TX, USA

RECURRENT FGFR4 AND ARID1A SOMATIC ALTERATIONS ARE DETECTED IN DESMOPLASTIC SMALL ROUND CELL TUMORS (DSRCT)

Warren Chow2; Walter Tsark3; Jiing-Kuan Yee2; Xiwei Wu2; Min Guan2; Sally Trabucco3; Jeffrey Ross1; Siraj Ali1; Sherri Z. Millis1

1Foundation Medicine, Inc., Phoenix, AZ, USA; 2City of Hope, Duarte, CA, USA

PRECLINICAL EFFICACY OF ANDROGEN RECEPTOR-BASED ANTI-SENSE THERAPY FOR THE TREATMENT OF DESMOPLASTIC SMALL ROUND CELL TUMOR

Brian Menegaz1; Salah-Eddine Lamhamied-Cherradi1; Branko Cuglievan2; Pamela Camacho1; Youngsoo Kim1; Robert MacLeod1; Andrea Hayes-Jordan1; Joseph A. Ludwig1

1Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 2Pediatric Oncology, MD Anderson Cancer Center, Houston, TX, USA; 3Ionis Pharmaceuticals, Carlsbad, CA, USA; 4Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA

IMPACT OF WHOLE ABDOMINOPELVIC RADIOTHERAPY AND INTRAPERITONEAL RADIOIMMUNOTHERAPY AFTER COMPLETE RESECTION ON SURVIVAL IN PATIENTS WITH DESMOPLASTIC SMALL ROUND CELL TUMOR

Shakeel Modak1; James Saltsman1; Neeta Pandit-Taskar2; Todd Heaton1; Sam Singer2; Nai-Kong Cheung1; Suzanne Wilden4; Michael LaQuaglia1

1Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 4Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

ADVANCED EPITHELIOID HAEMANGIOENDOTHELIOMA: FEVER, PAIN AND PLEURAL EFFUSION PREDICT A WORSE OUTCOME

Bruno Vincenzi1; Anna Maria Frezza3; Antonella Brunello3; Lorenzo D’Ambrosio4; Giacomo Giulio Baldi6; Giuseppe Badalamenti4; Tiziana Venesio1; Andrea Napolitano1; Sergio Valeri4; Luca Improta4; Mariella Spalato Ceruso1; Mariana Silletta1; Angelo Paolo Dei Tos4; Alessandro Gronchi2; Paolo Casali2; Silvia Stacchiotti2

1Oncology, Campus Bio-Medico, Rome, RM, Italy; 2Istituto Tumori Milano, Milano, MI, Italy; 3Istituto Oncologico Veneto, Padova, Italy; 4Istituto di Candiolo, Candiolo, Italy; 5Nuovo Ospedale Santo Stefano, Prato, Italy; 6Policlinico Giacone, Palermo, Italy; 7General Surgery, Campus Bio-Medico, Rome, Italy; 8University of Padova, Padova, Italy

THE PROGNOSTIC SIGNIFICANCE OF SURGICAL TREATMENT FOR EXCESSIVE ELDERLY PATIENTS WITH SOFT TISSUE SARCOMA

Hiroyuki Tsuchie1; Makoto Emori2; Hiroyuki Nagasawa1; Naohisa Miyakoshi1; Yasutaka Murahashi1; Emi Mizushima1; Toshihiko Yamashita1; Yoichi Shimada2

1Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; 2Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan

CLINICAL OUTCOMES AND COSTS FOLLOWING UNPLANNED EXCISIONS OF SOFT TISSUE SARCOMAS IN THE ELDERLY: DOES PREOPERATIVE PLANNING CHANGE OUTCOMES?

Sarah B. Bateni1; Alicia A. Gingrich1; Sun Y. Jeon1; Jeffrey S. Hoch1; Arta M. Monjazeb1; Steven W. Thorpe1; Amanda R. Kirane1; Richard J. Bold1; Robert J. Cant1

1UC Davis Medical Center, Sacramento, CA, USA
Poster 152 3041503
EXTREMITY SOFT TISSUE SARCOMA IN THE ELDERLY: ARE WE OVERTREATING OR UNDERTREATING THIS VULNERABLE PATIENT POPULATION?
Alicia A. Gingrich1; Sarah B. Bateni1; Steven W. Thorpe1; Arta M. Monjazeb1; Amanda R. Kirane1; Richard J. Bold1; Robert J. Canter1
1UC Davis, Sacramento, CA, USA

Poster 153 WITHDRAWN

Poster 154 3042808
INFLUENCE OF AGE AND SUBTYPE IN OUTCOME OF OPERABLE LIPOSARCOMA
Daniela Greto1; Giulia Stocchi1; Cristina Muntoni1; Giorgio Caramia1; Monica Lo Russo1; Anna Peruzzi1; Donato Pezzula1; Mauro Loi1; Isacco Desideri1; Pierluigi Bonomo1; Giulio Francolini1; Domenico Andrea Campanacci2; Francesco Muratori2; Filippo Frenos2; Lorenzo Livi1
1Radiation Oncology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy; 2Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

Poster 155 3042893
WORSE SURVIVAL IN OLDER ADULTS WITH RHABDOMYOSARCOMA: RESULTS OF A LARGE SINGLE INSTITUTIONAL COHORT
Ann Raldow1; Alex Jacobson2; Ruoyu Miao2; Saveli Goldberg2; Haotong Wang2; Edwin Choy2; Gregory M. Cote2; Kevin Raskin2; Francis Hornicek2; Thomas F. DeLaney2; Yen-Lin E. Chen2
1Radiation Oncology, UCLA, Los Angeles, CA, USA; 2Massachusetts General Hospital, Boston, MA, USA

Poster 156 2998752
PROGNOSIS OF ELDERLY PRIMARY OSTESARCOMA PATIENTS
Hiroyuki Tsuchie1; Makoto Emori2; Hiroyuki Nagasawa1; Naohisa Miyakoshi1; Yasutaka Murahashi1; Emi Mizushima1; Toshihiko Yamashita1; Yoichi Shimada1
1Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; 2Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan

Poster 157 3031071
POSTOPERATIVE COMPLICATIONS, CLINICAL AND FUNCTIONAL OUTCOME OF ELDERLY PATIENTS WITH PRIMARY HIGH GRADE MALIGNANT BONE AND SOFT TISSUE TUMOR
Masato Sugawara1; Daiichiro Takahara1; Michiaki Takagi1
1Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan

Poster 158 3007555
THE ADDITION OF CYCLES OF IRINOTECAN/TEMOZOLOMIDE TO CYCLES OF VINCRISTINE, DOXORUBICIN, CYCLOPHOSPHAMIDE (VDC) AND CYCLES OF IFOSFAMIDE, ETOPOSIDE (IE) FOR THE TREATMENT OF EWING SARCOMA (ES).
Paul Meyers1; Emily Slotkin1; Leonard Wexler1; Filemon Dela Cruz1
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Poster 159 3027523
INVESTIGATING THE ROLE OF LSD2 IN EWING SARCOMA
Priyal Patel1; Kathleen Pishas1; Julia Selich-Anderson1; Stephen Lessnick2
1Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children’s Hospital, Columbus, OH, USA; 2Center for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children’s Hospital, Nationwide Children’s Hospital, Columbus, OH, USA
PROGNOSTIC VALUE OF TUMOR VOLUME IN PATIENTS WITH LOCALIZED EWING SARCOMA TREATED WITH INTERVAL-COMPRESSED CHEMOTHERAPY: A REPORT FROM CHILDREN’S ONCOLOGY GROUP STUDY
AEWS0031
William T. Cash; Mark Krailo; Allen Buxton; Daniel West; Bruce Pawel; Paul Dickman; John Healey; John Dormans; Karen Marcus; Scott Sailer; Neyssa Marina; Holcombe Grier; Aaron Weiss; Katherine Janeway; Richard Gorlick; Richard Womer

Pediatric Hematology Oncology, Emory University/Children’s Healthcare of Atlanta, Atlanta, GA, USA; Statistics, Children’s Oncology Group, Monrovia, CA, USA; Pediatric Oncology, UCSF Medical Center-Mission Bay, San Francisco, CA, USA; Pathology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA; Pathology, Phoenix Children’s Hospital, Phoenix, AZ, USA; Orthopedics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; Orthopedics, Texas Children’s Hospital, Houston, TX, USA; Radiation Oncology, Dana-Farber Cancer Institute/Boston Children’s Hospital, Boston, MA, USA; Radiation Oncology, Duke University Medical Center, Raleigh, NC, USA; Five Prime Therapeutics, San Francisco, CA, USA; Pediatric Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; Pediatric Oncology, Maine Children’s Cancer Program, Scarborough, ME, USA; Pediatric Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; MD Anderson Cancer Center, Houston, TX, USA; Pediatric Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

PATTERN OF TRANSLOCATION TESTING IN PATIENTS ENROLLING TO A COOPERATIVE GROUP TRIAL FOR NEWLY DIAGNOSED METASTATIC EWING SARCOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG)
Steven DuBois; Mark Krailo; Allen Buxton; Stephen Lessnick; Lisa Teot; Dinesh Rakheja; Brian Crompton; Katherine Janeway; Richard Gorlick; Julia Glade-Bender

Dana-Farber Cancer Institute, Boston, MA, USA; Children’s Oncology Group, Monrovia, CA, USA; Nationwide Children’s Hospital, Columbus, OH, USA; Boston Children’s Hospital, Boston, MA, USA; UT Southwestern, Dallas, TX, USA; MD Anderson Cancer Center, Houston, TX, USA; Columbia University, New York, NY, USA

EXPERIENCE IN DIFFERENTIAL DIAGNOSIS OF EWING SARCOMA AND EWING-LIKE SARCOMA BY TARGETED RNA-SEQ
Juan Diaz-Martin; Michele Biscuola; Elena Aguado; Mercedes Delgado; David Marcilla; Enrique De Alava
UGC Anatomía Patológica, HUU Virgen del Rocio, Seville, Spain

ROLE OF P21-ACTIVATED KINASES IN DEVELOPMENT AND PROGRESSION OF EWING SARCOMA
Shawki L. Qasim
Pediatrics, Baylor College of Medicine-Texas Children’s Hospital, Houston, TX, USA

ACTIVATION OF SPECIFIC KINASE PATHWAYS ARE REQUIRED FOR CD99 INHIBITION MEDIATED EWING SARCOMA CYTOTOXICITY
Haydar Çelik; Levent Düşünceli; Anna Molotkova; David Allegakoen; Erin Conn; Jeffrey Petro; Jeffrey Torestky; Aykut Uren
Oncology, Georgetown University, Washington, DC, USA

FUNCTIONAL STUDIES REVEAL DYNAMIC ROLE OF FLI IN EWS/FLI-DRIVEN EWING SARCOMA
Megann A. Boone; Jesse Crow; Stephen Lessnick
Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA; College of Medicine, The Ohio State University, Columbus, OH, USA

INTEGRIN-MEDIATED SIGNALING AS A NOVEL THERAPEUTIC TARGET IN METASTATIC EWING SARCOMA
Jade Wulff; Gargi Ghosal; Lyazat Kurenbekova; Ryan Shuck; Jason T. Yustein
Pediatrics, Baylor College of Medicine, Houston, TX, USA; Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA
Poster 167 3042275

A RATIONAL COMBINATION THERAPY APPROACH WITH RADIATION THERAPY IN EWING SARCOMA
Jia Xie1; Marcia M. Mellado-Largarde1; Jessica Gartrell1; Brandon Bianiski1; Kaley Blankenship1; Sara Federico1; Elizabeth Stewart1; Anang Shelat1; Christopher L. Tinkle1
1St. Jude Children’s Research Hospital, Memphis, TN, USA

Poster 168 3042383

EVALUATION OF THE ROLE OF RADIOTHERAPY IN THE MULTIMODAL TREATMENT OF ADULT EXTRASKELTAL EWING SARCOMA: A NATIONAL CANCER DATABASE ANALYSIS
Augustine M. Sai1; Alicia A. Gingrich2; Robert J. Canter3; Amanda R. Kirane2; Arta M. Monjazeb3; R. Lor Randall1
1Department of Orthopaedic Surgery, University of California, Davis, Sacramento, CA, USA; 2Department of Surgery, University of California, Davis, Sacramento, CA, USA; 3Department of Radiation Oncology, University of California, Davis, Sacramento, CA, USA

Poster 169 3042421

THE ROLE OF HIGH DOSE CHEMOTHERAPY IN REFRACTORY AND RECURRENT EWING SARCOMA: REPORT OF A SINGLE CENTRE EXPERIENCE
Rachael Windsor1; Anthony Hamilton1; Palma Dileo1; Maria Michelagnoli1; Sandra Strauss1; Jeremy Whelan1
1The London Sarcoma Service, University College London Hospitals NHS Foundation Trust, London, United Kingdom

Poster 170 3042564

EWINGS SARCOMA IN ADULTS - IS SOFT TISSUE EWINGS DIFFERENT FROM BONY EWINGS?
Naresh Gundu1; Arun Garg1; Manish Pruthi1; Adarsh Barwad1; Ekta Dhamija1; Aditi Aggarwal1; Rambha Pandey2; Ankur Varshney1; Sameer Rastogi1
1Medical Oncology, Aiims -All India Institute of Medical Sciences, New Delhi, India; 2Musculoskeletal Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India; 3Pathology, All India Institute of Medical Sciences, Delhi, India; 4Radiology, All India Institute of Medical Sciences, Delhi, India; 5Radiotherapy, All India Institute of Medical Sciences, Delhi, India; 6Radiotherapy, Maulana Azad Medical College, Delhi, India

Poster 171 3027502

POTENTIAL EWS-FLI1- FOXM1- BUB1B AXIS CONTRIBUTES TO MITOTIC CELL CYCLE CONTROL IN EWING SARCOMA
Christiane Schaefer1; Yassmine El Gourari2; Birgit Lechtape1; Stephanie Klco-Brosius1; Eberhard Korschling3; Thomas G. Grünweald4; Julia S. Gerke5; Jenny Potratz2; Uta Dirksen1
1Pediatrics III, Hematology/ Oncology, University Hospital Essen, Essen, North Rhine-Westfalia, Germany; 2Department of General Pediatrics, University Hospital Münster, Münster, Germany; 3Institute of Bioinformatics, Westfälische Wilhelms-Universität Münster, Münster, Germany; 4Institute of Pathology, Ludwig-Maximilians-Universität München, München, Germany

Poster 172 3028111

CORRELATION BETWEEN PATHOLOGICAL, RADIOLOGICAL AND METABOLIC RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY IN LOCALIZED EWING SARCOMA
Anna Paioli1; Alessandra Longhi1; Roberto Luksch1; Giuseppe M. Milano1; Angela Tamburini1; Carla Manzitti1; Franca Fagioli1; Gianni Bisogno1; Luca Cocco1; Nadia Puma1; Carlo Morosi1; Eugenio Rimondi1; Marilena Cesari1; Massimo E. Abate1; Stefano F. Fanti1; Luca Coccoli1; Roberto Luksch1; Ardanea Longhi1; Angelo P. Dei Tos1; Stefano Ferrari1
1Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy; 2Department of Pediatric Onco-Hematology and Transfusion Medicine, Ospedale Bambino Gesù, Rome, Italy; 3Department of Pediatric Oncology, Istituto Nazionale Tumori, Milan, Italy; 4Department of Pediatric Oncology, Ospedale A. Meyer, Firenze, Italy; 5Department of Pediatric Hematology/Oncology, Ospedale Gaslini, Genova, Italy; 6Department of Pediatric Oncology, Ospedale Regina Margherita, Torino, Italy; 7Pediatric Hematology and Oncology Division, Padova University, Padova, Italy; 8Pediatric Hematology/Oncology Division, University of Pisa, Pisa, Italy; 9Department of Radiology, Istituto Nazionale Tumori, Milano, Italy; 10Department of Radiology, Istituto Ortopedico Rizzoli, Bologna, Italy; 11Department of Pathology, Gaetano Pini-CTO, Milano, Italy; 12Department of Pathology, Ospedale Treviso, Treviso, Italy; 13Department of Pathology, Istituto Ortopedico Rizzoli, Bologna, Italy; 14Department of Nuclear Medicine, Azienda Ospedaliera Universitaria Sant Orsola, Bologna, Italy
INITIAL REPORTS OF LOCAL CONTROL MODALITIES IN EURO EWING 2012: AN INTERNATIONAL RANDOMISED CONTROLLED TRIAL OF CHEMOTHERAPY FOR NEWLY DIAGNOSED EWING SARCOMAS (ES)

Bernadette Brennan1; Veronica Moroz2; Jennifer Anderton2; Perrine Marec-Bérard3; Line Claude3; Javier Martin-Broto4; Hans Gelderblom5; Sandra Strauss6; Beatrice Seddon6; Jeremy Whelan6; Keith Wheatley2
1Paediatric Oncology, Royal Manchester Children’s hospital, Manchester, United Kingdom; 2Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom; 3Centre Léon Bérard, Lyon, France; 4Grupo Español de Investigación en Sarcomas, Sevilla, Spain; 5European Organisation for Research and Treatment of Cancer, Brussels, Belgium; 6University College Hospital London, United Kingdom

EXPRESSIO OF SLFN11 AND MGMT IN ARCHIVAL TUMOR TISSUE AS POSSIBLE BIOMARKERS OF RESPONSE TO TEMOZOLOMIDE AND IRINOTECAN IN RELAPSED EWING SARCOMA PATIENTS

Brian Turpin1; Therese Bocklage1; Patrick O’Donnell4; Jeremy Rubinstein2; Kristina Prus3; Lars Wagner4
1Pediatrics, University of Kentucky, Lexington, KY, USA; 2Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 3Pathology, University of Kentucky, Lexington, KY, USA; 4Orthopaedic Surgery, University of Kentucky, Lexington, KY, USA

IGF-1R/MTOR TARGETED THERAPY FOR EWING SARCOMA: A META-ANALYSIS OF FIVE IGF-1R-RELATED TRIALS MATCHED TO PROTEOMIC AND RADIOLOGIC PREDICTIVE BIOMARKERS.

Hesham Amin1; Ajaykumar Morani1; Najat Daw1; Salah-Eddine Lamhamedi-Cherradi1; Vivek Subbiah1; Brian Menegaz4; Deeksha Vishwamitra1; Ghazaleh Eskandari1; Bhawana George1; Robert Benjamin1; Shreyashkumar Patel1; Juhee Song1; Alexander J. Lazar2; Wei-Lien Wang3; Razelle Kurzrock4; Albert Pappo6; Pete Anderson8; Gary K. Schwartz9; Dejka M. Araujo1; Branko Cuglievan2; Aung Naing3; Ravin Ratan4; John A. Livingston4; Joseph A. Ludwig4
1Hematopathology, MD Anderson Cancer Center, Houston, TX, USA; 2Nuclear Medicine, MD Anderson Cancer Center, Houston, TX, USA; 3Pediatric Oncology, MD Anderson Cancer Center, Houston, TX, USA; 4Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 5Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, USA; 6Biostatistics, MD Anderson Cancer Center, Houston, TX, USA; 7Pathology, MD Anderson Cancer Center, Houston, TX, USA; 8Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, San Diego, CA, USA; 9Pathology, St. Jude’s Cancer Research Hospital, Memphis, TN, USA; 10Pediatric Oncology, Cleveland Clinic, Cleveland, OH, USA; 11Hematology & Oncology, Columbia University Medical Center, New York, NY, USA

PRECLINICAL EFFICACY OF TARGETING EWSR1 IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMORS

Brian Menegaz4; Salah-Eddine Lamhamedi-Cherradi1; Branko Cuglievan2; Youngsoo Kim2; Robert MacLeod3; Joseph A. Ludwig1
1Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 2Pediatric Oncology, MD Anderson Cancer Center, Houston, TX, USA; 3Ionis Pharmaceuticals, Carlsbad, CA, USA

HOW DO WE ACHIEVE THE GREATER COLLABORATION NEEDED TO IMPROVE OUTCOMES FROM EWING SARCOMA: THE EXPERIENCE OF THE EURO EWING CONSORTIUM

Abigail Evans1; Elena Gatti2; Kimberly Cornfield2; Sandra Strauss2; Jeremy Whelan1
1UCLH, London, United Kingdom; 2University College London, United Kingdom

EWS-FLI1 EXPRESSION LEVEL MODULATES T-CELL MEDIATED TUMOR APOPTOSIS IN EWING SARCOMA

Claire Julian1; Heather Bernard1; Ariel Klinghoffer1; Linda McAllister-Lucas1; Kelly Bailey1
1University of Pittsburgh, Pittsburgh, PA, USA

THE ROLE OF DENOSUMAB IN JOINT PRESERVATION FOR PATIENTS WITH GIANT CELL TUMOUR OF BONE: NOT A MAGIC BULLET?

David L. Perrin1; Julia Visgauss1; David Wilson2; Anthony M. Griffin2; Peter Ferguson2; Jay Wunder2
1Section of Orthopaedic Surgery, University of British Columbia, Winnipeg, MB, Canada; 2Mount Sinai Hospital, Toronto, ON, Canada
EPIGENETIC COMPOUND SCREEN REVEALS HISTONE DEACYETYLASE INHIBITORS TO EFFECTIVELY TARGET THE NEOPLASTIC CELLS IN GIANT CELL TUMOR OF BONE
Sanne Venneker; Robin van Eenige; Marianne van der Vaart; Alice E. Taliento; Judith V. Bovee; Karoly Szuhai
1Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands; 2Pathology, Leiden University Medical Center, Leiden, Netherlands

GIANT CELL TUMOUR OF DISTAL RADIUS: RESULTS OF WIDE EXCISION AND AUTOGENOUS NONVASCULARIZED FIBULA GRAFT RECONSTRUCTION
Deepak Kumar
1Orthopaedics, King George's Medical University, Lucknow, Uttar Pradesh, India

DISCOVERY AND CHARACTERIZATION OF RECURRENT, TARGETABLE ALK FUSIONS IN LEIOMYOSARCOMA
Lara E. Davis; Kevin Nusser; Joanna Przybyl; Janet Pittsenbarger; Nicolle Hofmann; Sushama Varma
1Oregon Health & Science University, Portland, OR, USA; 2Stanford University, Stanford, CA, USA; 3KU Leuven, Leuven, Belgium

GENOME INFORMED THERAPY FOR OSTEOSARCOMA
Leanne Sayles; Marcus Breese; Amanda Koehne; Stan Leung; Avanthi T. Shah; Sheri Spunt; Steven DuBois; Douglas Hawkins; Alejandro Sweet-Cordero
1Pediatrics, University of California San Francisco, San Francisco, CA, USA; 2Pediatrics, Stanford University, San Francisco, CA, USA; 3Pediatrics, University of Washington, Seattle, WA, USA; 4Pediatrics, Dana Farber Cancer Institute, Boston, MA, USA

DISTINCT EVOLUTIONARY TRAJECTORIES UNDERLIE GENOMIC HETEROGENEITY AND COMPLEXITY IN UNDIFFERENTIATED SARCOMAS
Christopher D. Steele; Maxime Tarabichi; Ludmil Alexandrov; Dahmane Oukrif; Hongtao Ye; Matthew Fittall; Patrick Lombard; Íñigo Martincorena; Patrick Tarpey; Grace Collord; Sandra Strauss; Fitim Berisha; Marnix Jansen; Sam Behjati; Fernanda M. Amary; Roberto Tirabosco; Peter Campbell; Peter Van Loo; Adrienne Flanagan; Nischalan Pillay
1Research Department of Pathology, University College London - Cancer Institute, London, United Kingdom; 2Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital, London, United Kingdom; 3Cancer Genomics Laboratory, The Francis Crick Institute, London, United Kingdom; 4Cancer, Aging and Somatic Mutation Group, Wellcome Trust Sanger Institute, Cambridge, United Kingdom; 5Oncology, University College London Hospitals, London, United Kingdom; 6Department of Cellular and Molecular Medicine, University of California San Diego, San Diego, CA, USA

COMPREHENSIVE GENOMIC PROFILING OF SYNOVIAL SARCOMAS IDENTIFIES GENOMICALLY DEFINED SUBGROUPS WITH CHARACTERISTIC ALTERATION PATTERNS
Sherri Z. Millis; Peter Vorenkamp; Petra Vorenkamp; Jeffrey Ross; Siraj Ali; Sally Trabucco; James L. Chen
1Foundation Medicine, Inc., Phoenix, AZ, USA; 2The Ohio State University, Columbus, OH, USA; 3Live For Others Foundation, Laguna Beach, CA, USA

THE FUSION LANDSCAPE AND ACTIONABLE ALTERATIONS OF SARCOMA REVEALED BY “REAL WORLD” GENOMIC SEQUENCING
Jason Roszik; Anthony P. Conley; Roman Groisberg; Roberto Carmagnani Pestana; Shiraj Sen; Vivek Subbiah
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA
BRINGING A PERSONALIZED MEDICINE PIPELINE TO THE CLINIC: A CROSS-SPECIES APPROACH REVEALS NEW THERAPIES AND NEW CHALLENGES

Sneha Rao1; Jason Somarelli2; Laura Selmic3; Erdem Altunel4; Wayne Glover5; Maya Sheth6; Mark Byrum7; Timothy Fan8; Cindy Eward9; Suzanne Bartholf DeWitt10; Julia Visgauss11; Brian Brigman12; David Hsu13; William Eward14

1School of Medicine, Duke University, Durham, NC, USA; 2Medicine, Duke University, Durham, NC, USA; 3College of Veterinary Medicine, University of Illinois at Urbana–Champaign, Champaign, IL, USA; 4Triangle Veterinary Referral Hospital, HOLLY SPRING, NC, USA; 5Orthopaedic Surgery, Duke University, Durham, NC, USA

UTILITY OF FOUNDATIONONE HEME PROFILING IN SARCOMA: INSTITUTIONAL EXPERIENCE AND CLINICAL OUTCOMES

Adrienne Victor1; Deepak Sahasrabudhe1; Megan Baumgart1

1Medical Oncology, University of Rochester, Rochester, NY, USA

METASTATIC INITMAL SARCOMA CASE WITH NTRK3 GENE REARRANGEMENT TREATED WITH ENRECTINIB

Piotr Rutkowski1; Anna Mariuk-Jarzem1; Tomasz Switaj1; Pawel Rogala1; Michal Wagrodzki2; Monika Dudzisz-Sledz1

1Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; 2Pathology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland

EXTENDED CONTICAGIST ANALYSIS ADDS TO THE AMENDED PROGNOSTICATION IN GIST BASED ON TUMOR KIT/PDGFRα GENOTYPE STATUS

Agnieszka Wozniak1; Annoschka Laenen1; Antonio Gutierrez2; Elzieta Bylina3; Patrick Schöffski4; Jean-Yves Blay5; Isabelle Hostein1; Axel Le Cesne6; Eva Wardelman7; Sebastian Bauer8; Anna Klimeczak9; Raf Sciot10; Mehdi Brahimi11; Marco Fiore12; Czeslaw Osuch13; Maria Debiec-Rychter14; Jean-Michel Coindre15; Piotr Rutkowski16

1Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium; 2Laboratory of Experimental Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, KU Leuven, Leuven, Belgium; 3Hospital Universitario Son Espases, Palma, Spain; 4Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 5Department of Medical Oncology, Centre Leon Berard, Lyon, France; 6Department of Biopathology, Institut Bergonie, INSERM U916 and University Victor Segalen, Bordeaux, France; 7Institut Gustave Roussy, Villejuif, France; 8Gerhard Domagk Institute of Pathology, University Hospital Muenster, Muenster, Germany; 9Department of Internal Medicine, University of Essen Medical School, Essen, Germany; 10Department of Pathology, University Hospitals Leuven, Leuven, Belgium; 11Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy; 12Department of General, Oncological and Gastroenterological Surgery, University Hospital Cracow, Cracow, Poland; 13Department of Human Genetics, KU Leuven, Leuven, Belgium; 14Instituto de Biomedicina de Sevilla, Virgen del Rocio University Hospital, Sevilla, Spain

ONCOLOGICAL OUTCOME AFTER DIAGNOSTIC BIOPSIES IN GASTROINTESTINAL STROMAL TUMOURS

Anne M. Schrijver1; Eva A. Huis In 't Veld2; Dirk Strauss3; Nicos Fotiadis3; Neeltje Steeghs4; Stijn W. Heijmink5; Frits van Cooijvorden1; Andrew J. Hayes2; Myles J. Smith2; Winan J. van Houdt1

1Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; 2Surgical Oncology, Royal Marsden Hospital, London, United Kingdom; 3Radiology, Royal Marsden Hospital, London, United Kingdom; 4Medical oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; 5Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands

PAEDIATRIC, ADOLESCENT, WILD TYPE, SYNDROMIC GASTROINTESTINAL STROMAL TUMOURS (PAWS-GIST)

UNITED KINGDOM (UK) NATIONAL CLINIC: A JOINT PATIENTS/CARERS/SPECIALISTS INITIATIVE

Venkata Bulusu1; Ruth Casey2; Olivier Giger3; Eamonn Maher4; Richard Hardwick5; Nicholas Carroll6; Michael Leahy7; Robin Jones8; Charlotte Benson9; Palma Dileo10; Ian Judson11

1Oncology, Cambridge University Hospitals, Cambridge, United Kingdom; 2Dept of Endocrinology, Cambridge University Hospitals, Cambridge, United Kingdom; 3Dept of Molecular Pathology, Cambridge University Hospitals, Cambridge, United Kingdom; 4Dept of Clinical Genetics, Cambridge University Hospitals, Cambridge, United Kingdom; 5Dept of Upper GI Surgery, Cambridge University Hospitals, Cambridge, United Kingdom; 6Dept of Radiology, Cambridge University Hospitals, Cambridge, United Kingdom; 7Oncology, Christie Institute, Manchester, United Kingdom; 8Oncology, Royal Marsden Hospital, London, United Kingdom; 9Oncology, University College Hospital London, London, United Kingdom
THE RELATIONSHIP BETWEEN POSITIVE RESECTION MARGINS, TUMOUR RUPTURE AND PROGNOSIS IN GASTROINTESTINAL STROMAL TUMOUR. A POPULATION-BASED ANALYSIS

Toto Hølmebakk1; Bodil Bjørkehagen2; Ivar Hompland3; Stephan Stoldt4; Boye Kjetil5
1Dept. of Abdominal Surgery, Oslo University Hospital, Oslo, Norway; 2Dept. of Pathology, Oslo University Hospital, Oslo, Norway; 3Dept. of Oncology, Oslo University Hospital, Oslo, Norway

AN INTEGRATED RNA AND MICRORNA PROFILING OF THE MALIGNANT EVOLUTION OF MINIGIST TO GIST

Alessia Mondello1; Daniela Gasparotto1; Marta Sbaraglia2; Sabrina Rossi2; Maurizio Polano1; Chiara Pastrello1; Igor Jurisica1; Angelo Paolo Dei Tos1; Roberta Maestro1
1IRCCS CRO Aviano National Cancer Institute, Aviano, Italy; 2Treviso General Hospital, Treviso, Italy; 3University Health Network, Toronto, ON, Canada; 4University of Padova, Padova, Italy

NOVEL DIAGNOSTIC APPROACH FOR GASTROINTESTINAL STROMAL TUMOR USING AN ANTI-KIT DNA APTAMER

Sudeep Banerjee1; Partha Ray1; Mayra Yebra1; Chih-Min Tang1; Christian Allan1; Rebekah White1; Jason Sicklick1
1Surgical Oncology, UC San Diego, La Jolla, CA, USA

PLOCABULIN, A TUBULIN INHIBITOR, HAS ANTITUMOUR ACTIVITY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF GASTROINTESTINAL STROMAL TUMOUR (GIST)

Yannick Wang1; Agnieszka Wozniak2; Jasmien Wellens3; Yemarshet K. Gebreyohannes2; Maria Jose Guillén Navarro1; Carlos Galmarini1; Pablo Manuel Aviles Marin1; Maria Debiec-Rychter3; Raf Sciot4; Patrick Schöffski2
1PharmaMar, Madrid, Spain; 2Laboratory of Experimental Oncology, Department of Oncology and Department of General Medical Oncology, KU Leuven, University Hospitals Leuven and Leuven Cancer Institute, Leuven, Belgium; 3Department of Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium; 4Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium

MORE FREQUENT OCCURRENCE OF UNUSUAL CENTRAL NERVOUS SYSTEM METASTASES IN GIST PATIENTS

Amanda Parkes1; Filip Janku1; Shubham Pant1; Neeta Somaiah1
1MD Anderson Cancer Center, Houston, TX, USA

NEW PROTOCOL FOR IMAGE GUIDED SURGERY OF GASTROINTESTINAL STROMAL TUMOUR

Yvonne Schrage1; Kim de Valk1; Dirk Grünhagen1; Kees Verhoef1; John Frangioni2; Alexander Vahrmeijer1; Jos van der Hage1
1Surgery, Leiden University Medical Center, Leiden, Netherlands; 2Surgery, Erasmus MC, Rotterdam, Netherlands; 3Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

PRIMARY SARCOMA OF THE VULVA AND VAGINA: OUTCOMES AFTER DEFINITIVE THERAPY

Andrea Russo1; Alex Haynes2; Haotong Wang1; Ruoyu Miao1; John T. Mullen1; Thomas F. DeLaney1; Karen Bernstein1; Yen-Lin E. Chen1
1Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; 2Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA

INTEGRATED MOLECULAR ANALYSIS OF UNDIFFERENTIATED UTERINE SARCOMAS REVEALS CLINICALLY RELEVANT SUBTYPES

Amrei Binzer1; Elin Hardell1; Björn Viklund1; Mehran Ghaderi1; Tjalling Bosse1; Marisa R. Nucci2; Cheng Han Lee3; Debra Belf3; John K. Schoolmeester4; Anna Måsbäck5; Gunnar B. Kristensen1; Ben Davidson1; Anders Isaksson1; Joseph Carlson1
1Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; 2Dept of Medical Sciences, University of Uppsala, Uppsala, Sweden; 3Leiden University Medical Center, Leiden, Netherlands; 4Brigham and Women’s Hospital, Boston, MA, USA; 5VCH Research Institute, Vancouver, BC, Canada; 6The Mayo Clinic, Rochester, MN, USA; 7Skånes University Hospital, Lund, Sweden; 8The Norwegian Radium Hospital, Oslo, Norway
TREATMENT OF RECURRENT AND METASTATIC UTERINE ADENOSARCOMAS

Michael J. Nathenson1; Tianqi Chen2; Jyothi P. Jagannathan3; Christy Harris4; Marisa R. Nucci4; Matthew Hemming5; Priscilla Merriam6; Katherine Thornton7; Jeffrey A. Morgan1; Andrew Wagner1; Miranda B. Lam1; Chandrakirti Raut1; Paul Catalano1; Monica Bertagnolli1; George Demetri1; Suzanne George1
1Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 2Biostatistics & Computational Biology, Dana Farber Cancer Institute, Boston, MA, USA; 3Radiology, Dana Farber Cancer Institute, Boston, MA, USA; 4Pathology, Brigham and Women's Hospital, Boston, MA, USA; 5Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 6Surgical Oncology, Dana Farber Cancer Institute, Boston, MA, USA

EFFICACY OF TRABECTEDIN IN METASTATIC UTERINE LEIOMYOSARCOMA: A RETROSPECTIVE MULTICENTER STUDY OF THE SPANISH OVARIAN CANCER RESEARCH GROUP (GEICO)

Maria J. Rubio1; Maria J. Lecumberri2; Lydia Gaba3; Silvia Varela4; Jesus Alarcon5; Maria E. Ortega1; Jaime Espinos1; Gloria Marquina6; Julia Calzas7; Pilar Barretina8; Isabel Ruiz9; Ana Santaballa1
1Medical Oncology, Hospital Universitario Reina Sofia, Cordoba, Cordoba, Spain; 2Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; 3Medical Oncology, Hospital Universitari Sant Joan de Reus, Reus, Spain; 4Medical Oncology, Hospital Universitari i Politecnic La Fe, Valencia, Spain; 5Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain; 6Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca, Spain; 7Medical Oncology, Institut Catala d’Oncologia - ICO Girona, Girona, Spain; 8Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain; 9Medical Oncology, Hospital Universitario de Fuenlabrada, Madrid, Spain; 10Medical Oncology, Hospital Clinica de Barcelona, Barcelona, Spain; 11Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain; 12Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid, Spain

ACTIVITY OF HORMONAL TREATMENT IN A SUBSET OF CURRENTLY DEFINED UTERINE SMOOTH MUSCLE TUMORS OF UNCERTAIN MALIGNANT POTENTIAL (STUMP).

Robert Sanfilippo1; Marta Sbaraglia1; Elena Fumagalli1; Carlo Morosi1; Marta Barisella1; Angelo Paolo Dei Tos1; Paolo Casali1
1Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; 2General Hospital of Treviso, Treviso, Italy

PROGNOSTIC FACTORS IN ENDOMETRIAL STROMAL SARCOMA (ESS): A SUBGROUP ANALYSIS OF THE GEIS 26 STUDY (SPANISH GROUP FOR RESEARCH ON SARCOMAS)

Ana Sebio1; Nadia Hindi2; Josefin Cruz3; Juana Maria Cano4; Jeronimo Martinez-Garcia5; Luis Miguel de Sande Gonzalez6; Maria A. Vaz7; Jordi Rubio8; Jose A. Perez-Fidalgo9; Javier Martin-Broto2; Luis Vicioso10; Isabel Sevilla10
1Medical Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain; 2Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; 3Medical Oncology, Hospital Universitario de Canarias, Tenerife, Spain; 4Medical Oncology, Hospital General de Ciudad Real, Ciudad Real, Spain; 5Medical Oncology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; 6Medical Oncology, Complejo Hospitalario de Leon, Leon, Spain; 7Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; 8Medical Oncology, Institut Catala d’Oncologia - Girona, Girona, Spain; 9Medical Oncology, Hospital Clinico Universitario de Valencia, Valencia, Spain; 10Medical Oncology, Hospital Universitario Virgen de la Victoria, Malaga, Spain

UPFRONT ISOLATED LIMB PERFUSION (ILP) IN UNTREATED PATIENTS WITH UNRESECTABLE NON-METASTATIC PRIMARY SOFT-TISSUE SARCOMAS (STS) OF THE LIMB: A RETROSPECTIVE SERIES ON 41 PATIENTS

Tarek Assi1; Andrea Cavalcanti2; Axel Le Cesne3; Matthieu Faron1; Jean Francois H. honart5; Achraf Hadiji6; Olivier Camuzard2; Tony Ibrahim2; Cécile Le Péchoux3; Julien Adam4; Olivier Mir2; Sarah N. Dumont3; Philippe Terrier4; Charles Honoré5
1Pathology, Gustave Roussy, Paris, France; 2Medical Oncology, Gustave Roussy, Villejuif, France; 3Surgical Oncology, Gustave Roussy, Villejuif, France; 4Radiation Oncology, Gustave Roussy, Villejuif, France

Poster 201 3041759

Poster 202 3042707

Poster 203 3042714

Poster 204 3042769

Poster 205 3028803
SURVEILLANCE CHEST COMPUTED TOMOGRAPH (CT) IMAGING DURING CHEMOTHERAPY IN PEDIATRIC SARCOMA PATIENTS: IS THE RADIATION RISK JUSTIFIED?

Rhea M. Nambiar; Anna L. Tamulonis; Antonio Logan; Janay McKnight; Paul Kent
1Rush University Medical Center, Hawthorn Woods, IL, USA

ADVANCED IMAGING IS A COST-EFFECTIVE SURVEILLANCE STRATEGY FOLLOWING SOFT TISSUE SARCOMA RESECTION

Gireesh B. Reddy; Daniel Cunningham; Chinmay Paranjape; Brian Brigman; William Eward
1School of Medicine, Duke University, Durham, NC, USA; 2Department of Orthopaedic Surgery, Duke University, Durham, NC, USA; 3Department of Orthopaedic Surgery, University of North Carolina, Chapel Hill, NC, USA

RADIATION EXPOSURE IN PEDIATRIC SARCOMA PATIENTS RECEIVING INITIAL CHEMOTHERAPY

Kelsey Danley; Paul Kent; Antonio Logan
1Pediatric Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA

ACCU MERY OF FDG-POSITRON EMISSION TOMOGRAPHY (PET) SCAN IN DESMOPLASTIC SMALL ROUND CELL TUMOR

Manjusha Namuduri; James Saltzman; Emily Slotkin; Todd Heaton; Michael La Quaglia; Shakeel Modak
1Pediatrics, Memorial Sloan Kettering Cancer Center, Stamford, CT, USA

COMPLIANCE OF RADIOLOGICAL FOLLOW-UP FOLLOWING RESECTION OF PRIMARY INTRAABDOMINAL SOFT TISSUE SARCOMA WITH ESMO/ESNWG GUIDELINES: A 10-YEAR AUDIT OF PRACTICE FROM A UK QUATERNARY REFERRAL CENTRE

James Glasbey; James Bundred; Jennifer Hunt; Robert Tyler; Anant Desai; David Gourevitch; Max Almond; Samuel Ford
1Department of Soft Tissue Sarcoma Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

DIFFERENTIATING WELL-DIFFERENTIATED LIPOSARCOMAS FROM LIPOMAS USING A RADIOMICS APPROACH – PRELIMINARY RESULTS

Melissa Vos; Martijn P.A. Starmans; Milea Timbergen; Sebastian van der Voort; Guillaume Padmos; Wouter Kessels; Wiro Niessen; Dirk Grünhagen; Stefan Sleijfer; Kees Verhoef; Stefan Klein; Jacob Visser
1Medical Oncology and Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; 2Radiology and Nuclear Medicine & Medical Informatics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; 3Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; 4Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; 5Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

SIGNAL INTENSITY OF MRI COULD PEDICT THE EFFICACY OF MELOXICAM TREATMENT IN PATIENTS WITH DESMOID-TYPE FIBROMATOSIS

Koki Shimizu; Shunsuke Hamada; Tomohisa Sakai; Hiroshi Urakawa; Eisuke Arai; Kunihiro Ikuta; Takehiro Ota; Hiroshi Koike; Naoki Ishiguro; Yoshihiro Nishida
1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; 2Department of Orthopedic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan; 3Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan; 4Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan

THE UTILITY OF FLUORINE-18-FDG PET/MRI FOR DIAGNOSING BONE AND SOFT TISSUE MALIGNANCIES SECONDARY TO PREEXISTING BENIGN CONDITIONS

Yoichi Kaneuchi; Michiyo Takagi; Hiroshi Yamada; Takahiro Tajino; Osamu Hasegawa; Shin-ichi Konno
1Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan; 2Orthopaedic Surgery, Southern Tohoku Fukushima Hospital, Fukushima City, Fukushima, Japan; 3Radiology, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan
Poster 214 3042206
THE UTILITY OF PET/CT VERSUS BONE SCAN FOR DIAGNOSIS AND MONITORING OF PEDIATRIC SARCOMA PATIENTS
Adit L. Tal1; Hiten Doshi2; Fauziya Parkar3; Tony Abraham2; Charito Love2; Rui Yang3; Bang Hoang3; David Loeb1; Alexander Chou1; David Geller3; Renee Moadei2
1Pediatrics, Montefiore Medical Center, Bronx, NY, USA; 2Nuclear Medicine, Montefiore Medical Center, Bronx, NY, USA; 3Orthopedic Surgery, Montefiore Medical Center, Bronx, NY, USA

Poster 215 3041981
COMBINING ONCOLOYTIC VIROTHERAPY AND PD-1 INHIBITION IN AN ANIMAL MODEL OF ISOLATED LIMB PERFUSION TO IMPROVE LOCAL AND DISTANT DISEASE CONTROL IN ADVANCED EXTREMITY SOFT TISSUE SARCOMA
Andrew J. Hayes1; Henry Smith2; Michelle Wilkinson1; Joan Kyula-Currie2; Victoria Roulstone2; David Mansfield2; Martin McLaughlin2; Kevin Harrington2
1Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom; 2Targeted Therapy Team, Institute of Cancer Research, London, United Kingdom

Poster 216 3014823
NEOADJUVANT THERAPY INDUCES A POTENT INFLAMMATORY AND CORRESPONDING REGULATORY RESPONSE WITHIN THE SARCOMA IMMUNE MICROENVIRONMENT
Teresa Kim1; Matthew Spraker3; Y. David Seo1; Kimberly Smythe2; Robert Pierce2; Taylor Hain2; Edward Y. Kim3; Gabrielle Kane3; Isaac Jenkins5; Qianchuan (Chad) He4; Seth Pollack2
1Surgery, University of Washington, Seattle, WA, USA; 2Clinical Research Division, Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3Radiation Oncology, University of Washington, Seattle, WA, USA; 4Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 5Clinical Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Poster 217 3015167
PD-1 BLOCKADE COMBINED WITH ONCOLOYTIC HERPES HSV1716 VIROIMMUNOTHERAPY ENHANCES SURVIVAL IN AN IMMUNOGENIC MURINE OSTEOSARCOMA MODEL
Mary F. Wedekind1; Chun-Yu Chen2; Pin-Yi Wang2; Brian Hutzen2; Mark Currier2; Ryan Roberts1; Ben Kelly3; David Gordon3; Peter White3; Joe Conner4; Timothy Cripe1
1Pediatric Hematology/Oncology/BMT, Nationwide Children’s Hospital, Columbus, OH, USA; 2Center for Cancer and Blood Diseases, Research Institute, Nationwide Children’s Hospital, Columbus, OH, USA; 3Institute of Genomic Medicine, Nationwide Children’s Hospital, Columbus, OH, USA; 4Virttu Biologics, Ltd, Glasgow, United Kingdom

Poster 218 3025852
DECREASED T CELL INFILTRATION IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)—MEDIATED BY WNT, TGF-β AND MEX3B—PREDICTS POOR SURVIVAL
Benjamin J. DiPardo1; Catherine S. Grasso1; Arun S. Singh1; Bartosz Chmielowski3; Joseph G. Crompton1; James S. Tomlinson1; William H. McBride5; Fritz C. Eilber3; Antoni Ribas4; Anusha Kalbasi5
1Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA; 2Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA; 3Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; 4Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; 5Division of Molecular and Cellular Oncology, Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA

Poster 219 3041781
THE IMMUNE MICROENVIRONMENT IN LEIOMYSARCOMA, DEDIFFERENTIATED LIPOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Alexander T. Lee1; Connie Szecsei2; Martina Millighetti2; Khin Thway1; Ian Judson1; Robin Jones1; Paul Huang2
1Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom; 2Institute of Cancer Research, London, United Kingdom
KRAS/P53 MEDIATED MURINE MODEL OF RHABDOMYOSARCOMA HAS AN IMMUNE INERT MICROENVIRONMENT AND IS AN IDEAL MODEL TO TEST NOVEL IMMUNOTHERAPIES.

Michael J. Monument; Arvind K. Singla; Asmaa Affan; Joseph K. Kendal; Karys Hildebrand; Franz J. Zemp; Pinaki Bose; Douglas J. Mahoney; Frank R. Jirk
1Department of Surgery, University of Calgary, Calgary, AB, Canada; 2Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; 3Department of Microbiology, Immunology & Infectious Diseases, University of Calgary, Calgary, AB, Canada

HOST IMMUNE RESPONSE IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA - A 10-YEAR RETROSPECTIVE ANALYSIS

Joseph Sheridan; Andrew Horvai; Ross Okimoto; Rosanna Wustrack
1University of California San Francisco, San Francisco, CA, USA

TUMOR INFILTRATING LYMPHOCYTES MAY PREDICT FOR DISTANT METASTASIS IN SOFT TISSUE SARCOMAS TREATED WITH PREOPERATIVE RADIATION THERAPY

Meena Bedi; John Charlson; Mohamed Mostafa; Callisia Clarke; Candice Johnstone; Saul Suster
1Medical College of Wisconsin, Milwaukee, WI, USA

IMMUNE PROFILING OF INTRATUMORAL TERTIARY LYMPHOID STRUCTURES IN DEDIFFERENTIATED LIPOSARCOMA

Jennifer Wang; Tom Wei-Wu Chen; Shefali Chopra; Jen C. Lee; William W. Tseng
1University of Southern California Keck School of Medicine, Los Angeles, CA, USA; 2National Taiwan University College of Medicine, Taipei, Taiwan

COMPREHENSIVE GENOMIC PROFILING IDENTIFIES A POTENTIAL IMMUNOTHERAPEUTIC OPPORTUNITY IN GASTROINTESTINAL STROMAL TUMORS

Dexter X. Jin; Ethan Sokol; Sherri Millis; Garrett Frampton; Siraj Ali; Sally Trabucco
1Foundation Medicine, Inc., Cambridge, MA, USA

INTERLEUKIN-13 IN THE SARCOMA MICROENVIRONMENT PROMOTES EXPRESSION OF THE INTERLEUKIN-13 RECEPTOR ALPHA-2

Ian W. Folkert; Samir Devalaraja; Zahidul Alam; Minghong Li; Patricia Young; Malay Haldar
1Surgery, University of Pennsylvania, Philadelphia, PA, USA; 2Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

IMMUNOMODULATORY ROLE OF PAZOPANIB IN ADVANCED SOFT-TISSUE SARCOMAS

David S. Moura; Nadia Hindi; Paloma Sanchez-Bustos; Maria Lopez-Alvarez; Josefinia Cruz; Magda Conceicao; Javier Martinez-Trufero; Roberto Diaz-Beveridge; Claudia Valverde; Miguel Taron; Javier Martin-Broto
1Group of Advanced Therapies and Biomarkers in Oncology, Institute of Biomedicine of Seville, Seville, Seville, Spain; 2Group of Advanced Therapies and Biomarkers in Oncology, Institute of Biomedicine of Seville, University Hospital Virgen del Rocio, Seville, Spain; 3Medical Oncology Department, Vall d’Hebron Hospital, Barcelona, Spain; 4Medical Oncology Department, University Hospital of Canarias, Tenerife, Spain; 5Medical Oncology Department, University Hospital Son Espases, Palma, Spain; 6Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain; 7Medical Oncology Department, Hospital Universitario y Politècnic La Fe, Valencia, Spain
SOX2/OCT4-HIGH SUBGROUP OF RELAPSED AND METASTATIC OSTEOSARCOMA HAS HIGH PD-L1

Hannah Beird1; Chia-Chin Wu2; John A. Livingston3; Shailesh Advani4; Zhenlin Ju4; Alexandre Reuben4; Davis Ingram5; Wei-Lien Wang6; Alexander J. Lazar6; Cheuk Hong Leung7; Akash Mitra8; Richard Gorlick8; Najat Daw8; Valerae Lewis9; Phillip Futreal1
1Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX, USA; 2Department of Sarcoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA; 3Georgetown University, Washington, DC, USA; 4Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX, USA; 5Department of Thoracic/Head & Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA; 6Department of Biostatistics, UT MD Anderson Cancer Center, Houston, TX, USA; 7Department of Pathology, UT MD Anderson Cancer Center, Houston, TX, USA; 8Department of Pediatrics, UT MD Anderson Cancer Center, Houston, TX, USA; 9. Department of Orthopedic Oncology, UT MD Anderson Cancer Center, Houston, TX, USA

INDUCTION OF ANTI-TUMOR IMMUNITY AND EFFECTS ON SURVIVAL OF NEOADJUVANT ONCOLYTIC VIROTHERAPY IN DOGS WITH OSTEOSARCOMA: AN UPDATE OF THE VIGOR CLINICAL TRIAL

Kelly M. Makielski1; Shruthi Naik1; Michael S. Henson1; Kathleen M. Stuebner1; Alexandru-Flaviu Tabaran2; Ingrid Cornax2; M. G. O’Sullivan2; Nagendra Palani2; Daryl Goh1; Rochelle Hartson2; Andrea Eckert3; Donna Groschen2; Kelly Bergsru2; Julia Zyla1; Kristina Kiefer1; Lauren Mills1; Milcak C. Scott2; Aaron L. Sarver2; Michael Farrar2; Stephen J. Russell1; Jaime F. Modiano1
1Mayo Clinic, Rochester, MN, USA; 2University of Minnesota, Minneapolis, MN, USA

RESPONSE TO SUBSEQUENT THERAPY IN NY-ESO-1 POSITIVE SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY

Sant P. Chawla1; Seth Pollack2; Matthew Block3; Mihaela Druta4; Khanh Do5; John C. Morris6; Joseph W. Kim6; Chet Bohac8; Hailing Lu8; Sacha Gnjatic10; Robin L. Jones11; P. Hwu12; Neeta Somaiah13
1Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; 2Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; 3Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; 4Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 5Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; 6Medical Oncology, Yale University, New Haven, CT, USA; 7Medical Oncology, Mayo clinic, Rochester, MN, USA; 8Clinical Development, Immune Design, South San Francisco, CA, USA; 9Science, Immune Design, Seattle, WA, USA; 10Immunology, Mt. Sinai, New York City, NY, USA; 11Medical Oncology, Royal Marsden, London, United Kingdom; 12Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 13Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

IMMUNE RESPONSE, SAFETY, AND OVERALL SURVIVAL OF NY-ESO-1+ SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY

Sant P. Chawla1; Seth Pollack2; Matthew Block3; Mihaela Druta4; Khanh Do5; John C. Morris6; Joseph W. Kim6; Chet Bohac1; Hailing Lu1; Sacha Gnjatic3; R. L. Jones3; P. Hwu5; Neeta Somaiah10
1Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; 2Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; 3Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; 4Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 5Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; 6Medical Oncology, Yale University, New Haven, CT, USA; 7Science, Immune Design, Seattle, WA, USA; 8Immunology, Mt. Sinai, New York City, NY, USA; 9Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; 10Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 11Medical Oncology, Mayo clinic, Rochester, MN, USA

MACROPHAGES DOMINATE THE IMMUNE LANDSCAPE ACROSS MOST SARCOMA SUBTYPES

Amanda R. Dancsok1; David M. Thomas2; Maya Kansara3; Jean-Yves Clay1; Robert Maki4; Torsten O. Nielsen1; Elizabeth G. Demicco5
1Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; 2Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; 3Centre Léon Bérard, Lyon, France; 4Northwell Health Monter Cancer, Lake Success, NY, USA; 5Mount Sinai Hospital, Toronto, ON, Canada

SOLUBLE PD-L1 IN PATIENTS WITH SOFT TISSUE TUMORS

Kunihiro Asanuma1; Tomoki Nakamura1; Tomohito Hagi1; Koji Kita1; Akihiro Sudo1
1Orthopedic Surgery, Mie University, Tsu, Mie, Japan
PROGNOSTIC ROLE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH SARCOMA TREATED WITH IMMUNOTHERAPY

Vaia Florou1; Wungki Park1; Breelyn A. Wilky1
1Medicine, University of Miami, Miami, FL, USA

DISULFIRAM INDUCES IMMUNOGENIC CELL DEATH AND ENHANCES ANTI-PD-1-MEDIATED TUMOR SUPPRESSION IN OSTEOSARCOMA

Gangyang Wang1; Fei Yin1; Tao Zhang; Jing Xu; zhuoying wang; Xinghui Wang2; Yingqi Hua1; Zhengdong Cai1
1Shanghai General Hospital, Shanghai, China; 2Department of Surgery, Massachusetts General Hospital, Boston, MA, USA

CHARACTERIZING THE IMMUNE LANDSCAPE IN ALVEOLAR SOFT PART SARCOMA

Akash Mitra1; Hyun Jun Kim1; Hannah Beird1; Phillip Futreal1
1Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2University of Cincinnati College of Medicine, Cincinnati, OH, USA

EXPRESSION OF PROGRAMMED DEATH LIGAND 1 (PD-L1) AND EFFECT OF IMMUNOTHERAPY IN MALIGNANT SOFT TISSUED SARCOMA

Song Ee Park1; Joo Young Ha2; Edward Hyunseung Oh1; Min suk Kwon3; Hee Jun Kim1
1Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea (the Republic of); 2Department of Internal Medicine, Asan medical center, Seoul, Korea (the Republic of); 3Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea (the Republic of)

THE SAINT: INITIAL RESULTS OF A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB AND TRABECTEDIN AS FIRST LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA

Erlinda M. Gordon1; Victoria M. Chua-Alcala1; Katherine M. Kim1; S. Sreenath M. Andrali1; Doris M. Quon1; Steven M. Wong1; William W. Tseng1; Seth Pollack2; Amornchit M. Srikureja1; Noah Federman1; Sant P. Chawla1
1Sarcoma Oncology Center, Santa Monica, CA, USA; 2Surgery, USC Keck School of Medicine, Los Angeles, CA, USA; 3Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 4Pediatrics, UCLA School of Medicine, Los Angeles, CA, USA

ACTIVITY OF TREMELIMUMAB AND DURVALUMAB IN ADVANCED SARCOMAS: PRELIMINARY RESULTS OF A SIGNAL-SEEKING PHASE 2 TRIAL

Maya Kansara1; Subotheni Thavaneswaran1; John Grady1; Mark Cowley1; Audrey Silvestri1; Mandy L. Ballinger1; Elektra Hajdu1; Emily Collignon1; Lucille Sebastian2; Katrin Sjoquist2; Wendy Hague3; Amy Prawira3; Anthony Joshua3; Charles Bailey3; Ulf Schmitz3; Trevor Pugh3; Torsten O. Nielsen3; Amanda R. Dancsok3; Chee Lee3; John Simes3; David M. Thomas1
1Cancer Genomic Medicine, Garvan Institute, Sydney, NSW, Australia; 2NHMRC Clinical Trials Centre, Sydney, NSW, Australia; 3Gene and Stem Cell Therapy Program, Centenary Institute, Sydney, NSW, Australia; 4Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; 5Vancouver Coastal Health Research Institute and Faculty of Medicine, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada

ACTIVITY OF SINGLE-AGENT PD-1 INHIBITOR (PD-1I) THERAPY IN ADVANCED SARCOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS

Dionisia M. Quiroga1; David Liebner1; Jennifer Philippon1; Sarah Hoffman1; Yubo Tan1; James L. Chen1; Scott Lenobel1; Paul Wakely1; Gabriel Tinoco1
1The Ohio State University, Columbus, OH, USA
INTERFERON GAMMA MAKES “COLD” SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA “HOT”: RESULTS OF A PHASE 0 TRIAL
Shihong Zhang¹; Venu Pillarisetty¹; Lee D. Cranmer¹; Stanley Riddell¹; R. L. Jones³; Seth Pollack¹
¹Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ²Surgery, University of Washington, Seattle, WA, USA; ³Royal Marsden Hospital, London, United Kingdom

SARCOMA MOUSE MODEL FOR COMBINED ONCOLYTIC VIRUS AND IMMUNE CHECKPOINT INHIBITOR THERAPY
Shailaja Raj²; Eric Routh¹; Mitra Kooshki¹; Shelby Puckett¹; Pierre Triozzi¹; Paul Savage²; Douglas Lyles¹
¹Oncology, Wake Forest Baptist University Hospital, Winston Salem, NC, USA; ²Section of Hematology and Oncology, Wake Forest Baptist University Hospital, Winston Salem, NC, USA

EFFICACY OF CHECKPOINT INHIBITORS IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMAS
Varun Monga¹; Keith M. Skubitz²; Umang Swami³; Sarah Mott⁴; Angela C. Hirbe⁴; Brian Van Tine⁴; Peter Oppelt⁴; Hillary Dietz⁴; Scott Okuno⁴; Steven Robinson⁴; Madeline OConnor⁴; Mahesh Seetharam⁴; Steven Attia⁴; John Carlson⁴; Mark Agulnik¹; Mohammed Milhem¹
¹Internal Medicine, University of Iowa, Iowa City, IA, USA; ²University of Minnesota, Iowa City, IA, USA; ³Washington University, St Louis, MO, USA; ⁴Medical College of Wisconsin, Milwaukee, WI, USA; ⁵Mayo Clinic, Rochester, MN, USA; ⁶Holden Comprehensive Cancer, Iowa City, IA, USA; ⁷Northwestern University, Chicago, IL, USA

TUMOR SLICE CULTURE REPRESENTS A UNIQUE MODEL IN WHICH TO INTERROGATE THE IMMUNE RESPONSE TO HUMAN SOFT TISSUE SARCOMA
Teresa Kim¹; Xiuyun Jiang¹; Y. David Seo¹; Kevin Sullivan¹; Heidi Kenerson¹; Raymond Yeung¹; Venu Pillarisetty¹
¹Surgery, University of Washington, Seattle, WA, USA

EXPANSION AND CHARACTERIZATION OF TUMOR-INFILTRATING LYMPHOCYTES IN SOFT TISSUE SARCOMA
Alice Ko¹; Minji Lee²; Nalan Gokgoz²; Jay Wunder²; Irene Andrilis²
¹Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada; ²Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada

KAPOSI’S SARCOMA IN THE ERA OF HAART: A SINGLE INSTITUTIONAL RETROSPECTIVE REVIEW
Kamya Sankar²; Kelly Foster¹; Chad Achenbach²; Mark Agulnik¹
¹Hematology/Oncology, Northwestern University, Chicago, IL, USA; ²Medicine, Northwestern University, Chicago, IL, USA

KAPOSI SARCOMA, A SINGLE CENTER EXPERIENCE
Cecilia de Melo Alvim Moreira¹; Isabel Fernandes¹; Teresa Pacheco¹; Rita Paiva¹; Raquel Brás¹; Soares de Almeida²; Daniela Macedo¹; Luis Costa¹; João Borges-Costa²
¹Medical Oncology, Centro Hospitalar Lisboa Norte, Bobadela, Loures, Portugal; ²Dermatology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal

THE MEF2-CLASS IIA HDAC AXIS IN LEIOMYOSARCOMAS; PROLIFERATIVE OPTIONS AND POSSIBLE THERAPEUTIC TARGETS
Eros Di Giorgio¹; Elisa Franforte¹; Harikrishnareddy Paluvali¹; Claudio Brancolini¹
¹Medical sciences, Università degli studi di Udine, Udine, Italy

PEDIATRIC LIPOSARCOMA: A REPORT FROM THE TEXAS CHILDREN’S RARE TUMOR REGISTRY
Sarah Whittle¹; Murali Chintagumpala¹; Rajkumar Venkatramani¹
¹Pediatrics, Texas Children’s Cancer Center, Baylor College of Medicine, Pearland, TX, USA
INTEGRATED WHOLE EXOME AND RNA SEQUENCING FOR DEDIFFERENTIATED LIPOSARCOMA

Makoto Hirata1; Naofumi Asano2; Kotoe Katayama1; Yusuke Tsuda1; Akihiko Yoshida1; Toru Moto1; Yoshinao Oda6; Masaya Sekimizu2; Eisuke Kobayashi2; Takahiro Goto2; Yukihide Iwamoto2; Shintaro Iwata2; Yoshiihiro Nishida2; Toru Hiruma2; Hiroaki Hiraga10; Hirotaka Kawano11; Robert Nakayama12; Tadashi Kondo2; Hidekichi Nakagawa13; Akira Kawasaki1; Rui Yamaguchi1; Hitoshi Ichikawa2; Koichi Matsuda2
1Institute of Medical Science, University of Tokyo, Tokyo, Japan; 2National Cancer Center Research Institute, Tokyo, Japan; 3Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan; 4National Cancer Center Hospital, Tokyo, Japan; 5Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; 6Graduate School of Medical Sciences, Kyushu University, Tokyo, Japan; 7Chiba Cancer Center, Chiba, Japan; 8Nagoya University Graduate School of Medicine, Nagoya, Japan; 9Kanagawa Cancer Center, Yokohama, Japan; 10Hokkaido Cancer Center, Sapporo, Japan; 11Faculty of Medicine, University of Tokyo, Tokyo, Japan; 12Keio University School of Medicine, Tokyo, Japan; 13RIKEN Center for Integrative Medical Sciences, Tokyo, Japan
STAGING AND SURVEILLANCE OF MYXOID LIPOSARCOMA: IS CT SCAN ENOUGH?
Julia Visgauss; David Wilson; David Perrin; Anthony M. Griffin; Peter Ferguson; Jay Wunder
1Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

DEVELOPMENT OF A MODEL TO PREDICT OVERALL SURVIVAL OF MYXOID LIPOSARCOMA PATIENTS
Dayton D. McMillan; Pramod N. Kamalapathy; Adam Z. Kline; Aditya Karhade; Santiago Lozano Calderon; Joseph H. Schwab
1Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA

TIME TRENDS AND PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN MYXOID LIPOSARCOMA: 901 CASES WITH A MEDIAN FOLLOW-UP OF 8 YEARS
Jules Lansu; Winan J. van Houdt; Michael Schaapveld; Iris van Walraven; Michiel van de Sande; Vincent Ho; Marcel Verheij; Rick Haas
1Radiotherapy, Netherlands Cancer Institute, Amsterdam, Netherlands; 2Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; 3Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands; 4Orthopedic Surgery, LUMC, Leiden, Netherlands; 5Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, Netherlands

SHORT TAU INVERSION RECOVERY MAGNETIC RESONANCE IMAGING FOR STAGING AND SCREENING IN MYXOID LIPOSARCOMA
Alexander Chien; Craig Zuppan; Li Lei; Troy G. Shields; Joseph Elsissy; Peter Pham; Lee M. Zuckerman
1Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; 2Radiology, Loma Linda University Medical Center, Loma Linda, CA, USA; 3Pathology, Loma Linda University Medical Center, Loma Linda, CA, USA

MANAGEMENT OF MYXOID LIPOSARCOMA: A SURVEY OF THE MEMBERS OF THE CONNECTIVE TISSUE ONCOLOGY SOCIETY
Troy G. Shields; Joseph Elsissy; Nadine L. Williams; Lee M. Zuckerman
1Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA

ONCOLOGICAL OUTCOMES OF MYXOID LIPOSARCOMA IN EXTREMITIES AND TRUNK AFTER WIDE EXCISION AND ADJUVANT TREATMENT
Young-Hyun Choi; Wanlim Kim; JongSeok Lee; Hye Won Chung
1Department of Orthopedic Surgery, Asan Medical Center, Seoul, Korea (the Republic of); 2Department of Radiology, Asan Medical Center, Seoul, Korea (the Republic of)

OVERCOMING TRABECTEDIN RESISTANCE OF MYXOID LIPOSARCOMA BY COMBINING IT WITH PPARγ AGONISTS
Roberta Frapolli; Ezia Bello; Silvia Brich; Ilaria Craparotta; Sara Ballabio; Laura Mannarino; Sergio Marchini; Laura Carrassa; Roberta Sanfilippo; Alessandro Gronchi; Paolo Casali; Silvana Pilotti; Maurizio D’Incalci
1Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 2Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 3Medical Oncology Unit 2; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 4Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

A COMPARISON OF ONCOLOGICAL AND SURGICAL OUTCOMES IN ENDOPROSTHETIC RECONSTRUCTION VERSUS ROTATIONPLASTY FOR PEDIATRIC LOWER EXTREMITY BONE SARCOMAS
Kim Tsol; Tony Tan; Sevan Hopyan
1Division of Orthopaedic Surgery, University of Toronto, Toronto, ON, Canada; 2Division of Orthopaedic Surgery, Hospital for Sick Children, Toronto, ON, Canada
PRESS FIT VS. CEMENTED FEMORAL STEMS IN ARTHROPLASTY FOR ONCOLOGIC INDICATIONS
Courtney Kaiser; Jason Kim; Joseph H. Schwab; Kevin Raskin; Santiago Lozano Calderon
1Massachusetts General Hospital Orthopaedic Oncology, Boston, MA, USA

THE IMPACT OF FACILITY VOLUME ON SURVIVAL IN PATIENTS WITH PRIMARY BONE TUMORS OF THE VERTEBRAL COLUMN
Alexander L. Lazarides; Brian L. Dial; David Kerr; John Steele; Whitney Lane; Dan Blazer III; William Eward; Brian Brigman; Melissa Erickson; Sergio Mendoza
1Department of Orthopedics, Duke University Medical Center, Durham, NC, USA; 2Department of Surgery, Duke University Medical Center, Durham, NC, USA

POSITIVE MARGIN STATUS IS PROGNOSTIC OF POORER SURVIVAL IN PRIMARY BONE TUMORS OF THE SPINE: A NATIONAL CANCER DATABASE STUDY
Brian L. Dial; David Kerr; Alexander L. Lazarides; Anthony Catanzano; Whitney Lane; Dan Blazer III; Melissa Erickson; Sergio Mendoza
1Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA; 2General Surgery, Duke University Medical Center, Durham, NC, USA

EPIDEMIOLOGIC AND SURVIVAL TRENDS IN PRIMARY MALIGNANT OSSEOUS TUMORS OF THE SPINE: A NATIONAL CANCER DATABASE STUDY
David Kerr; Brian L. Dial; Alexander L. Lazarides; Anthony Catanzano; Whitney Lane; Dan Blazer III; Melissa Erickson; Sergio Mendoza
1Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA; 2General Surgery, Duke University Medical Center, Durham, NC, USA

PIN OR REPLACE: AN ALGORITHM FOR THE MANAGEMENT OF NON-PATHOLOGIC FEMORAL NECK FRACTURES IN CANCER PATIENTS
Jonathan Morris; Eugenia Schwarzkopf; Patrick Boland; John Healey; Daniel Prince
1Orthopedic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

SOFT TISSUE SARCOMAS OF THE ANKLE AND FOOT: CLINICAL OUTCOME AND PROGNOSTIC FACTORS
Hideto Obata; Takaumi Ueda; Norifumi Naka; Hidetatsu Outani; Hideki Yoshikawa
1orthopaedic surgery, Yukoukai General Hospital, Ibaraki, Osaka, Japan; 2orthopaedic surgery, National Hospital Organization Osaka National Hospital, Osaka, Osaka, Japan; 3orthopaedic surgery, Osaka International Cancer Institute, Osaka, Osaka, Japan; 4orthopaedic surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

EFFECT OF BODY MASS INDEX (BMI) ON OUTCOMES OF PATIENTS WITH BONE TUMORS WHO UNDERGO ENDOPROSTHETIC JOINT RECONSTRUCTION
Joseph Elsissy; Ikenna Nwachuku; Troy G. Shields; Jonathan Creech; Lee M. Zuckerman
1Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; 2Loma Linda University School of Medicine, Loma Linda, CA, USA

COMPUTER-ASSISTED NAVIGATION FOR SURGERY OF ILIOSACRAL BONE SARCOMAS: WHAT IS THE EVIDENCE?
Mohamed Yakoub; Patrick Boland; John Healey; Nicola Fabbri
1Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
FUNCTION AFTER DISTRACTION OSTEOGENESIS FOR BONE RECONSTRUCTION OF OSSEOUS TUMORS IN THE UPPER AND LOWER EXTREMITY
Eugenia Schwarzkopf¹; Molly Friel Klima¹; Yoely Tavarez¹; Daniel Prince¹
¹Orthopaedic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

USE OF MAGNETIC GROWING INTRAMEDULLARY NAILS IN COMPRESSION DURING INTERCALARY ALLOGRAFT RECONSTRUCTION
Robert C. Vercio¹; Troy G. Shields¹; Lee M. Zuckerman¹
¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA

LONG TERM (>15 YEARS) OUTCOME OF CUSTOM CROSS-PIN FIXATION OF TUMOR ENDOPROSTHESES STEMS
Nicholas N. Bernthal¹; Alexander Upfill-Brown¹; Zachary D. Burke¹; Francis Hornicek¹; Jeffery J. Eckardt¹
¹Department of Orthopaedic Surgery, University of California, Los Angeles, Santa Monica, CA, USA

OPTIMIZING THE USE OF INDOCYANINE GREEN FOR OSTEOSARCOMA TUMOR DETECTION USING A XENOGRAFT MURINE MODEL
Yoav Zvi¹; Brian Batko¹; Kenji Sato¹; Rui Yang¹; Bang Hoang¹; David Geller¹
¹Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA

TARGETED MUSCLE REINNERVATION: A STRATEGY TO PREVENT NEUROMAS AND PHANTOM LIMB PAIN IN ONCOLOGIC AMPUTEES
John Alexander¹; Julie West²; Jason Hehr²; Byers Bowen²; Steven Schulz²; Joel Mayerson¹; Ian Valerio²; Thomas Scharschmidt¹
¹Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, OH, USA; ²Plastic Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

USE OF FLAP RECONSTRUCTION AFTER RADICAL SURGERY FOR TRUNCAL AND EXTREMITY SARCOMAS
Sergio D. Quildrian¹; Gonzalo Cervelo¹; Julieta Gerino¹; Anabella Dafinoti¹; Leandro Nikisch¹; Jorge Chapela¹
¹Surgery of Soft Tissue Tumors - Sarcoma and Melanoma Unit, Angel H Roffo Institute of Oncology - University of Buenos Aires, Ciudad de Buenos Aires, Ciudad de Buenos Aires, Argentina

MIDTERM FOLLOW-UP OF A CUSTOM NON-FLUTED DIAPHYSEAL PRESS-FIT TUMOR PROSTHESIS SYSTEM
Julia Visgauss¹; David Wilson¹; David Perrin¹; Anthony M. Griffin¹; Jay Wunder¹; Peter Ferguson¹
¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

DUAL MOBILITY COMPONENTS CEMENTED INTO AN ACETABULAR RECONSTRUCTIVE CAGE FOR LARGE OSSEOUS DEFECTS IN THE SETTING OF PERIACETABULAR METASTATIC DISEASE
Darren Plummer¹; John Alexander¹; Sravya Vajapey¹; Travis Frantz¹; Steven Niedermeier¹; Robert Pettit¹; Thomas Scharschmidt¹
¹Orthopaedic Surgery, The Ohio State University James Cancer Hospital, Columbus, OH, USA

LONG TERM OUTCOMES OF TOTAL HUMERAL REPLACEMENT FOR PRIMARY BONE TUMORS IN 18 PATIENTS
Nicholas N. Bernthal¹; Zachary D. Burke¹; Alexander Upfill-Brown¹; Richard Hwang¹; Francis Hornicek¹; Jeffery J. Eckardt¹
¹Department of Orthopaedic Surgery, University of California, Los Angeles, Santa Monica, CA, USA
CHARACTERIZATION OF A BONE BIOREPOSITORY: COMPARISON OF SARCOMAS AND BONE METASTASES FROM BREAST, PROSTATE, RENAL, LUNG CANCERS, AND MYELOMA
Kerith R. Wang, William K. Kelly, Scot A. Brown, Peter McCue, Matthew J. Schiewer, Karen M. Bussard, Alessandro Fatatis, Lucia Languino, Benjamin Leiby, Raymond O'Neill, Jianhong Li, Emily R. Bochner, Eric V. Mastrolonardo, John A. Abraham
1Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA; 2Orthopaedic Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 3Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 4Pharmacology & Physiology, Drexel University, Philadelphia, PA, USA; 5Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA; 6Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

AN INVESTIGATION OF BONE REGENERATION BY USING BONE SUBSTITUTE MATERIALS AFTER BONE TUMOR CURETTAGE
Shinichirou Yoshida, Munenori Watanuki, Masami Hosaka, Takuya Sekiguchi, Toshihisa Yano, Eiji Ito, Shin Hitachi, Mika Watanabe
1Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan; 2Diagnostic Radiology, Tohoku University Hospital, Sendai, Japan; 3Pathology, Tohoku University Hospital, Sendai, Japan

FUNCTIONAL OUTCOME AND COMPLICATIONS OF EXTERNAL HEMIPELVECTOMY IN THE SEVEN PATIENTS UNDERWENT FOR MALIGNANT BONE AND SOFT TISSUE TUMORS
Daiichiro Takahara, Masato Sugawara, Yuya Takakubo, Michiaki Takagi
1Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan

RELATIVE PERCENTAGE OF CIRCULATING ACTIVATED EFFECTOR NKT CELLS FOLLOWING FIRST CYCLE OF CHEMOTHERAPY CORRELATES WITH HISTOLOGIC NECROSIS IN OSTEOSARCOMA PATIENTS
Thomas Badgett, Jacob Bleesing, Jennifer Pope, Rajaram Nagarajan, Nicholas Yeager, Kerry McGowan, Joseph Walden, Zi Ye, Philip Westgate, Lars Wagner
1Pediatrics, University of Kentucky, Lexington, KY, USA; 2Pediatrics, Carolinas Medical Center, Charlotte, OH, USA; 3Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 4Pediatrics, Nationwide Children’s Hospital, Columbus, OH, USA; 5Pediatrics, Norton Children’s Hospital, Louisville, KY, USA; 6Statistics, University of Kentucky, Lexington, KY, USA

IDENTIFYING JUDICIOUS APPLICATIONS FOR SPONTANEOUS BONE CANCER OF DOGS AS A MODEL FOR PEDIATRIC OSTEOSARCOMA
Jaime F. Modiano, Lauren Mills, Nuri A. Temiz, Aaron L. Sarver
1Veterinary Clinical Sciences and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 2Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 3Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 4Institute for Health Informatics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

MODULATION OF MRNA TRANSLATION REGULATION IN HIGHLY METASTATIC OSTEOSARCOMA CELLS INHIBITS LUNG METASTASIS PROGRESSION
Michael M. Lizardo, Haifeng Zhang, Gian Luca Negri, Poul H. Sorensen
1Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada

FACTORS ASSOCIATED WITH LIFE IN ADULTS WITH LOCALIZED OSTEOSARCOMA
Alexander L. Lazarides, David Kerr, Girish B. Reddy, Whitney Lane, Jason Somarelli, Dan Blazer III, Brian Brigman, William Eward
1Department of Orthopaedics, Duke University Medical Center, Durham, NC, USA; 2Department of Surgery, Duke University Medical Center, Durham, NC, USA
Poster 289  3027652
HIGH GRADE INTRAMEDULLARY OSTEOSARCOMA: DOES HISTOLOGIC SUBTYPE AFFECT OUTCOME?
James H. Flint1; Wei-Lien Wang2; Alexis Pascoe3; John A. Livingston4; Justin Bird1; Patrick Lin1; Bryan Moon1; Robert L. Satcher4; Valerai Lewis1
1Orthopedic Oncology, MD Anderson Cancer Center, Houston, TX, USA; 2Pathology, MD Anderson Cancer Center, Houston, TX, USA; 3University of Texas Health Science Center, Houston, TX, USA; 4Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 290  3042179
THE CLINICAL OUTCOME OF THE OSTEOARTICULAR EXTRACORPOREAL IRRADIATED AUTOGRAFT FOR BONE SARCOMA
Satoshi Takenaka1; Nobuhito Araki2; Takafumi Ueda3; Shigeki Kakunaga1; Yoshinori Imura4; Norifumi Naka5; Hidetatsu Otsuna1; Kenichiro Hamada1; Naohiro Yasuda1; Hideki Yoshikawa1
1Orthopaedic surgery, Osaka University, Suita Osaka, Osaka, Japan; 2Orthopaedic surgery, Ashiya Municipal Hospital, Ashiya, Japan; 3Orthopaedic surgery, Osaka National Hospital, Osaka, Japan; 4Orthopaedic surgery, Osaka International Cancer Institute, Osaka, Japan

Poster 291  3042183
OSTEOBLASTOMA-LIKE OSTEOSARCOMA: IS GRADING USEFUL?
Marco Gambarotti1; Angelo Paolo Dei Tos2; Daniel Vanel1; Piero Picci1; Dino Gibernoti2; Michael Klein4; Alberto Righi4
1Anatomy and Pathological Histology, Rizzoli Orthopaedic Institute, Bologna, BO, Italy; 2Department of Pathology & Molecular Genetics, Treviso General Hospital, Treviso, Italy; 3Unit of Hygiene, Public Health and Biostatistics, Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 4Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, NY, USA

Poster 292  3042200
CXCR4 AS POTENTIAL MARKER IN OSTEOSARCOMA
Elisa Bientinesi1; Laura Pazzaglia1; Barbara Dozza2; Amalia Conti3; Serena Pollino1; Emanuela Palmerini4; Enrico Lucarelli1; Piero Picci1; Maria Serena Benassi1
1Experimental Oncology Lab, Ortopedico Rizzoli, Bologna, Italy; 2Osteoarticular Regeneration Lab, Ortopedico Rizzoli, Bologna, Italy; 3Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 4Chemotherapy Unit, Ortopedico Rizzoli, Bologna, Italy

Poster 293  3042729
ONCOLOGIC OUTCOME IN PATIENTS WITH OSTEOSARCOMA OF THE EXTREMITIES AND PATHOLOGIC FRACTURES: DIFFERENCES IN MICRO RNA PROFILE
Santiago Lozano Calderon1; Cassandra Garbutt1; Jason Kim1; Ivan Chebib1; Vikram Deshpande1; Petur Nielsen1; Dimitrios Spentzos2
1Massachusetts General Hospital Orthopaedic Oncology, Boston, MA, USA

Poster 294  3042782
CSF-1R IS A POTENTIAL PREDICTIVE BIOMARKER OF THE THERAPEUTIC RESPONSE OF OSTEOSARCOMA IN THE GSF-GETO OS2006 STUDY
Régis Brion1; Julia Gilhodes2; Bastien Ouvrard3; Nathalie Gaspar2; Charlotte Syrykh4; Aurore Siegfried4; Corinne Bouvier5; Laurence Brugieres5; Sophie Pipemo-Neumann4; François Rédimi6; Anne Gomez-Brouchet7
1Univ Nantes, INSERM UMR1238; Nantes, France; 2Claudius Regaud institute, IUCT-Oncopole, Biostatistics Unit, Toulouse, France; 3Gustave Roussy Cancer campus, Dept of children and adolescent oncology, Villejuif, France; 4IUCT-Oncopole, Department of pathology, Toulouse, France; 5CHU La Timone, Department of pathology, Marseille, France; 6Curie institute, Department of medical oncology, Paris, France

Poster 295  3042798
DO POSTOPERATIVE INFECTIONS INFLUENCE THE SURVIVAL OF OSTEOSARCOMA PATIENTS? RESULTS OF A MULTICENTER TRIAL
Dimosthenis Andreou1; Christine Schwering1; Georg Goshberger1; Maya Niethard2; Maria A. Smolle4; Frank Traub3; Simon Adam3; Hans Roland Dümö; Jendrik Hahnes1; Per-Ulf Tunn2; Andreas Leithner4
1Department of General Orthopedics and Tumororthopedics, Münster University Hospital, Münster, Germany; 2Department of Orthopedic Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany; 3Department of Orthopedics, Tübingen University Hospital, Tübingen, Germany; 4Department of Orthopedic Surgery and Traumatology, Medical University of Graz, Graz, Austria; 5Department of Orthopedics, Ludwig-Maximilians University Munich, Campus Grosshadern, Munich, Germany
MYC AMPLIFICATION IN OSTEOSARCOMA PATIENTS IS A BIOMARKER FOR POOR OUTCOME AND VERY RAPID DISEASE PROGRESSION

Theresa Beech; Christiane M. Robbins; Colleen Pearson; Sherri Millis; Pete Anderson
1Osteosarcoma Collaborative, Rockville, MD, USA; 2Because of Daniel, Rockville, MD, USA; 3Boston University Medical Center, Boston, MA, USA; 4Foundation Medicine, Cambridge, MA, USA; 5Ped Heme Onc/BMT Onc, Cleveland Clinic, Cleveland, OH, USA

A PHASE II STUDY OF PAZOPANIB WITH ORAL TOPOTECAN IN PATIENTS WITH METASTATIC OSTEOSARCOMA

Mark Agulnik; Nisha Mohindra; Mohammed Milhem; Steven Attia; Steven Robinson; Alfred Rademaker; Scott Okuno; Brian Van Tine
1Hematology/Oncology, Northwestern University, Chicago, IL, USA; 2University of Iowa, Iowa City, IA, USA; 3Mayo, Jacksonville, FL, USA; 4Mayo, Rochester, MN, USA; 5Washington University, St. Louis, MO, USA

MULTI-ARM TRIAL IN LOCALIZED OSTEOSARCOMA: MOVING FROM A DREAM TO REALITY

Gauthier Bouche; Pan Pantziarka
1The Anticancer Fund, Strombeek-Bever, Belgium

ANGIOPOIETIN LIKE 2: A POTENTIAL NOVEL BIOMARKER FOR PATIENTS WITH OSTEOSARCOMA

Bhuvana Setty; Maren Cam; Hakan Cam
1Pediatrics-Hematology/Oncology/BMT, Nationwide Children’s Hospital, Columbus, OH, USA; 2The Research Institute at Nationwide Children’s Hospital, Nationwide Children’s Hospital, Columbus, OH, USA

EVALUATION OF THE EFFICACY AND TOXICITY OF HIGH DOSE OF THIOTEPA (HDT) AS ADJUVANT TREATMENT TO STANDARD CHEMOTHERAPY (SCT) IN RELAPSED OSTEOSARCOMA: FINAL RESULTS OF THE MULTI-CENTRIC RANDOMIZED PHASE II TRIAL OSIITTP

Perrine Marec-Berard; Cécile DALBAN; Laurence Brugieres; Nathalie Gaspar; Jean-Claude Gentet; Cyril Lervat; Nadège Corradini; Marie-Pierre Castex; Claudine Schmitt; Helene Pacquement; Marie-Dominique Tabone; Caroline Hernandez; David Perol; Jean-Yves Blay
1Pediatric Oncology, Centre Leon Berard/IHOPe, Lyon, France; 2Biostatistics Unit - Department of Clinical Research and Innovation, Centre Leon Berard, Lyon, France; 3Institut Gustave Roussy, Villejuif, France; 4Centre Oscar Lambret, Lille, France; 5La Timone Hospital, Marseille, France; 6Centre Hospitalier, Toulouse, France; 7Pediatric Oncology, Institut Curie, Paris, France; 8A. Trousseau Hospital, Paris, France; 9Biostatistics Unit - Department of Clinical Research and Innovation, Centre Léon Berard, Lyon, France; 10Medicine, Centre Léon Berard, Lyon, France

EFFICACY AND SAFETY OF CHEMOTHERAPY IN RELAPSED OSTEOSARCOMA

Takeshi Okamoto; Akio Sakamoto; Junya Toguchida
1Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto prefecture, Japan; 2Institute for Frontier Medical Sciences, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto Prefecture, Japan

UTILIZING A NOVEL FORMULATION OF NICLOSAMIDE TO TREAT CANINE METASTATIC OSTEOSARCOMA

Gireesh B. Reddy; David Kerr; Artak Tovmasyan; Prasad Walke; Brian Brigman; David Hsu; Jason Somarelli; David Needham; William Eward
1School of Medicine, Duke University, Durham, NC, USA; 2Department of Orthopaedic Surgery, Duke University, Durham, NC, USA; 3Duke Cancer Institute, Duke University, Durham, NC, USA; 4University of Southern Denmark, Odense, Denmark
COMBINED RADIATION THERAPY AND SURGERY PROVIDE EXCELLENT LOCAL CONTROL FOR PATIENTS WITH EXTRASKELETAL OSTEOSARCOMA

Andrew J. Bishop; John A. Livingston; Dejka M. Araujo; Bryan Moon; Shreyaskumar Patel; Wei-Lien Wang; Alexander J. Lazar; B. Ashleigh Guadagnolo

1Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; 2Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 3Orthopedic Surgery, MD Anderson Cancer Center, Houston, TX, USA; 4Pathology, MD Anderson Cancer Center, Houston, TX, USA

CLINICAL OUTCOME OF PERIOSTEAL OSTEOSARCOMA: A SINGLE INSTITUTIONAL STUDY

Shigeki Kakunaga; Satoshi Takenaka; Yoshinori Imura; Hidetatsu Outani; Kenichiro Hamada; Norifumi Naka; Takafumi Ueda; Yasuaki Aoki

1Osaka National Hospital, Osaka, Japan; 2Osaka University, Suita, Japan; 3Osaka International Cancer Center, Osaka, Japan; 4Himeji Red Cross Hospital, Himeji, Japan

THE EFFECT OF RADIOTHERAPY COMBINED WITH IRON OXIDE-BASED NANOVEHICLE AND PHOTOSENSITIZER IN OSTEOSARCOMA

Yu-Chi Wang; Tse-Ying Liu

1Biomedical Engineering, National Yang-Ming University, Taipei, Taiwan

OSTEOFIBROUS DYSPLASIA LIKE ADAMANTINOMA IS NOT ADAMANTINOMA

Georges Basile; Mark Gebhardt; Antonio Perez-Atayde; Emily Rademacher; Megan Anderson

1Orthopaedic Surgery, Boston Children’s Hospital, Boston, MA, USA

REFERRAL PATTERNS OF SOFT TISSUE SARCOMAS TO A TERTIARY SARCOMA CENTER OVER A 20 YEAR PERIOD

Nicholas Wallace; Joseph Nelson; Caitlin McCarthy; Erin Ackert; Taylor Wood; Sybil Biermann; Geoffrey Siegel

1Orthopedic Surgery, University of Michigan, Ann Arbor, MI, USA

THE INFLUENCE OF HEALTH INSURANCE STATUS ON OUTCOMES IN SOFT TISSUE SARCOMA

Jacob E. Shabason; Sriram Venigalla; Ronnie Sebro; Giorgos C. Karakousis; Robert J. Wilson; Kristy L. Weber

1Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; 2Department of Surgery, Division of Endocrine and Oncologic Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; 3Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; 4Department of Orthopaedic Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

CLINICOPATHOLOGIC FEATURES, TREATMENT UTILIZATION TRENDS AND OUTCOMES OF PRIMARY BREAST SARCOMA: A POPULATION BASED ANALYSIS

Vipul Pareek; Malla Mithun; Sagilla George; Sixia Chen; Alexander Stubblefield; Abhishek Tripathi; Sanjay Patel; Hassan Hatoum

1Hematology and Oncology, Stephenson Cancer Center // University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 2Urologic Oncology, Stephenson Cancer Center // University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; 3Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Poster 310 3042849
INDETERMINATE PULMONARY NODULES AT DIAGNOSIS IN PEDIATRIC RHABDOMYOSARCOMA: ARE WE UNDERTREATING PATIENTS? A REPORT FROM THE EUROPEAN PAEDIATRIC SOFT-TISSUE SARCOMA STUDY GROUP-RMS-2005 STUDY
Bas Vaarwerk1; Kieran McHugh1; Gianni Bisogno1; Nadege Corradini1; Meriel Jenney1; Daniel Orbach1; Julia C. Chisholm1; Andrea Ferrari1; Ilaria Zanetti1; Gian Luca De Salvo1; Carlo Morosi1; Hervé J. Brisse1; Rick R. van Rijn1; Johannes H. Merks1
1Princess Máxima Center for Pediatric Oncology, Amsterdam, Noord-Holland, Netherlands; 2Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, Netherlands; 3Department of Radiology, Great Ormond Street Hospital for Children, London, United Kingdom; 4Pediatric Hematology and Oncology Division, Department of Woman and Children’s Health, Padova University Hospital, Padova, Italy; 5Institut d’Hématologie et d’Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France; 6Department of Pediatric Oncology, Children’s Hospital for Wales, Cardiff, United Kingdom; 7SIREDO Oncology Center, PSL University, Paris, France; 8Children and Young People’s Department, Royal Marsden Hospital, Sutton, United Kingdom; 9Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy; 10Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy; 11Imaging department, Institut Curie, Paris, France; 12Department of Pediatric Radiology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, Netherlands

Poster 311 3042865
THE USE OF HEALTHCARE SERVICES TWO YEARS BEFORE DIAGNOSIS IN DANISH SARCOMA PATIENTS, 2000-2013
Mathias Raedkjaer1; Katja Marety-Kongstad2; Thomas Baad-Hansen2; Akmal Safwat2; Michael M. Petersen3; Johnny Keller2; Peter Vedsted4
1Department of Experimental Clinical Oncology, Aarhus University Hospital, Silkeborg, Denmark; 2Aarhus University Hospital, Aarhus, Denmark; 3Copenhagen University Hospital, Copenhagen, Denmark; 4Aarhus University, Aarhus, Denmark

Poster 312 3042880
THE ASSOCIATION BETWEEN SOCIOECONOMIC POSITION AND TUMOUR SIZE, GRADE, STAGE, AND MORTALITY IN DANISH SARCOMA PATIENTS – A NATIONAL, OBSERVATIONAL STUDY FROM 2000 TO 2013
Mathias Raedkjaer1; Katja Marety-Kongstad2; Thomas Baad-Hansen2; Akmal Safwat2; Michael M. Petersen3; Johnny Keller2; Peter Vedsted4
1Department of Experimental Clinical Oncology, Aarhus University Hospital, Silkeborg, Denmark; 2Aarhus University Hospital, Aarhus, Denmark; 3Copenhagen University Hospital, Copenhagen, Denmark; 4Aarhus University, Aarhus, Denmark

Poster 313 3042903
NODAL INVOLVEMENT AND SURVIVAL IN SYNOVIAL, CLEAR CELL, ANGIO, RHABDO AND EPITHELIOID SARCOMA
Haotong Wang1; Ruoyu Miao1; Graham Boyd1; Saveli Goldberg1; Gregory M. Cote1; Edwin Choy1; Thomas F. DeLaney1; Yen-Lin E. Chen1
1Radiation Oncology, MGH, Burlington, MA, USA

Poster 314 3042961
SARCOMA TREATMENT IN ONTARIO: A POPULATION-BASED STUDY
Anthony Bozzo1; Greg Pong1; Hsien Seow1; Michelle Ghert1
1McMaster University, Hamilton, ON, Canada

Poster 315 3030594
THE ROUTE TO DIAGNOSIS (RTD) OF SARCOMA PATIENTS: A QUALITATIVE STUDY IN THE NETHERLANDS (NL) AND THE UNITED KINGDOM (UK)
Victorien Soomers1; Ingrid Desar2; Shane Zaidi2; Suzanne E. Kaal1; Andrew J. Hayes3; H.W.B. Schreuder4; R. L. Jones3; Winette van der Graaf5; Olga Husson2
1Medical Oncology, Radboudumc, Nijmegen, Netherlands; 2Institute of Cancer Research, London, United Kingdom; 3Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom; 4Orthopaedic Surgery, Radboudumc, Nijmegen, Netherlands
OUTCOME DATA OF ADVANCED SOFT TISSUE SARCOMA PATIENTS FROM A TERTIARY REFERRAL CENTER: NOT SO BAD AS OFTEN REPORTED?
Jakob Lochner¹; Franka Menge¹; Jens Jakob¹; Peter Hohenberger¹; Bernd Kasper¹
¹Mannheim University Medical Center, Mannheim, Germany

A CLINICOPATHOLOGIC EXAMINATION OF MYXOFIBROSARCOMA. RATES OF LOCAL RECURRENCE, METASTASES AND PATIENT SURVIVAL FROM A SINGLE INSTITUTION
Fan Yang¹; Farnaz Dadrass¹; Julie Bloom¹; Yale Fillingham¹; Matthew Colman¹; Steven Gitelis¹; Alan Blank¹
¹Orthopedics, Rush University, Chicago, IL, USA

METASTASECTOMY IN SOFT TISSUE SARCOMA IS ASSOCIATED WITH A POST-METASTASIS SURVIVAL BENEFIT. RESULTS FROM A BI-CENTRE STUDY INCLUDING 135 PATIENTS.
Maria A. Smolle¹; Veroniek M. Van Praag³; Florian Posch³; Marko Bergovec³; Ronald Heregger³; Joanna Szkander³; Bernadette Liegl-Atzwanger³; Freyja-Maria Smolle-Jütten³; Michiel A. van de Sande³; Andreas Leithner³
¹Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria; ³Department of Orthopaedic Surgery, Leiden University Medical Centre, Leiden, Netherlands; ²Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria; ¹Institute of Pathology, Medical University of Graz, Graz, Austria; ²Division of Thoracic and Hyperbaric Surgery, Medical University of Graz, Graz, Austria

SOFT TISSUE SARCOMA OF THE EXTREMITY: ASSOCIATION BETWEEN TREATMENT DELAY, TUMOR FEATURES AND SURVIVAL
Ambria S. Moten¹; Sujana Movva²; Margaret von Mehren²; Sanjay Reddy²; Krisha Howell²; Elizabeth Handorf²; Jeffrey Farma³
¹Surgery, Temple University Hospital, Philadelphia, PA, USA; ²Dept of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; ³Surgery, Fox Chase Cancer Center, Philadelphia, PA, USA; ²Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; ²Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, USA

DESCRIPTIVE ANALYSIS OF LONG-TERM SURVIVORS AMONG PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA
Armelle Dufresne¹; Melodie Carbonnax¹; Mehdi Brahmi¹; Camille Schiffler¹; Pierre Méeus¹; Marie-Pierre Sunyach¹; Amine Bouhamama¹; Marie Karanian¹; Daniel Pissaloux¹; Gualter Vaz¹; Jean-Yves Blay¹
¹Centre Leon Berard, Lyon, France

CHANGING ODDS OF SURVIVAL OVER TIME AMONG PATIENTS UNDERGOING SURGICAL RESECTION OF EXTREMITY SOFT TISSUE SARCOMA
Yong Sung Kim¹; Han-Soo Kim¹; Ilkyu Han¹
¹Department of Orthopaedic Surgery, Seoul National University Hospital, Seoul, Korea (the Republic of)

THE CLINICAL CHARACTERISTICS AND OUTCOMES OF PRIMARY BREAST SARCOMA: RETROSPECTIVE STUDY OVER 20 YEARS FROM A SINGLE, TERTIARY CENTER
Hye Yeong Kim¹; Jae Ho Jeong²; Jeong Eun Kim²; Jin-Hee Ahn²
¹Internal Medicine, Asan Medical Center, Seoul, Korea (the Republic of); ²Medical Oncology, Asan Medical Center, Seoul, Korea (the Republic of)
TWENTY-EIGHT-YEAR EXPERIENCE OF SOFT-TISSUE AND BONE SARCOMAS AT A TERTIARY CARE HOSPITAL IN KOREA

Hyeon-Su Im; Jae Ho Jeong; Jeong Eun Kim; Wanlim Kim; Jong Seok Lee; Kyung-Ja Cho; Joon Seon Song; Si Yeol Song; Hye Won Chung; Min Hee Lee; Jin-Hee Ahn
1Department of Oncology, Asan medical center, Seoul, Korea (the Republic of); 2Department of Internal Medicine, Asan medical center, Seoul, Korea (the Republic of); 3Department of Orthopedic Surgery, Asan medical center, Seoul, Korea (the Republic of); 4Department of Pathology, Asan medical center, Seoul, Korea (the Republic of); 5Department of Radiation Oncology, Asan medical center, Seoul, Korea (the Republic of); 6Department of Radiology, Asan medical center, Seoul, Korea (the Republic of)

MULTIMODAL TREATMENT IN PATIENTS (PTS) WITH ADVANCED/METASTATIC SOFT TISSUE SARCOMA (A/M STS): IMPROVEMENT IN OVERALL SURVIVAL (OS) IS MAINLY ASSOCIATED WITH COMBINATION OF CHEMOTHERAPY (RX) AND SURGERY (SX).

Philipp Ivanyi; Katharina Stange; Hendrik Eggers; Christoph Reuter; Martin Panzica; Patrick Zardo; Florian Laenger; Hans Christiansen; Arnold Ganser; Viktor Gruenwald
1Dep. for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; 2Department for trauma and tumor surgery, Hannover Medical School, Hannover, Hannover, Germany; 3Department for Pathology, Hannover Medical School, Hannover, Germany; 4Department for Radiotherapy, Hannover Medical School, Hannover, Germany; 5Department for Thoracic surgery, Hannover Medical School, Hannover, Germany

PROGNOSTIC SIGNIFICANCE OF SARCOPENIA IN PATIENTS WITH SOFT TISSUE SARCOMA

YoungHyun Choi; Wanlim Kim; JongSeok Lee; Hye Won Chung
1Department of Orthopedic Surgery, Asan Medical Center, Seoul, Korea (the Republic of); 2Department of Radiology, Asan Medical Center, Seoul, Korea (the Republic of)

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA RECEIVING SYSTEMIC THERAPY IN BRAZIL

Andreia C. de Melo; Patricia X. Santi; Sabina B. Aleixo; Cicero L. Martins; Patricia M. Beato; Fabio L. Fernandez; Claudia M. Guimaraes; Renato W. de Oliveira; Henrique F. de Souza; Guilherme S. Julian; Fabiana G. de Menezes
1Evidências – Kantar Health, Sao Paulo, Sao Paulo, Brazil; 2Eli Lilly and Company, Windlesham, United Kingdom; 3Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, RJ, Brazil; 4Centro de Estudos e Pesquisas de Hematologia e Oncologia / FM ABC, Santo Andre, Brazil; 5Hospital Evangélico de Cachoeiro de Itapemirim, Hospital Evangélico de Cachoeiro de Itapemirim, Brazil; 6Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil; 7Fundação Amaral Carvalho, Jau, Brazil; 8Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil; 9. Eli Lilly do Brasil, Sao Paulo, Brazil

NETWORK META-ANALYSIS OF RANDOMIZED TRIALS FOR SECOND OR LATER-LINE TREATMENTS OF METASTATIC LIPOSARCOMA

Moon Hee Lee; Jinchul Kim; Joo Han Lim; Jinhyun Cho; Hyunkyung Park
1hematology-oncology, Inha university college of medicine and hospital, Incheon, Korea (the Republic of)
Poster 329 3038308

PATTERNS OF CARE OF ADVANCED SOFT TISSUE SARCOMAS (STS) NON-GIST IN FOUR EUROPEAN COUNTRIES (EU4)

Ettore Mari1; Alejandra Martinez de Pinillos2; Paola Nasuti2; Filippo Guglielmetti2; Caroline Anger2
1IQVIA, Milan, Italy; 2IQVIA, London, United Kingdom

Poster 330 3042802

A MATCHED COHORT STUDY OF ADJUVANT RADIO-CHEMOTHERAPY VERSUS RADIOTHERAPY ALONE IN SOFT TISSUE SARCOMA PATIENTS

Daniela Greto1; Anna Peruzzi1; Giulia Stocchi1; Monica Lo Russo1; Cristina Muntoni1; Giorgio Caramia1; Sara Lucidi1; Pierluigi Bonomo1; Mauro Loi1; Giulio Francolini1; Isacco Desideri1; Domenico Andrea Campanacci2; Davide Matera2; Nicola Mondanelli2; Lorenzo Livi1
1Radiation Oncology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy; 2Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

Poster 331 3042925

RISK STRATIFICATION OF SOFT TISSUE SARCOMA FOR PREDICTION OF LOCAL RECURRENCE

Cameron Killen2; Cathleen Cahill2; Julie Stoner3; Pravina Kota3; Kimberley Hollabaugh3; Lukas M. Nystrom1; Jeremy White3
1Orthopaedic Surgery, Cleveland Clinic, Cleveland, OH, USA; 2Loyola University Chicago, Maywood, IL, USA; 3Oklahoma University, Oklahoma City, OK, USA

Poster 333 3042160

CLINICAL IMPLEMENTATION OF A NANOSTRING-BASED PANSARCOMA FUSION ASSAY

Angela Goytain1; Julie Ho1; Samuel Leung1; Chick H. Kuick2; Huiyi Chen1; Cheng Han Lee1; Kenneth T. Chang2; Tony Ng1; Torsten O. Nielsen1
1Department of Pathology, University of British Columbia and Vancouver Coastal Health Research Institute, Vancouver, BC, Canada; 2Department of Pathology and Laboratory Medicine, KK Women’s and Children’s Hospital and the Duke-NUS Medical School, Singapore, Singapore

Poster 334 3041833

VIRTUAL BIOBANKING FOR RETROPERITONEAL SARCOMA – A TARPSWG INITIATIVE

Winan J. van Houdt1; Sally M. Burtenshaw2; Chandrajit Raut3; Marco Fiore4; Alessandro Gronchi5; Rebecca Gladdy2
1Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; 2Surgical Oncology, Princess Margaret Cancer Centre, Mount Sinai Hospital, Toronto, ON, Canada; 3Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 4Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

Poster 335 3041966

IDENTIFICATION OF RECURRENT FUSIONS WITHIN SUCCINATE DEHYDROGENASE A (SDHA) IN WELL DIFFERENTIATED RETROPERITONEAL LIPOSARCOMA

Robert Tyler1; Anant Desai1; Valerie Pestinger1; Andrew Beggs1
1Surgical Research Laboratory, Institute of Cancer and Genomic Sciences, Birmingham University, Birmingham, United Kingdom; 2Sarcoma and General Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

Poster 336 3025780

SENSITIVITY OF DIFFERENT BIOPSY METHODS IN SOFT TISSUE AND BONE SARCOMAS: CORE NEEDLE VS. INCISIONAL BIOPSY

Alexander Klein1; Theresa Fell1; Volkmar Jansson1; Hans Roland Dürr1; Thomas Knösel1
1Musculoskeletal Oncology; Department of Orthopaedic Surgery, Physical Medicine and Rehabilitation, University Hospital, LMU Munich, Munich, Germany; 2Institute of Pathology, University of Munich, LMU Munich, Munich, Germany

Poster 337 3028837

UTILITY OF CORE NEEDLE BIOPSY IN RETROPERITONEAL LIPOSARCOMA: A FIFTEEN YEAR REVIEW

Ashley N. Flaman1; Carolyn Nessim1; Denis H. Grave2; Iris Y. Teo2; Bibianna Purgina2
1Surgery, The Ottawa Hospital, Ottawa, ON, Canada; 2Pathology, The Ottawa Hospital, Ottawa, ON, Canada
WHAT IS THE DIAGNOSTIC ACCURACY OF BIOPSIES OF SOFT TISSUE SARCOMAS?

Anthony M. Griffin1; Nicolle Clements1; Jay Wunder1; Peter Ferguson1

1Orthopaedic Surgery, Mount Sinai Hospital, Toronto, ON, Canada

DIAGNOSTIC ACCURACY OF PERCUTANEOUS BIOPSY IN RETROPERITONEAL SARCOMA

Max Almond1; Fabio Tirotta1; Alessandro Gronchi2; Carlo Morosi2; Hannah Tattersall3; James Hodson1; Tommaso Cascella1; Marta Barsella1; Alfonso Marchian2; Giorgio Greco2; Anant Desai5; Samuel Ford1; Marco Fiore2

1Sarcoma Surgery, University Hospital Birmingham, Birmingham, United Kingdom; 2Istituto dei Tumori, Milan, Italy

MDM2 AMPLIFICATION AND FUSION GENE SS18-SSX IN A POORLY DIFFERENTIATED SARCOMA: A RARE BUT PUZZLING CONJUNCTION

Florence Pedeutour1; Ilaria Di Mauro2; Lénaïg Mescam-Mancini2; Bruno Chetaille2; Marick Lae5; Gaelle Pierron5; Dominique Ranchere-Vince4; Berengere Dadone-Montaudie1; Thibault Fabas1; Jean-François Michiels4

1Laboratory of Solid Tumors Genetics, Nice University Hospital, Nice, France; 2Biology of Cancer, Institut Paoli Calmettes, Marseille, France; 3Pathology, Centre Léon-Bérard, Lyon, France; 4Pathology, Nice University Hospital, Nice, France; 5Pathology, Institut Curie, Paris, France; 6Somatic Genetics, Institut Curie, Paris, France

DESMOID FIBROMATOSIS THROUGH THE PATIENTS’ EYES: TIMES TO CHANGE THE FOCUS AND ORGANISATION OF CARE?

Olga Husson1; Eugenie Younger2; Alison Dunlop2; Lucy Dean2; Dirk Strauss2; Charlotte Benson2; Andy Hayes2; Aisha Miah2; Winan J. van Houdt3; Shane Zaidi4; Myles J. Smith2; John Williams5; Robin Jones2; Winette van der Graaf1

1Institute of Cancer Research, Sutton, London, United Kingdom; 2Royal Marsden Hospital, London, United Kingdom; 3Netherlands Cancer Institute, Amsterdam, Netherlands

IS ANYBODY LISTENING? CLINICIAN UNDER-RECOGNITION OF SYMPTOM SEVERITY IN RETROPERITONEAL SARCOMA PATIENTS: A COMPARISON OF PHYSICIAN ASSESSMENTS AND PATIENT SELF-REPORTED OUTCOMES

Andrea M. Covelli1; Deanna Ng2; Sally Burtenshaw2; Rebecca Gladdy2; Savtaj Brar3; Carol Swallow2

1Surgical Oncology, University of Toronto, Toronto, ON, Canada; 2Surgical Oncology, Princess Margaret Cancer Centre, Mount Sinai Hospital, Toronto, ON, Canada; 3Surgical Oncology, Mount Sinai Hospital, Toronto, ON, Canada

EXPERIENCES OF PATIENTS WITH BONE CANCER: THE ROLE OF ILLNESS AND DEVELOPMENT TRAJECTORIES, HEALTHCARE PROFESSIONALS, SOCIAL SUPPORT AND COPING STRATEGIES

Ana Martins1; Lesley Storey1; Mary Wells1; Lorna A. Fern4; Lindsey Bennister3; Craig Gerrand1; Maria Onasanya2; Julie Woodford1; Rachael Windsor1; Jeremy Whelan1; Rachel Taylor1

1The Royal National Orthopaedic Hospital, London, United Kingdom; 2Queens University Belfast, Belfast, United Kingdom; 3Imperial College Healthcare NHS Trust, London, United Kingdom; 4National Cancer Research Institute, London, United Kingdom; 5-, London, United Kingdom; 6patient representative, London, United Kingdom; 7University College London Hospitals NHS Trust, London, United Kingdom

PERCEPTIONS OF CLINICAL TRIAL ENROLLMENT AND MOLECULAR PROFILING IN PATIENTS WITH BONE AND SOFT TISSUE SARCOMA

Ari Rosenberg1; Sheetal Kircher1; Elizabeth Hahn1; Karl Bilimoria1; Jeffrey Wayne3; Alfred Rademaker1; Mark Agulnik1

1Hematology and Oncology, Northwestern University, Chicago, IL, USA; 2Medical Social Sciences and Preventative Medicine, Northwestern University, Chicago, IL, USA; 3Surgical Oncology, Northwestern University, Chicago, IL, USA; 4Preventive Medicine, Northwestern University, Chicago, IL, USA
PATIENT-REPORTED FUNCTIONAL OUTCOMES IN A COHORT OF HAND AND FOOT SARCOMA SURVIVORS TREATED WITH LIMB SPARING SURGERY AND RADIATION THERAPY

Safia K. Ahmed¹; Suneetha Kaggal³; Jessica Sawyer²; William S. Harmsen³; Ivy Petersen¹
¹Radiation Oncology, Mayo Clinic, Rochester, MN, USA; ²Radiation Oncology, Essentia Health- Duluth Clinic, Duluth, MN, USA; ³Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

A SCANDINAVIAN POINT OF VIEW - CARING FOR PATIENTS WITH SARCOMA ACROSS BOUNDARIES

Stine Naess¹
¹Department of Early Cancer Trials and Research Support, Oslo University Hospital, Oslo, Norway

DEPRESSION AND ANXIETY AMONG NEWLY DIAGNOSED SARCOMA PATIENTS

Amirrtha Srikanthan¹; Bonnie Leung³; Aria Shokoohi³; Alannah Smrke³; Heather Rennie³; Alan Bates³; Cheryl Ho²
¹Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; ²Medical Oncology, The BC Cancer, Vancouver, BC, Canada

RELAX: AN IMMERSION VIRTUAL REALITY RELAXATION INTERVENTION FOR QUALITY OF LIFE IMPROVEMENT IN CANCER PATIENTS

Erlinda M. Gordon¹; Bryan M. Li²; Seiya M. Liu²; Sant P. Chawla¹; Seiji M. Liu²; Stephen M. Liu²
¹Sarcoma Oncology Center, Santa Monica, CA, USA; ²IFGCURE, Santa Monica, CA, USA

CAREER AND FINANCIAL SITUATION OF PATIENTS DIAGNOSED WITH SOFT TISSUE SARCOMAS

Nele Laros¹; Ulf Seifart²; Susanne Gutermuth³; Markus Wartenberg⁴; Peter Hohenberger⁵; Bernd Kasper⁶
¹Mannheim University Medical Center, Mannheim, Germany; ²Klinik Sonnenberg, Marburg, Germany; ³Das Lebenshaus e.V., Wölfersheim, Germany

PREFERENCES FOR END-OF-LIFE DISCUSSIONS AND CARE AMONG PATIENTS WITH ADVANCED OR RECURRENT SARCOMA

Aiko Maejima¹; Kan Yonemori²; Motokiyo Komiyama³; Akira Kawai³; Hiroyuki Fujimoto¹
¹Department of Urology, National Cancer Center Hospital, Tokyo, Japan; ²Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; ³Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan

A NOVEL APPROACH FOR ASSESSING FUNCTIONAL BURDEN OF SOFT TISSUE SARCOMA SURGERY: DIGITAL PHENOTYPING AND RECOVERY AFTER RESECTION OF RETROPERITONEAL AND ABDOMINAL SOFT TISSUE TUMORS

Ian Solsky¹; Josh Barbakc; Emily Huang; Karen De Amorim Bernstein; Yen-Lin E. Chen; Thomas F. DeLaney; John T. Mullen; JP Onnela; Alex Haynes¹
¹Ariadne Labs, Boston, MA, USA; ²Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA; ³Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁴Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA

DEFINITIVE HIGH DOSE PROTON THERAPY FOR UNRESECTED OSTEOSARCOMAS OF THE SPINE AND PELVIS: A VIABLE ALTERNATIVE?

Haotong Wang¹; Ruoyu Miao¹; Joseph H. Schwab¹; Edwin Choy²; Gregory M. Cote²; David Ebb³; Francis Hornicek³; Thomas F. DeLaney¹; Yen-Lin E. Chen¹
¹Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA; ³Orthopedic Oncology, UCLA, Los Angeles, CA, USA
RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA: THE ROLE OF A NORMAL SOFT TISSUE STRIP IN VMAT PLANNING

Chan-Kyung J. Cho; Nevin McVicar; Robynn Ferris; Kerry James; Karen Goddard; Steven Thomas

Radiation Oncology, BC Cancer, Vancouver, BC, Canada

FEMUR FRACTURE IN PRIMARY SOFT-TISSUE SARCOMA OF THE THIGH AND GROIN TREATED WITH INTENSITY-MODULATED RADIATION THERAPY: OBSERVED VS EXPECTED RISK

Michael Folkert; Dana Casey; Sean Berry; Aimee M. Crago; Nicola Fabbrì; Sam Singer; Kaled Alektiar

Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA; Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Orthopedic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

HISTOPATHOLOGIC RESPONSE TO NEOADJUVANT RADIATION THERAPY DOES NOT PREDICT ONCOLOGIC OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITY

Sneha Rao; Alexander L. Lazarides; Bruce Leckey; Whitney Lane; Julia Visgauss; Jason Somarelli; Daniel Nuessbaum; David Kirsch; Brian Brigman; Dan Blazer III; Diana Cardona; William Eward

School of Medicine, Duke University, Durham, NC, USA; Orthopaedics, Duke University, Durham, NC, USA; Pathology, Duke University, Durham, NC, USA; Surgery, Duke University, Durham, NC, USA; Radiation Oncology, Duke University, Durham, NC, USA

ACUTE POST-OPERATIVE WOUND COMPLICATIONS FOLLOWING PRE-OPERATIVE PROTON BEAM IRRADIATION FOR SOFT TISSUE SARCOMAS

Colleen Kiernan; Nikita Rajkot; Andrew J. Bishop; Stephen Hahn; B. Ashleigh Guadagnolo; Christina Roland; Quynh-Nhu Nguyen; Barry Feig

MD Anderson Cancer Center, Houston, TX, USA

PROTON-BASED HIGH-DOSE PRE-OPERATIVE RADIATION IS ASSOCIATED WITH HIGHER LOCAL CONTROL THAN LOW-DOSE PRE-OPERATIVE RADIATION WITH EQUIVALENT RATE OF WOUND COMPLICATION IN SACROCOCCYGEAL CHORDOMAS

Genevieve Maquilan; Aashish Bhatt; Ruoyu Miao; Francis Hornicek; Joseph H. Schwab; Thomas F. DeLaney; Yen-Lin E. Chen

Radiation Oncology, Massachusetts General Hospital Cancer Center at Cooley Dickinson Hospital, Northampton, MA, USA; Radiation Oncology, The Ohio State University, Columbus, OH, USA; Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; Orthopaedic Surgery, University of California, Los Angeles, Santa Monica, CA, USA; Orthopaedics, Massachusetts General Hospital, Boston, MA, USA

URETERAL STRICTURE AND RADIATION DOSE CONSTRAINT IN THE TREATMENT OF RETROPERITONEAL SARCOMA

Graham Boyd; Kyung-Wook Jee; Ruoyu Miao; John T. Mullen; Francis McGovern; Alex Haynes; Thomas F. DeLaney; Yen-Lin E. Chen

Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA; Urology, Massachusetts General Hospital, Boston, MA, USA

LONG TERM OUTCOMES AND TOXICITIES FROM A PHASE II TRIAL OF FOCAL CONFORMAL RADIATION THERAPY (RT) FOR CHILDREN WITH RHABDOMYOSARCOMA (RMS)

Matthew J. Krasin; Christopher L. Tinkle; Sue Kaste; Mary Elizabeth McCarville; Chia-ho Hua; Andrew M. Davidoff; Barry Shulkin; Alberto Pappo

Diagnostic Imaging, St. Jude Children’s Research Hospital, Memphis, TN, USA; Radiation Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA; Surgery, St. Jude Children’s Research Hospital, Memphis, TN, USA; Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA
ACHIEVING HIGH RATES OF LOCAL CONTROL AND FAVORABLE TOXICITY USING STEREOTACTIC BODY RADIOTHERAPY FOR SARCOMA PULMONARY METASTASES: A MULTI-INSTITUTIONAL EXPERIENCE
Karen De Amorim Bernstein; Brian Baumann; Edwin Choy; Kristy L. Weber; Ashok Muniappan; Abigail Berman; Arthur Staddon; Lee Hartner; Brian Van Tine; Stephen Hahn; Eli Glatstein; Charles Simone II; Suneel Nagda; William Levine; James Kolker; Thomas F. DeLaney; Yen-Lin E. Chen
1 Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA; 2 Radiation Oncology, Washington University, Saint Louis, MO, USA; 3 Radiation Oncology, UPenn, Philadelphia, PA, USA; 4 Radiation Oncology, MD Anderson, Houston, TX, USA; 5 Radiation Oncology, University of Maryland School Of Medicine, Baltimore, MD, USA

TIME DEPENDENT DYNAMICS OF WOUND COMPLICATIONS AFTER PREOPERATIVE RADIOTHERAPY IN EXTREMITY SOFT TISSUE SARCOMAS
Jules Lansu; Jan Groenewegen; Frits van Coevorden; Winan J. van Houdt; Alexander van Akkooi; Hester van Boven; Marcel Verheij; Rick Haas
1 Radiotherapy, Netherlands Cancer Institute, Amsterdam, Netherlands; 2 Surgery, Netherlands Cancer Institute, Amsterdam, Netherlands; 3 Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands

EFFICACY OF ADJUVANT RADIOTHERAPY IN NON-EXTREMITY SOFT TISSUE SARCOMA WITH MODERATE CHEMOSENSITIVITY
Hyojeong Kim; Young Mi Seol; Young Jin Choi; Eun Mi Lee
1 Hematooncology, Pusan National University Hospital, Busan, Korea (the Republic of); 2 Hematooncology, Kosin University Gaspel Hospital, Busan, Korea (the Republic of)

IMPACT OF RADIATION DOSE AND METHOD OF DELIVERY ON SURVIVAL IN CHORDOMAS
Brian L. Dial; David Kerr; Alexander L. Lazarides; Anthony Catanzano; Whitney Lane; Dan Blazer III; Brian Brigman; William Eward; Melissa Erickson; Sergio Mendoza
1 Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA; 2 General Surgery, Duke University Medical Center, Durham, NC, USA

EARLY ANALYSIS OF PROSPECTIVE PHASE II CLINICAL TRIAL ON PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY (RT) COMBINED WITH CHEMOTHERAPY IN PRIMARY MARGINALY RESECTABLE HIGH GRADE SOFT TISSUE SARCOMAS (STS) OF EXTREMITIES OR TRUNK WALL
Piotr Rutkowski; Mateusz Spalek; Aneta Borkowska; Michal Wagrodzki; Andrzej Cieszanowski; Patricia Castaneda-Wysocka; Tomasz Switala; Sławomir Falkowski; Monika Dudzisz-Sledz; Anna M. Czarnecka; Edyta Dabrowska-Szewczyk; Hanna Kosela-Paterczyk
1 Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; 2 Radiotherapy, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; 3 Pathology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; 4 Radiology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland

PATTERNS OF PRACTICE SURVEY: RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA
Chan-Kyung J. Cho; Charles Catton; Caroline Holloway; Karen Goddard
1 Radiation Oncology, BC Cancer, Vancouver, BC, Canada; 2 Princess Margaret Hospital, Toronto, ON, Canada

EFFECT OF RADIOTHERAPY ON MRI MEASURES OF TUMOR INVASIVENESS AND OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIOTHERAPY AND SURGICAL EXCISION
Dustin C. Buller; Courtney Toombs; Francis Lee; Gary Friedlaender; Dieter Lindskog
1 Department of Orthopaedic Surgery, University of Texas Southwestern Medical School, Dallas, TX, USA; 2 Department of Orthopaedics & Rehabilitation, Yale University School of Medicine, New Haven, CT, USA
PHASE 1 TRIAL OF PREOPERATIVE IMAGE GUIDED INTENSITY MODULATED PHOTON RADIATION THERAPY (IMRT) WITH SIMULTANEOUSLY INTEGRATED BOOST TO THE HIGH-RISK MARGIN FOR RETROPERITONEAL SARCOMAS

Thomas F. DeLaney¹; Yen-Lin E. Chen¹; Beow Yeap¹; Ying J. Hitchcock²; Kilian Salerno³; John Kane⁵; Alex B. Haynes¹⁰; Rachel M. Deering¹; Claire Clendenen⁴; Dan Blazer III¹; David Kirsch⁶; Jeff M. Michalski⁴; Elizabeth H. Baldini⁵; Dian Wang⁶

¹Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Radiation Oncology, Huntsman Cancer Institute, Salt Lake City, UT, USA; ³Radiation Oncology, Roswell Park Memorial Cancer Institute, Buffalo, NY, USA; ⁴Cancer Center, Massachusetts General Hospital, Boston, MA, USA; ⁵Surgical Oncology, Roswell Park Memorial Cancer Institute, Buffalo, NY, USA; ⁶Radiation Oncology, Duke University Medical Center, Durham, NC, USA; ⁷Radiation Oncology, Washington University Medical Center, St. Louis, MO, USA; ⁸Radiation Oncology, Brigham and Women’s Hospital/Dana Farber Cancer Institute, Boston, MA, USA; ⁹Radiation Oncology, Rush University Medical Center, Chicago, IL, USA; ¹⁰Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA

NOVEL THERAPY WITH 103PD-DIRECTIONAL BRACHYTHERAPY DEVICE FOR RECURRENT SOFT TISSUE SARCOMAS: SAFETY AND EARLY POSTOPERATIVE OUTCOMES

Francisco Igor Macedo¹; Matthew Studenski²; Raphael Yechiel³; Breelyn A. Wilky¹; Jonathan Trent¹; Dido Franceschi¹; Alan S. Livingstone³

¹Division of Surgical Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA; ²Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA; ³Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA

TOMOTHERAPY IMRT IN MANAGEMENT OF EXTREMITY SOFT TISSUE SARCOMAS - 8 YEARS’ EXPERIENCE, NORTHERN CENTRE FOR CANCER CARE, FREEMAN HOSPITAL

Jayshree Veeratterapillay¹; Anthony Waton¹; Judith Mott¹; Tracy Wintle¹; Daniela Lee¹

¹Clinical Oncology, Northern Centre for Cancer Care, Newcastle Upon Tyne, United Kingdom

COMPLETION RATE AND TOXICITY OF HYPO-FRACTIONATED RADIOTHERAPY FOR RETROPERITONEAL AND PELVIC SOFT TISSUE SARCOMAS

Hilario Yankey¹; Casey Hollawell¹; Krisha Howell¹; Joshua E. Meyer¹; Margaret von Mehren²; John Abraham²; Sujana Movva²; Jeffrey Farma²; Sanjay Reddy²; Eric Ross²

¹Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; ²Fox Chase Cancer Center, Philadelphia, PA, USA

EFFICACY AND SAFETY OF STEREOTACTIC BODY RADIATION THERAPY SBRT WITH CONCURRENT TRABECTIDIN IN METASTATIC SOFT-TISSUE SARCOMA PATIENTS. A SINGLE INSTITUTION EXPERIENCE

Daniela Greto¹; Monica Lo Russo¹; Cristina Muntoni¹; Giorgio Caramia¹; Anna Peruzzi¹; Giulia Stocchi¹; Virginia Maragna¹; Maria Ausilia Teriaca¹; Isacco Desideri¹; Giulio Francolini¹; Mauro Loi¹; Pierluigi Bonomo¹; Domenico Andrea Campanacci¹; Giovanni Beltrami¹; Guido Scocciamenti¹; Pierluigi Cuomo¹; Lorenzo Livi¹

¹Radiation Oncology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy; ²Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

OPTIMIZING TREATMENT DECISIONS FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA (STS): INDIVIDUAL IDENTIFICATION OF RESPONDERS TO ADJUVANT RADIOTHERAPY (AXRT).

David J. Blau¹; Peter Ferguson²; Anthony M. Griffin²; Peter Chung³; Charles Catton³; Justine Jacot³; Raphael Porcher³; Jay Wunder²

¹Hôpital Cochin, Paris, IDF, France; ²Surgical Oncology - orthopedics, Mount Sinai, Toronto, ON, Canada; ³Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada; ⁴Hospital Hotel Dieu, Paris, IDF, France
ANGIOSARCOMA OF THE SCALP AND FACE TREATED WITH HIGH-DOSE-RATE SURFACE APPLICATOR (HDR SA) BRACHYTHERAPY

Miranda B. Lam1; Michelle Nezolosky1; Chandrajit P. Raut1; Katherine Thornton2; Ivan Buzurovic1; Phillip M. Devlin1; Elizabeth H. Baldini1
1Radiation Oncology, Brigham and Women’s Hospital / Dana Farber Cancer Institute, Boston, MA, USA; 3Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 3Surgery, Brigham and Women’s Hospital / Dana Farber Cancer Institute, Boston, MA, USA

GEORGE Q. YANG1; ARASH NAGHAVI1
1Radiation Oncology, H. L Moffitt, Tampa, FL, USA

PENCIL BEAM SCANNING PROTON RADIOTHERAPY REDUCES DOSE TO THE PLANNED SURGICAL SKIN FLAP AND UNINVOLED BONE IN PREOPERATIVE RADIOTHERAPY FOR SOFT TISSUE SARCOMAS OF THE LOWER EXTREMITY

Sommer Nurkc1; Benjamin Wilke2; Zuofeng Li1; Xing Shen1; MengWei Ho1; Danny Indelicato1; Parker Gibbs2; Andre Spiguel1; Mark Scarborough1; Michael Rutenberg1
1Radiation Oncology, University of Florida, Jacksonville, FL, USA; 2Orthopedic Surgery, University of Florida, Gainesville, FL, USA; 3Orthopedic Surgery, Mayo Clinic, Jacksonville, FL, USA

PRELIMINARY DATA OF PROSPECTIVE PHASE II CLINICAL TRIAL WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY (RT) IN PATIENTS WITH LOCALIZED MYXOID LIPOSARCOMAS

Piotr Rutkowski1; Hanna Kosela-Paterczyk1; Michal Wagrodzk1; Aneta Borkowska2; Anna Szumera-Cieckiewicz2; Andrzej Cieszanowski3; Tadeusz Morysinski1; Jakub Palucki1; Mateusz Spalek3
1Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; 2Pathology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; 3Radiotherapy, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; 4Radiology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland

ADVANCED RADIATION TECHNIQUES TO PRESERVE FERTILITY IN FEMALE PATIENTS RECEIVING PELVIC RADIOTHERAPY FOR SOFT TISSUE TUMORS

Edward Y. Kim1; Elizabeth Loggers1; Seth Pollack1; Lee D. Cranmer2; Teresa Kim1; Gary Mann1; Gabrielle Kane1
1Radiation Oncology, University of Washington, Seattle, WA, USA; 2Medical Oncology, Seattle Cancer Care Alliance, Seattle, WA, USA; 3Surgical Oncology, Roswell Park, Buffalo, NY, USA; 4Surgery, University of Washington, Seattle, WA, USA

IS SURVEILLANCE IMAGING IN PAEDIATRIC PATIENTS TREATED FOR LOCALIZED RHABDOMYOSARCOMA USEFUL? THE EUROPEAN EXPERIENCE

Bas Vaarwerk12; Coralie Mallebranche2; Maria C. Affinita4; Madeleine R. Adams5; Johanna H. van der Lee2; Mienel Jenney3; Andrea Ferrari4; Julia C. Chisholm7; Anne S. Defachelle6; Nadege Corradini6; Veronique Minard-Colin10; Kieran McHugh11; Gianni Bisogno13; Rick R. van Rijn13; Daniel Orbach3; Johannes H. Merks1
1Princess Máxima Center for pediatric oncology, Utrecht, Netherlands; 2Paediatric Clinical Research Office, Emma Children’s Hospital/Academic Medical Center, Amsterdam, Netherlands; 3Siredo Oncology Center, PSL Research University, Paris, France; 4Paediatric Haematology and Oncology Division, Department of Woman and Children’s Health, Padova University Hospital, Padova, Italy; 5Department of Paediatric Oncology, Children’s Hospital for Wales, Heath Park, Wales, United Kingdom; 6Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy; 7Children and Young People’s Department, Royal Marsden Hospital, Sutton, United Kingdom; 8Department of Paediatric Oncology, Centre Oscar Lambret, Lille, France; 9Department of Paediatric Oncology, Centre Léon Bérard, Lyon, France; 10Department of Paediatric and Adolescent Oncology, Gustave-Roussy, Villejuif, France; 11Department of Radiology, Great Ormond Street Hospital for Children, London, United Kingdom; 12Department of Pediatric Oncology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, Netherlands; 13Paediatric Radiology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, Netherlands
MANAGEMENT OF PEDIATRIC PERITONEAL RHABDOMYOSARCOMATOSIS WITH CYTOREDUCTIVE SURGERY (CRS), HYPERTERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) AND WHOLE ABDOMINAL RADIOTHERAPY (WART)
Gideon Sandler\(^1\); Lianchun Xiao\(^1\); Winston Huh\(^1\); Andrea Hayes-Jordan\(^1\)
\(^1\)Oncology, M D Anderson Cancer Center, Sydney, NSW, Australia

EMBRYONAL AND ALVEOLAR RHABDOMYOSARCOMAS IN ADULTS: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS
Cas Drabbe\(^1\); Charlotte Benson\(^1\); Eugenie Younger\(^1\); Robin Jones\(^1\); Ian Judson\(^2\); Julia C. Chisholm\(^1\); Shane Zaidi\(^1\); Cyril Fisher\(^2\); Khin Thway\(^1\); Omar Al-Muderis\(^1\); Christina Messiou\(^1\); Dirk Strauss\(^1\); Olga Husson\(^1\); Aisha Miah\(^1\); Winette van der Graaf\(^6\)
\(^1\)Royal Marsden Hospital, London, UK, Nijmegen, Netherlands; \(^2\)The Institute of Cancer Research, London, United Kingdom

DISEASE OUTCOME IN PATIENTS WITH INTERMEDIATE- AND HIGH- RISK RHABDOMYOSARCOMA BASED ON CHEMOTHERAPY REGIMEN: A SINGLE CENTER RETROSPECTIVE ANALYSIS
Kathryn S. Sutton\(^1\); Leah N. Bryan\(^2\); Karen Wasilewski\(^2\); Thomas A. Olson\(^1\); Bradley A. George\(^1\); William G. Woods\(^1\)
\(^1\)Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA; \(^2\)Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA

RHABDOMYOSARCOMA IN ADULTS: A SEER POPULATION-BASED STUDY OF 1942 PATIENTS
Sheng Yang\(^1\); Jiping Wang\(^2\)
\(^1\)Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China; \(^2\)Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

VAC REGIMEN TO RHABDOMYOSARCOMA: THE DIFFERENCES OF RESPONSE AND PROGNOSIS IN PATIENTS OF AYA AND OLDER AGES
Kenji Nakano\(^1\); Junichi Tomomatsu\(^1\); Mayu Yunokawa\(^1\); Masatoshi Nishizawa\(^1\); Makiko Ono\(^1\); Shinichiro Taira\(^1\); Shunji Takahashi\(^1\); Keisuke Ae\(^2\); Seiichi Matsumoto\(^2\)
\(^1\)Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; \(^2\)Orthopedic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

OPTIONAL PET SCAN UPSTAGING FOR CASES OF PEDIATRIC RHABDOMYOSARCOMA
Anna L. Tamulonis\(^1\); Berkelee Asare\(^1\); Antonio Logan\(^1\); Paul Kent\(^1\)
\(^1\)Rush University Medical Center, Chicago, IL, USA
LIPOSARCOMA-SPECIFIC RADIATION THERAPY FOR RETROPERITONEAL SARCOMA - A REPORT FROM TARPSWG

Rick Haas1; Sylvie Bonvalot2; Rosalba Miceli3; Dirk Strauss4; Carol Swallow5; Peter Hohenberger6; Frits van Coevorden7; Piotr Rutkowski8; Danio Callegaro9; Andrew J. Hayes10; Charles Honoré11; Mark Fairweather12; Rebecca Gladdy13; Jens Jakob14; Milena Szacht15; Marco Fiore16; Peter Chung17; Winan J. van Houdt18; Chandrajit Raut19; Alessandro Gronchi20

1Department of Surgery, Institute Curie, Paris, France; 2Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, Netherlands; 3Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 4Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; 5Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada; 6Division of Surgical Oncology & Thoracic Surgery, Mannheim University Hospital, Mannheim, Germany; 7Department of Surgical Oncology, the Netherlands Cancer Institute, Amsterdam, Netherlands; 8Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 9Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 10Department of Surgery, Institute Gustave Roussy, Paris, France; 11Department of Surgery, Brigham and Women’s Hospital and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 12Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada

MALNUTRITION AND PERIOPERATIVE NUTRITIONAL SUPPORT IN RETROPERITONEAL SARCOMA (RPS) PATIENTS. RESULTS FROM A PROSPECTIVE FEASIBILITY STUDY

Paola Previtali1; Daniela Codazzi2; Luigi Mariani3; Chiara Colombo4; Giuseppe Cottone5; Jacopo Colombo6; Jessica Petti7; Nicolò N. Rampello8; Roberta Casirani9; Lavinia Bergesio10; Virna Berto11; Franco Valenza12; Alessandro Gronchi13; Marco Fiore1

1Anaesthesiology and Intensive Care, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2Biometrics and Statistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 3Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

POST-OPERATIVE RADIOTHERAPY IMPROVES OVERALL SURVIVAL IN MARGIN-POSITIVE RETROPERITONEAL SARCOMAS

Alexandra C. Istl1; Stephanie A. Terezakis2; Christian Meyer3; Nita Ahuja4; Fabian M. Johnston5

1General Surgery, Western University, London, ON, Canada; 2Medical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA; 3Surgical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA; 4Surgical Oncology, Yale University , New Haven, CT, USA; 5Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD, USA

MEASURING THE IMPACT OF COMPLICATIONS AFTER SURGERY FOR RETROPERITONEAL SARCOMA (RPS): IS COMPREHENSIVE COMPLICATION INDEX (CCI) BETTER THAN CLAVIEN-DINDO CLASSIFICATION (CDC)?

Ferdinando Carlo Maria Cananzi1; Laura Ruspi1; Damiano Gentile1; Federico Sicoli1; Laura Samà1; Vittorio Quaglificio2

1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy; 2Surgical Oncology Unit, Humanitas Clinical and Research Center, Rozzano (Milan), Italy

MANAGEMENT AND OUTCOME OF INTERMEDIATE-HIGH GRADE RETROPERITONEAL SARCOMAS: A SINGLE INSTITUTION STUDY

Ruoyu Miao1; Graham Boyd1; Matthew DiMaria1; Haotong Wang1; Genevieve Maquilan1; Alex Haynes2; Thomas F. DeLaney1; Edwin Choy1; Gregory M. Cote3; John T. Mullen2; Yen-Lin E. Chen1

1Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; 2Department of Orthopedic Oncology, Massachusetts General Hospital, Boston, MA, USA; 3Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA
MANAGEMENT OF LOCOREGIONAL RECURRENCE AFTER RADICAL RESECTION OF A PRIMARY NON-METASTATIC RETROPERITONEAL SOFT TISSUE SARCOMA: RESULTS OF A RETROSPECTIVE SERIES IN A TERTIARY CARE CENTER

Charles Honoré; Matthieu Faron; Olivier Mir; Leila Haddag; Sarah N. Dumont; Julien Adam; Philippe Terrier; Cécile Le Péchoux; Axel Le Cesne
1Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; 2Radiology, Gustave Roussy Cancer Campus, Villejuif, France; 3Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; 4Pathology, Gustave Roussy Cancer Campus, Villejuif, France; 5Radiation Therapy, Gustave Roussy Cancer Campus, Villejuif, France

OUTCOME AND QUALITY OF LIFE AFTER RESECTION FOR RETROPERITONEAL SARCOMA

Martin Almquist; Daniel Andulv; Pall Hallgrimsson
1Dept. of Surgery, Skåne University Hospital, Klagshamn, Sweden

NO BENEFIT OF PREOPERATIVE CHEMOTHERAPY FOR PRIMARY RETROPERITONEAL SARCOMAS: RESULTS FROM A SINGLE CENTER PROPENSITY MATCHED ANALYSIS

Matthieu Faron; Sarah N. Dumont; Olivier Mir; Julien Adam; Leila Haddag; Cécile Le Péchoux; Philippe Terrier; Axel Le Cesne; Charles Honoré
1Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; 2Radiology, Gustave Roussy Cancer Campus, Villejuif, France; 3Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; 4Pathology, Gustave Roussy Cancer Campus, Villejuif, France; 5Radiation Therapy, Gustave Roussy Cancer Campus, Villejuif, France

EVALUATION OF TREATMENT RESPONSE TO PREOPERATIVE THERAPY IN RETROPERITONEAL LEIOMYOSARCOMA

Naruhiko Ikoma; Wei-Lien Wang; Christina Roland; Kiela E. Torres; Ravi Vinod; Kelly Hunt; Janice Cormier; Barry Feig
1Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 2Pathology, MD Anderson Cancer Center, Houston, TX, USA; 3Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

ROLE OF NUTRITIONAL STATUS IN THE EARLY POSTOPERATIVE PROGNOSIS OF PATIENTS OPERATED FOR RETROPERITONEAL LIPOSARCOMA (RLS): A SINGLE CENTER EXPERIENCE

Krassen M. Kirov; HaoPing Xu; Pascal Crenn; Philippe Goater; Dimitri Tzanis; Mohammed Toufik Bouhadiba; Khoubeyb Abdelhafidh; Youlia M. Kirova; Sylvie Bonvalot
1Institut Curie, Paris, France; 2Unit of Nutrition, Hôpital Raymond Poincaré (APHP), Garches, France

WHY WERE NON-METASTATIC PRIMARY RETROPERITONEAL SARCOMAS NOT RESECTED?

Deanna Ng; Sally M. Burtenshaw; Ana Olteanu; Rebecca Gladdy; Savtaj Brar; Peter Chung; Charles Catton; Korosh Khallili; Carol Swallow
1Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; 2Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; 3Joint Department of Medical Imaging, University of Toronto, Toronto, ON, Canada
WHY PRIMARY RETROPERITONEAL SARCOMA (PRPS) PATIENTS (PTS) UNDERGOING TREATMENT AT STRASS INSTITUTIONS DID NOT ENROLL IN STRASS: THE STREXIT STUDY FROM EORTC STBSG AND TARPSWG

Chandrjit Raut1; Dirk Strauss2; Rick Haas3; Hans Gelderblom4; Sylvie Bonvalot5; Charles Honoré6; Monica Bertagnolli7; Sally Burtneshaw8; Mark Fairweather9; Deanna Ng10; Saskia Litière11; Bianca Colleoni12; Angelique Deleersnijder13; Sandrine Marreaud14; Winan J. van Houdt15; Nikolaos Vassos16; Lorenzo Conti17; Dario Callegaro18; Alessandro Gronchi19; Carol Swallow20

1Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA; 2Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; 3Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; 4Department of Clinical Oncology, Leiden University Medical Centre, Leiden, Netherlands; 5Department of Surgery, Curie Institute, Paris, France; 6Department of Surgery, Gustave Roussy Institute, Villejuif, France; 7Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; 8Division of Surgical Oncology, Department of Surgery, Brigham and Women’s Hospital and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 9European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; 10Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; 11Department of Surgery, Fondazione ICRSS Istituto Nazionale dei Tumori, Milan, Italy

SHOULD LOCALIZED RETROPERITONEAL SARCOMAS BE TREATED IN REFERENCE CENTERS?: RESULTS OF A SINGLE INSTITUTION

Marta Carmona-Campos1; Anna C. Virgili Manrique2; Ana Sebio3; Oscar Gallego4; Vicens Artigas4; Silvia Daniela Camacho5; Sara Moron6; Manuel Rodríguez-Blanco7; Katerina Majerkacova8; Jose Isem9; Silvia Bagué10; Ruth Orellana11; Isidro Gracia12; Ana Peiró13; Laura Trullols14; Jaume Llaurer15; Diana Hernández16; Sandra Valverde17; Jaume Palmer18; Manuel Fernandez-Garrido19; Maria J. Quintana20; Antonio Lopez-Pousa20

1Medical Oncology, Sant Pau Hospital, Barcelona, Barcelona, Spain; 2Radiation Oncology, Sant Pau Hospital, Barcelona, Spain; 3Orthopedic surgery and traumatology, Sant Pau Hospital, Barcelona, Spain; 4Epidemiology, Sant Pau Hospital, Barcelona, Spain; 5Plastic and reconstructive surgery, Sant Pau Hospital, Barcelona, Spain; 6General and Digestive Surgery, Sant Pau Hospital, Barcelona, Spain; 7Pathology, Sant Pau Hospital, Barcelona, Spain; 8Radiology, Sant Pau Hospital, Barcelona, Spain; 9Pathology, Royal Marsden Hospital, London, United Kingdom

PREDICTIVE FACTORS FOR COMPLICATIONS AFTER SURGICAL TREATMENT FOR SCHWANNOMAS OF THE EXTREMITIES

Toshihide Hirai1; Hiroshi Kobayashi2; Toru Akiyama3; Tomotake Okuma4; Hiroyuki Oka5; Yusuke Shinoda6; Masachika Ikekami7; Takahiro Ohkii8; Ryoko Sawada9; Takahiro Goto10; Sakae Tanaka11

1Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan; 2Department of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan; 3Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; 4Department of Medical Research and Management for Musculoskeletal Pain, 22nd Century Medical & Research Center, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan

CLINICOPATHOLOGICAL AND RADIOLOGIC FEATURES OF GASTRIC SCHWANNOMA

Yohei Oguri1; Haruhiko Cho1; Haruna Onoyama2; Ryouki Oohinata3

1surgery, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan

SOLITARY FIBROUS TUMOR - A SINGLE INSTITUTION RETROSPECTIVE STUDY

Ninna Aggerholm-Pedersen1; Rasmus Blechingberg Friis2; Thomas Baad-Hansen3; Akmal Safwat4

1Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; 2Department of Orthopedic Surgery, Aarhus University Hospital, Aarhus, Denmark
HIGH-GRADE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA (USRCS): A CLINICAL-PATHOLOGICAL STUDY BY THE ITALIAN SARCOMA GROUP (ISG)
Emanuela Palmerini1; Piero Picci2; Rossella Bertulli2; Giacomo Giulio Baldi2; Virginia Ferraresi2; Tiziana Venesio2; Antonella Brunello2; Salvatore Provenzano2; Lorenzo D’Ambrosio2; Marco Gambarotti2; Alessandra Longhi2; Emanuela Marchesi2; Alessandro Franchi3; Elisabetta Setola2; Angelo Paolo Dei Tos2; Marta Sbaraglia2; Stefano Ferrari2; Bruno Vincenzi2
1Istituto Ortopedico Rizzoli, Bologna, BO, Italy; 2Medical Oncology Unit 2 – Adult mesenchymal tumours and rare cancer, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 3Medical Oncology Department, Hospital of Prato, Prato, Italy; 4Istituto Nazionale Tumori “Regina Elena”, Roma, Italy; 6Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS Candiolo, Candiolo, Italy; 6Department of Experimental and Clinical Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto - IOV, IRCCS, Padova, Italy; 7Azienda ULSS n. 2; Treviso, Italy; 8Policlinico Universitario Campus Biomedico, Roma, Italy; 9. Department of translational research, University of Pisa, Pisa, Italy

DESIGNING A RATIONAL FOLLOW-UP SCHEDULE FOR SOFT TISSUE SARCOMA
David A. Wilson1; Julia Visgauss1; David L. Perrin1; Aaron Gazendam1; Anthony M. Griffin1; Peter Ferguson1; Jay Wunder1
1Surgery, University of Toronto, Toronto, ON, Canada

RADIATION-ASSOCIATED SARCOMA AFTER BREAST CANCER IN FINLAND DURING 1953-2014: A STRONG INCREASE OF ANGIOSARCOMA
Samuli Salminen1; Mika M. Sampo2; Tom Böhling2; Maija Tarkkanen1; Carl Blomqvist1
1Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; 2Department of Pathology, University of Helsinki and HUSLAB Helsinki University Hospital, Helsinki, Finland

MULTIDISCIPLINARY TUMOR BOARD RECOMMENDATIONS FOR SARCOMA PATIENTS WITH OLIGOMETASTATIC DISEASE
Christian Galata1; Elisabeth Wimmer1; Peter Hohenberger1; Bernd Kasper2; Jens Jakob3
1Department of Surgery, Division of thoracic surgery and surgical oncology, Medical Faculty Mannheim, University of Heidelberg, Germany, Mannheim, Germany; 2Interdisciplinary Tumor Center, University Medical Center Mannheim, Mannheim, Germany; 3Universitätsmedizin Göttingen Georg-August-Universität, Göttingen, Germany

ULCERATING SOFT TISSUE SARCOMAS
Brooke M. Crawford1; Warren Chow2; Sagus Sampath2; Joseph D. Femino1; Santiago Lozano Calderon4; Marilyn Heng4
1Surgery, City of Hope Cancer Center, Duarte, CA, USA; 2Medical Oncology, City of Hope Cancer Center, Duarte, CA, USA; 3Radiation Oncology, City of Hope Cancer Center, Duarte, CA, USA; 4Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA

THE PROGNOSTIC VALUE OF INTERLEUKIN-6 IN PATIENTS WITH SOFT TISSUE SARCOMA
Tomohito Hagi1; Tomoki Nakamura1; Koji Kita1; Kunihiro Asanuma1; Akihiro Sudo1
1Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan
TRABECTEDIN IN 473 PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS): AN ITALIAN SARCOMA GROUP (ISG), OBSERVATIONAL, MULTICENTER, RETROSPECTIVE STUDY

Emanuela Palmerini; Paolo Casali; Tiziana Venesio; Virginia Ferraresi; Bruno Vincenzi; Antonella Romanini; Alessandro Comandone; Giuseppe Badalamenti; Antonio Pizzolorusso; Elisabetta Setola; Antonella Brunello; Gabriele Luppi; Angelo Buonadonna; Tommaso De Pas; Toni Ibrahim; Laura Mlesi; Federica Grosso; Maria Abbondanza Pantaleo; Francesca Zanelli; Emanuela Marchesi; Irene Quattrini; Alberto Righi; Piero Picci; Stefano Ferrani

1Istituto Ortopedico Rizzoli, Bologna, BO, Italy; 2IRCC Candioli, Turin, Italy; 3Istituto Nazionale Tumori, Milan, Italy; 4Istituto Regina Elena, Rome, Italy; 5Polincinico Campus Biomedico, Roma, Italy; 6Humanitas Gradenigo, Torino, Italy; 7Polincinico P. Giaccone, Palermo, Italy; 8Istituto Nazionale Tumori `Fondazione Pascale`, Napoli, Italy; 9Istituto Oncologico Veneto, Padova, Italy; 10Polincinico di Modena, Modena, Italy; 11Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; 12Centro di Riferimento Oncologico CRO, Aviano, Italy; 13Istituto Europeo di Oncologia, Milano, Italy; 14Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy; 15ASST Papa Giovanni XXIII, Bergamo, Italy; 16Azienda Ospedaliero Nazionale SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy; 17Policlinico Sant’Orsola Malpighi, Bologna, Italy; 18IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

FASCIA-INFILTRATING SARCOMA*: A CATEGORY OF HIGH RISK OF RECURRENTNESS AND POOR OUTCOME

Eberhard Stocke; Audrey Michot; Amandine Crombé; Brice Richez; Maud Toulmonde; Paul Sargos; Michele Kind; Veronique Brouste; Antoine Italiano; François Le Loarer

1Surgery, Institut Bergonié, Bordeaux, France; 2Radiology, Institut Bergonié, Bordeaux, France; 3Anaesthesia, Institut Bergonié, Bordeaux, France; 4Medical Oncology, Institut Bergonié, Bordeaux, France; 5Radiotherapy, Institut Bergonié, Bordeaux, France; 6Clinical and epidemiological research unit, Institut Bergonié, Bordeaux, France; 7Pathology, Institut Bergonié, Bordeaux, France

ESOPHAGEAL GASTROINTESTINAL STROMAL TUMOR VERSUS LEIOMYOSARCOMA: NATIONAL CANCER DATABASE COMPARATIVE STUDY

Basem Azab; Francisco Igor Macedo; Syed Raz; Caroline Ripat; Omar Picado; Dido Franceschi; Alan S. Livingstone; Danny Yakoub

1Surgical oncology, University of Miami, Miami, FL, USA; 2Cardiothoracic surgery, University of Miami, Miami, FL, USA

PRIMARY SARCOMA OF LUNG (PSL): A RETROSPECTIVE SERIES.

Jose Duran Moreno; Stefania Kokkali; Vasilieos Ramfidis; Maria Salomidou; Antonia Digkli; Anna Koumarianou; Periklis Tomos; Nektarios Koufopoulo; Ioannis Vamvakaris; Eleni Psychogiou

1Oncology, Lausanne University Hospital and University of Lausanne, Lausane, Switzerland; 2Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens, Greece; 33rd Department of Internal Medicine, University General Hospital Athens, Greece; 44th Department of Internal Medicine - Department of Oncology, Attikon University General Hospital, Athens, Greece; 5Department of Thoracic surgery, Attikon University General Hospital, Athens, Greece; 6Pathology department, Saint-savvas anticancer hospital, Athens, Greece; 7First Department of Pathology, Medical School, University of Athens, Athens, Greece

SCLEROSESING EPITHELIOD FIBROSARCOMA OF SOFT TISSUE AND BONE: REPORT OF 12 CASES.

Alessandra Longhi; Stefano Bandiera; Marco Gambarotti; Alberto Righi; Angelo Toscano; Cristina Ferrari; Alessandro Gasbarrini; Elisabetta Setola; Anna Paioli; Marilena Cesari; Massimo Abate; Davide M. Donati

1Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy

PREDICTORS OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH PRIMARY SOFT TISSUE SARCOMA

Pramod N. Kamalapathy; Adam Z. Kline; Dayton D. McMillian; Aarti Patel; Marilyn Johnson; Alexandra Bachinsky; Karen De Amorim Bernstein; Kevin Raskin; Joseph H. Schwab; Santiago Lozano Calderon

1Orthopedics, Massachusetts General Hospital, Mount Laurel, NJ, USA
DYNABIC PREDICTION FOR PATIENTS WITH HIGH-GRADE EXTREMIT Y SOFT TISSUE SARCOMA - PERSONALIZED SARCOMA CARE (PERSARC DYNAMIC)

Anja Rueten-Buddé; Veroniek V. Praag; Michiel van de Sande; Marta Fiocco
1Orthopedic Surgery, Leiden University Medical Center, Den Haag, Netherlands; 2Mathematical Institute, Leiden University, Leiden, Netherlands

SPONTANEOUS REGRESSION OF SOFT TISSUE SARCOMA

Michioo Susa; Keisuke Horuchi; Masato Saito; Chiaki Sato; Robert Nakayama; Hideo Morioka; Kazuhiro Chiba
1Orthopaedics, National Defense Medical College, Tokorozawa, Japan; 2Orthopaedics, Keio University School of Medicine, Tokyo, Japan; 3Orthopaedics, Tokyo Medical Center, Tokyo, Japan

SOFT TISSUE SARCOMA OF THE EXTREMITY: THE IMPACT OF TREATMENT AT MULTIPLE FACILITIES

Ambria S. Moten; Sujana Movva; Margaret von Mehren; Sanjay Reddy; Krisha Howell; Elizabeth Handorf; Jeffrey Farma
1Surgery, Temple University Hospital, Philadelphia, PA, USA; 2Dept of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; 3Surgery, Fox Chase Cancer Center, Philadelphia, PA, USA; 4Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; 5Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, USA

TREATMENT AND FOLLOW-UP OF 5 PATIENTS WITH INFANTILE MYOFIBROMATIS - A SINGLE CENTER EXPERIENCE

Michal Manisterski; Marganit Benish; Dror Levin; Rina Dvir; Hila Rosenfeld-Keidar; Sivan Berger-Achituv; Yair Peled; Osnat Sher; Yair Gortzak; Ronit Elhasid
1Pediatric Hemato-Oncology, Tel Aviv Medical Center, Tel Aviv-Yafo, Israel; 2Pathology, Tel Aviv Medical Center, Tel Aviv-Yafo, Israel; 3Orthopedic – Oncology, Tel Aviv Medical Center, Tel Aviv-Yafo, Israel

INTIMAL SARCOMA: A CLINICOPATHOLOGIC AND IMMUNOHISTOCHEMICAL EXPRESSION IN SEVEN CASES IN THE NATIONAL CANCER INSTITUTE.

Claudia Haydee Sarai Caro Sanchez; Dorian Yarih Garcia Ortega; Hugo R. Dominguez Malagon; Miguel Angel Clara Altamirano; Mario Cuellar Hubbe; Hector Martinez Said; Jorge Martinez Tlahuel; Diana Aguilar Leon; Guillermo Corredor Alonso
1Skin and Soft Tissue Tumors, National Cancer Institute (Mexico), Tlalpan, Mexico City, Mexico

MORBIDITY, QUALITY OF LIFE AND PAIN IN RETROPERITONEAL SARCOMA (RPS). RESULTS FROM A PROSPECTIVE STUDY

Marco Fiore; Michele Manara; Cinzia Brunelli; Rosalba Miceli; Dario Callegaro; Nicolò N. Rampello; Chiara Colombo; Stefano Radaelli; Gonzague De Pinieux; Emmanuelle Bompas; Juliette Thariat; Agnes Leroux; François Bertucci; Nicholas Isambert; Corinne Delcambre; Jean-Yves Blay; Marie-Pierre Sunyach; Jean-Michel Coindre; Paul Sargos; Nicolas Penel; Sylvie Bonvalot
1Medical Oncology, Centre Oscar Lambret, Lille, France; 2Institut Gustave Roussy, Villejuif, France; 3Institut Bergonie, Bordeaux, France; 4Centre Leon Berard, Lyon, France; 5Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France; 6Hopital de la Timone, Marseille, France; 7Hopital Trousseau, Tours, France; 8Institut de cancérologie de l'Ouest, Saint-Herblain, France; 9Centre Antoine Lacassagne, Nice, France; 10Institut Paoli-Calmettes, Marseille, France; 11Centre Georges François Leclerc, Dijon, France; 12Centre François Baclesse, Caen, France; 13Institut Curie, Paris, France; 14Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
MANAGEMENT AFTER UNPLANNED EXCISION IN ADULT EXTREMITY AND SUPERFICIAL TRUNK SOFT TISSUE SARCOMA: ABSTENTION OF SYSTEMATIC RE EXCISION DOES NOT AFFECT OVERALL SURVIVAL, NOR AMPUTATION RATE

Gauthier Decanter; Eberhard Stoeckle; Charles Honoré; Pierre Méeus; Jean-Camille Mattei; Pascale Dubray-Longeras; Gwenaël Ferron; Sébastien Carrère; Sylvain Casuret; Jean-Marc Guillot; Magali Fau; Louis-Romée Le Nail; Jean-Christophe Machiavello; Jean-Baptiste Delorme; Nicolas Regenet; François Gouin; Jean-Yves Blay; Jean-Michel Coindre; Nicolas Penel; Sylvie Bonvalot

1Medical Oncology, Centre Oscar Lambret, Lille, France; 2Institut Bergonie, Bordeaux, France; 3Institut Gustave Roussy, Villejuif, France; 4Centre Leon Berard, Lyon, France; 5Hôpital de la Timone, Marseille, France; 6Centre Jean Perrin, Clermont Ferrand, France; 7Institut universitaire de cancérologie de Toulouse Oncopole, Toulouse, France; 8Institut du Cancer de Montpellier, Montpellier, France; 9Centre Georges François Leclerc, Dijon, France; 10Centre François-Baclesse, Caen, France; 11Institut de Cancérologie de Lorraine, Nancy, France; 12Centre Antoine Lacassagne, Nice, France; 13Institut Curie, Paris, France; 14Centre Paul Strauss, Strasbourg, France; 15CHU, Tours, France; 16CHU, Nantes, France

INCREASED SURVIVAL AFTER SURGICAL MANAGEMENT OF HIGH-GRADE AND DEEP-SEATED SOFT TISSUE SARCOMA IN HIGH-VOLUME HOSPITALS: A NATIONWIDE STUDY

Melissa Vos; Harriët Blaauwgeers; Vincent Ho; Winan J. van Houdt; Jos van der Hage; Lukas Been; Johannes Bonenkamp; Marc H. Beemelmans; Thijs van Dalen; Dirk Grünhagen; Kees Verhoeof

1Medical Oncology and Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; 2Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, Netherlands; 3Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; 4Surgical Oncology, Leiden University Medical Center, Leiden, Netherlands; 5Surgical Oncology, Radboud University Medical Center, Nijmegen, Netherlands; 6Surgical Oncology, Maastricht University Medical Center, Maastricht, Netherlands; 7Surgical Oncology, University Medical Center Utrecht, Utrecht, Netherlands; 8Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; 9. Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

OUTCOMES OF SOFT TISSUE SARCOMA RESECTED WITH CLOSE OR POSITIVE MARGINS ON PRIMARY SURGERY

Paul Pou; Christian Carrie; Gualter Vaz; Pierre Méeus; Isabelle Ray-Coquard; Jean-Yves Blay; Patrice Peyrat; Armelle Dufresne; Mehdi Brahmi; Marie Karanian; Marie-Pierre Sunyach

1Radiation Oncology, Centre Léon Bérard, Irigny, France; 2Centre Léon Bérard, Lyon, France

CLINICAL OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA WHO RECEIVED ADDITIONAL EXCISION AFTER UNPLANNED EXCISION: REPORT FROM THE BONE AND SOFT TISSUE TUMOR REGISTRY IN JAPAN

Tomoki Nakamura; Akira Kawai; Tomohito Hagi; Koji Kita; Kunihiro Asanuma; Akihiro Sudo

1Orthopaedic Surgery, Meisei University Graduate School of Medicine, Tsu, Japan; 2National Cancer Center, Tokyo, Japan

ASSESSMENT OF THE TIME TO TREATMENT INITIATION = 0 COHORT IN SOFT TISSUE SARCOMA PATIENTS AT A TERTIARY CANCER CENTER: ARE WE DEFINING THIS CORRECTLY?

Joshua M. Lawrenz; Jose Vega; Jaiben George; Gannon L. Curtis; Jaymeson Gordon; Amanda Maggiotto; Lukas M. Nystrom; Nathan W. Mesko

1Orthopaedic Surgery, Cleveland Clinic, Cleveland Heights, OH, USA

PROGNOSTIC RELEVANCE OF SYSTEMIC INFLAMMATORY MARKERS IN SOFT-TISSUE SARCOMA PATIENTS TREATED WITH CURATIVE RESECTION

In Hee Lee; Byung Woog Kang; Yee Soo Chae; Jong Gwang Kim; Soo Jung Lee

1Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Daegu, Korea (the Republic of)
Kaitlyn Dinkins; Cecilia G. Ethun; Aileen Johnsson; Thuy B. Tran; George Poultsides; Valerie P. Grigno; J. H. Howard; Meena Bedi; John Charlston; Jennifer Tseng; Kevin K. Roggin; Konstantinos Votanopoulos; Konstantinos Votanopoulos; Darren Cullinan; Ryan C. Fields; David Monson; Shervin Oskouei; Nickolas Reimer; Monica Rizzo; Kenneth Cardona; Maria C. Russell
1Division of Surgical Oncology, Department of Surgery, Emory University, Atlanta, GA, USA; 2Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH, USA; 3Department of Surgery, Stanford University, Palo Alto, CA, USA; 4Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 5Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 6Department of Surgery, University of Chicago Medicine, Chicago, IL, USA; 7Department of Surgery, Wake Forest University, Winston-Salem, NC, USA; 8Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA

NUTRITIONAL PREDICTORS OF WOUND COMPLICATIONS IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE LOWER EXTREMITIES
Adam Z. Kline; Pramod N. Kamalopathy; Dayton D. McMillan; Katharine E. Bruce; Aarti Patel; Marilyn Johnson; Alexandra Bachinsky; Karen De Amorim Bernstein; Kevin Raskin; Santiago Lozano Calderon; Joseph H. Schwab
1Orthopaedics, Massachusetts General Hospital, Boston, MA, USA; 2Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

PRIMARY VERSUS STAGED SOFT TISSUE RECONSTRUCTION HAVE SIMILAR WOUND AND ONCOLOGIC OUTCOMES AFTER SOFT TISSUE SARCOMA EXCISION
Joshua M. Lawrenz; Danielle C. Marshall; Jaiben George; Aparna Vijayasekaran; Jaymeson Gordon; Graham S. Schwarz; Lukas M. Nystrom; Nathan W. Mesko
1Orthopaedic Surgery, Cleveland Clinic, Cleveland Heights, OH, USA; 2Plastic Surgery, Cleveland Clinic, Cleveland, OH, USA

SURGICAL ADJUVANT THERAPY USING ACRIDINE ORANGE AFTER INTRA-LESIONAL OR MARGINAL RESECTION IN PATIENTS WITH HIGH-GRADE SOFT TISSUE SARCOMA, A PILOT STUDY.
Tomoki Nakamura; Katsuyuki Kusuzaki; Kunihiro Asanuma; Tomohito Hagi; Koji Kita; Hiroaki Murata; Takao Matsubara; Akihiro Sudo
1Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan; 2Orthopaedic Surgery, Takai Hospital, Nara, Japan; 3Orthopaedic Surgery, Matsushita Memorial Hospital, Osaka, Japan; 4Matsubara Orthopaedics, Tsu, Japan

LONG-TERM OUTCOME IN PATIENTS WITH COMPLICATED NON-METASTATIC RETROPERITONEAL SOFT TISSUE SARCOMAS REQUIRING UNPLANNED EMERGENCY SURGERY
Alexandru Bárbálan; Matthieu Faron; Leila Haddag; Sarah N. Dumont; Cécile Le Péchoux; Julien Adam; Olivier Mir; Philippe Terrier; Axel Le Cesne; Charles Honoré
1Department of Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; 2Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; 3Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France; 4Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France; 5Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France

BENEFIT OF SURGICAL TREATMENT FOR PULMONARY METASTASIS IN SOFT TISSUE SARCOMA PATIENTS
Teruya Kawamoto; Toshihiro Akisue; Ikuo Fujita; Takuya Fujimoto; Hitomi Hara; Naomasa Fukase; Yohei Kawakami; Masayuki Morishita; Toshiyuki Takemori; Shuichi Fujiwara; Kazumichi Kityama; Ryosuke Kuroda
1Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; 2Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan; 3Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan
Poster 434 3038338
ALGORITHMS FOR THE SURGICAL MANAGEMENT OF SOFT TISSUE TUMOURS OF THE ABDOMINAL WALL: RETROSPECTIVE SINGLE CENTRE STUDY ON 120 PATIENTS
Isabelle Sourrouille1; Cecilia Ceribelli1; Sara Baleri1; Olivier Mir1; Matthieu Faron1; Julien Adam1; Sarah N. Dumont1; Axel Le Cesne1; Philippe Terrier1; Charles Honoré1
1Oncological Surgery, Gustave Roussy, Paris, France; 2Cancer Medicine, Gustave Roussy, Villejuif, France; 3Pathology, Gustave Roussy, Villejuif, France

Poster 435 3042592
FLUORESCENCE-GUIDED LYMPH VESSEL SEALING TO PREVENT LYMPHOCELE AFTER SARCOMA RESECTION
Jens Jakob2; Andreas Gerken1; Ioannis Karampinis1; Peter Hohenberger1
1Department of Surgery, Division of thoracic surgery and surgical oncology, Medical Faculty Mannheim, University of Heidelberg, Germany, Mannheim, Germany; 2Universitätsmedizin Göttingen Georg-August-Universität, Göttingen, Germany

Poster 436 3028381
TUMOR NECROSIS FOLLOWING NEOADJUVANT CHEMOTHERAPY FOR SYNOVIAL SARCOMA: A REPORT FROM CHILDREN’S ONCOLOGY GROUP STUDY ARST0332
Rajkumar Venkatramani1; Douglas Hawkins2; David Parham3; Jennifer Black4; Andrea Hayes-Jordan5; Suzanne Wolden6; Stephen Skapek7; Yueh-Yun Chi8; Jing Tian9; Sheri Spunt10
1Pediatrics, Baylor College of Medicine, Houston, TX, USA; 2Seattle Children’s Hospital, Seattle, WA, USA; 3Children’s Hospital Los Angeles, Los Angeles, CA, USA; 4Children’s Hospital Colorado, Aurora, CO, USA; 5M D Anderson Cancer Center, Houston, TX, USA; 6Memorial Sloan Kettering Cancer Center, New York, NY, USA; 7UT Southwestern/Simmons Cancer Center-Dallas, Dallas, TX, USA; 8University of Florida, Gainesville, FL, USA; 9COG data center, Gainesville, FL, USA; 10Lucile Packard Children’s Hospital Stanford University, Palo Alto, CA, USA

Poster 437 3012136
COMBINATION PREOPERAIVE CHEMOTHERAPY AND SURGERY FOR LOCALIZED SYNOVIAL SARCOMA: RETROSPECTIVE ANALYSIS OF 117 PATIENTS AT A SINGLE INSTITUTE FOR 26 YEARS.
Takuji Seo1; Kazuki Sudo1; Emi Noguchi1; Akihiko Shimomura1; Masaki Tanikoa1; Akihiko Yoshida1; Tomoaki Morii2; Eisuke Kobayashi3; Fumihiko Nakatani3; Shintaro Iwata4; Akira Kawaj4; Masanaka Sugiyama4; Ayumu Arakawa4; Tadashi Kumamoto4; Chitose Ogawa4; Yasuhiro Fujiwara4; Kan Yonemori1; Kenji Tamura1
1Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; 2Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan; 3Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan; 4Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan

Poster 438 3009765
PAZOPANIB IN ADVANCED SYNOVIAL SARCOMA: THE GUSTAVE ROUSSY EXPERIENCE
Marine Sroussi1; Sixtine De Percin1; Miruna Grecea1; Marc-Antoine Benderra1; Maud Velev1; Sarra Akla1; Naima Lezghed2; Sarah N. Dumont1; Cécile Le Péchoux2; Charles Honoré3; Leila Haddag3; Matthieu Faron3; Philippe Terrier3; Olivier Mir4; Axel Le Cesne1
1Medical Oncology Department, Gustave Roussy Institute, Montrouge, France; 2Radiation Oncology Department, Gustave Roussy Institute, Villejuif, 94800, France; 3Surgery Department, Gustave Roussy Institute, Villejuif, 94800, France; 4Radiology Department, Gustave Roussy Institute, Villejuif, 94800, France; 5Pathology Department, Gustave Roussy Institute, Villejuif, 94800, France

Poster 439 3028032
SYNERGISM OF P53 ACTIVATORS WITH BCL-2 INHIBITORS IN SYNOVIAL SARCOMA
Toshihiko Nishisho1; Angela Goytain2; Xiu Q. Wang2; Neal M. Poulin2; Bertha Brodin2; Kevin B. Jones2; Jamie S. Yu1; Torsten O. Nielsen1
1Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada; 2Department of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; 3Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City, UT, USA
SURVIVAL PREDICTION MODEL OF SYNOVIAL SARCOMA USING ARTIFICIAL NEURAL NETWORKS WITH THE SEER DATABASE

Sung Wook Seo; Kyeu Back Kwon; Ji Hye Sohn; Ji Soo Kim
1Dept of Orthopaedic Surgery, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea (the Republic of)

DOES CSF1 OVER-EXPRESSION OR REARRANGEMENT INFLUENCE BIOLOGICAL BEHAVIOUR IN TENOSYNOVIAL GIANT CELL TUMOURS OF THE KNEE?

Monique Mastboom; Daisy Hoek; Judith V. Bovee; Michiel A. van de Sande; Karoly Szuhai
1Orthopaedics oncology, Leiden University Medical Center, Amsterdam, Noord Holland, Netherlands

SURGERY IN TENOSYNOVIAL GIANT CELL TUMORS IMPROVES PATIENT REPORTED QUALITY OF LIFE AND JOINT FUNCTION

Floortje Verspoor; Monique J.L. Mastboom; Gerjon Hannink; Michiel van de Sande; H.W.B. Schreuder
1Radboud University Medical Center, Nijmegen, Netherlands; 2Leiden University Medical Center, Leiden, Netherlands

CHEMOTHERAPY IN THE TREATMENT OF UNDIFFERENTIATED HIGH GRADE PLEOMORPHIC SARCOMA (UPS) OF BONE

John A. Livingston; Kristi Posey; Wei-Lien Wang; Alexander J. Lazar; Cheuk Hong Leung; Heather Lins; Valerae Lewis; Patrick Lin; Dejka M. Araujo; Ravin Ratan; Vinod Ravi; Neeta Somaiah; Anthony P. Conley; Robert Benjamin; Shreyas Kumar Patel
1Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; 2Pathology, MD Anderson Cancer Center, Houston, TX, USA; 3Biostatistics, MD Anderson Cancer Center, Houston, TX, USA; 4Orthopedic Oncology, MD Anderson Cancer Center, Houston, TX, USA

HIGH-RISK UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) TREATED WITH PERIOPERATIVE CHEMOTHERAPY: A SECONDARY ANALYSIS OF A ISG-GEIS RANDOMISED CLINICAL TRIAL (RCT) COMPARING 3 VERSUS 5 CHEMOTHERAPY CYCLES FOR HIGH-RISK SOFT TISSUE SARCOMA (STS)

Sandro Pasquali; Chiara Colombo; Sara Pizzamiglio; Paolo Verderio; Dario Callegaro; Silvia Stacchiotti; Javier Martin-BROTO; Antonio Lopez-Pousas; Stefano Ferrari; Andres Povedas; Antonio De Paoli; Vittorio Quagliuolo; Josefinz Cruz; Alessandro Comandone; Tiziana Venesio; Rita De Sanctissup; Elena Palassini; Antonio Llomboart-Bosch; Angelo P. Dei Tos; Paolo Casalli; Piero Picci; Alessandro Gronchi
1Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 2Hospital Universitario Virgen del Rocio, Sevilla, Spain; 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 4Istituto Ortopedico Rizzoli, Bologna, Italy; 5Valencian Oncologic Institute, Valencia, Spain; 6Centro di Riferimento Oncologico, Aviano, Italy; 7Humanitas Cancer Center, Milano, Italy; 8University of Canarias Hospital, La Laguna, Spain; 9Presidio Sanitario Gradensigo, Spain, Italy; 10IRCCS Fondazione Piemontese per la Ricerca sul Cancro, Candiolo, Italy; 11Medical School of Valencia, Valencia, Spain; 12Treviso General Hospital, Treviso, Italy